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Abstract 
 
The aim of this thesis is to investigate the role of inflammatory infiltrates 
and chemokines in metastasis of high-grade serous ovarian cancer, 
HGSC, to the omentum using human tissue biopsies and a 3-
dimensional (3D) cell culture model.  
 
In ten patients with metastatic HGSC, omental tumour deposits 
contained a prominent leukocyte infiltrate of CD3+ T cells (9% of total 
cells) and CD68+ macrophages (11% of total cells). The presence of 
CD68+ macrophages showed a significant positive correlation with 
tumour cell proliferation analysed by Ki67 expression.  
 
Four ovarian cancer cell lines were co-cultured on a 3D model mimicking 
the microenvironment of the omentum for two weeks. The model was 
composed of collagen embedded human fibroblasts covered in a 
confluent layer of human primary mesothelial cells. The mesothelial cells 
in the 3D model significantly increased the growth (p = 0.002) and 
invasion (p = 0.0004) of the ovarian cancer cells.  
 
CXCL12 is the macrophage chemoattractant and ligand for the major 
chemokine receptor expressed on ovarian cancer cells. An association 
between CXCL12 and extracellular matrix remodelling was identified in 
two independent gene expression microarrays of ovarian cancer 
biopsies. The expression of CXCL12 in the HGSC omental metastases 
measured by quantitative Real Time-PCR positively correlated with 
decorin expression. Antibody mediated neutralisation of CXCL12 
reduced growth (p = 0.012) and invasion (p = 0.029) in the 3D model. 
Mimicking an infiltrate of CD68+ macrophages in this multicellular 3D in 
vitro system also produced measurable changes in inflammatory 
cytokine and chemokine expression.  
 
Abstract 
 9 
There is currently a demand for more accurate models of HGSC and a 
necessity to study its metastasis that presents itself as the major clinical 
problem in patients. Therefore the development of this 3D model to 
mimic tumour-promoting inflammation in HGSC metastasis will provide 
researchers with an essential tool for testing novel therapeutic 
strategies. 
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1. Introduction 
 
Ovarian cancer is the fifth most common cancer affecting women in the 
United Kingdom (UK). Generally women who are older, overweight or 
infertile are at a greater risk of developing ovarian cancer (Vaughan et 
al., 2011). Platinum therapies were introduced approximately thirty years 
ago, and together with Paclitaxel, Carboplatin treatment followed by 
interval-debulking surgery remains to be the standard regime of care for 
ovarian cancer patients  
 
The latest recorded five-year survival rates in the UK equates to 42.9% 
(Cancer Research UK). Given the stagnated survival rates since current 
therapeutic strategies were introduced, there is a demand for novel drug 
targets.  
 
1.1. The origin and pathogenesis of ‘ovarian’ 
carcinoma 
 
The theory that acquired general consensus until recent times was that 
ovarian cancer originated from aberrations in the ovarian surface 
epithelium, (Radisavljevic, 1977). Two modes of malignant 
transformation of the epithelial cells were thought to exist (Erickson et 
al., 2013). Firstly overstimulation of the surface epithelial cells with 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) were 
thought to promote the occurrence of genetic mutations (Cramer and 
Welch, 1983). Perimenopausal women produced high levels of these 
gonadotropin hormones, and there was an increased incidence of 
ovarian cancer in women ten years after their menopause. Secondly the 
process of ovulation itself was thought to cause malignant 
transformation through the development of cortical inclusion cysts (Nik et 
al., 2014). This was first identified where an excessive production of 
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eggs in hens increased the development of epithelial ovarian cancer 
(Fathalla, 1971). It was thought that the surface epithelial cells became 
damaged during the ovulation process, and within the inclusion cyst 
were exposed to growth factors that would normally be dispersed in the 
peritoneal fluids. These abnormal cellular interactions were thought to 
promote malignant transformation. This theory was supported by the 
lower incidence of ovarian cancer in women who had experienced 
breaks in ovulation through pregnancy, and also those who had reduced 
ovulation cycles regulated by the oral contraceptive pill (Cramer et al., 
1982). Malignant ovarian surface epithelial cells were then thought to 
disseminate from the ovarian surface, where they were then free-floating 
in the peritoneal fluids and metastasised to surrounding tissues (Shield 
et al., 2009). 
 
Attempts to try and identify the precursor lesions of ovarian cancer on 
the ovaries themselves however, were met with very little success (Nik 
et al., 2014). In fact, the molecular pathology of ovarian carcinoma 
carried very little resemblance to that of the ovaries. The disease was 
considered to be so heterogeneous that it was doubted a disease of 
single origin (Kurman and Shih Ie, 2010). It is now clear that there are 
five defined histological subtypes of ovarian carcinoma, each showing 
similarities to the epithelium of tissues within close proximity to the 
ovaries (Table 1-1) (Kurman and Shih Ie, 2011; Li et al., 2011). Early 
lesions of high-grade serous carcinoma (HGSC) originated as serous 
tubal intraepithelial carcinoma (STIC) involving the secretory cells of the 
endosalpinx of the fallopian tubes (Crum et al., 2012). It appeared that 
the original concept of a ‘cortical inclusion cyst’ initiating malignant 
transformation still applied, but the cells of the cyst may have originated 
in the fimbria, and were included in the ovaries as a secondary site 
during cyst development (Kurman, 2013). 
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Histological ovarian carcinoma 
subtype 
Tissue resemblance 
High grade serous Fallopian tube 
Low grade serous Fallopian tube 
Endometrioid Endometrium 
Clear cell Endometrium 
Mucinous Gastrointestinal tract 
 
Table 1-1 Summary of the histological subtypes of ovarian carcinoma. 
The five histological subtypes of ovarian carcinoma bear more molecular and 
pathological resemblance to different tissues that are anatomically close to the ovaries, 
than they do to the ovaries themselves. A new and alternative theory with growing 
supportive evidence suggests that the tissue types resembled by the carcinomas are in 
fact the true origin of the precursor lesions, and the ovaries are sites of secondary 
metastases (Kurman and Shih Ie, 2011; Li et al., 2011). 
 
 
Figure 1-1 illustrates the differences in the histopathology of four of the 
ovarian cancer subtypes, HGSC, endometrioid, clear cell and mucinous 
carcinoma. Figure 1-1 also diagrammatically indicates the tissue source 
of each subtype. 
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Figure 1-1 The origins and histopathology of four subtypes of ovarian 
carcinoma. 
Diagram illustrating H & E stained sections of four of the subtypes of ovarian cancer, 
and arrows indicating the tissue of origin. Mucinous ovarian cancers arise from the 
gastrointestinal tract, including the colon, appendix and stomach. High-grade serous 
carcinoma (HGSC) may originate from the ovaries but are more likely to involve the 
epithelial cells of the fimbria. Endometrioid and clear cell carcinoma is initiated in the 
endometrium (Kurman and Shih Ie, 2011; Li et al., 2011).  
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1.1.1. High grade serous ovarian carcinoma (HGSC) 
 
HGSC is the most common and the most aggressive of the histological 
subtypes accounting for approximately 60% of ovarian cancer deaths 
(Bowtell, 2010; Kurman, 2013). HGSC is generally sensitive to platinum-
based therapies at least initially, but due to the clonal diversity of the 
disease, it quickly adapts and acquires resistance (Vaughan et al., 
2011). Resistance to therapy in HGSC may develop from the selected 
survival of a sub-clonal population that pre-exists within the tumour 
(Cooke et al., 2010). Genomic aberrations were studied in a group of 
sensitive and resistant HGSC cell lines derived from the same patient. 
The degree of aneuploidy between the sensitive and resistant lines was 
highly dissimilar suggesting the resistant cell population was not a 
descendant of the sensitive cell lines. This was further supported when 
paired pre- and post chemotherapy samples collected from six HGSC 
patients were also divergent in their genetic instability and copy number 
aberrations.  
 
1.1.1.1.  HGSC is a cancer of the fallopian tube 
 
Recently pre-neoplastic lesions were identified in the fimbria of the 
fallopian tubes in patients with HGSC. (Ahmed et al., 2010; Kindelberger 
et al., 2007; Nik et al., 2014). This suggested that the epithelial cells of 
the fimbria themselves were the true initiating cells of HGSC. 75% of 
patients with sporadic HGSCs were found to have STICs (Kindelberger 
et al., 2007). Involvement of the fallopian tube equally applied to HGSC 
patients with BRCA mutations who had an inherited genetic 
predisposition to the disease (Crum et al., 2007). In the HGSC cases 
positive for fimbria involvement the same TP53 mutation signature found 
in the carcinoma was also identified in the STICs (Lee et al., 2007b). 
TP53 mutations were identified in 96% of HGSCs (Cancer Genome 
Atlas Research, 2011). A comprehensive study of the type and 
frequency of TP53 mutations in HGSC patients did not significantly 
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associate with patient prognosis (Ahmed et al., 2010). 56.3% of the 
mutations studied were missense mutations and located within exons 4-
8. The most frequently mutated codon was 273 involving R273C, R273H 
and R273L mutations occurring in 13.4% of all cases. The high 
frequency of TP53 mutations in high stage disease suggested that it was 
an early driver of HGSC development and progression. Ahmed and 
colleagues noted that in HGSC cases that were negative for TP53 
mutations, there were copy number gains in MDM (mouse double 
minute) 2 and 4, which regulate and target p53 for degradation, 
indicating that there was still a loss of p53 function where mutations 
were absent. 
 
An array of secreted proteins from an ex vivo culture model of the 
human fallopian tube were collectively very representative of secreted 
markers seen in HGSC (Levanon et al., 2010) and very few of these 
proteins were detected in the ovarian surface epithelium. This further 
supported the theory that HGSCs did not originate in the ovary at all, but 
were actually carcinomas of the fallopian tube incorporated within the 
ovary by the process of endosalpingiosis (Nik et al., 2014). 
 
1.1.1.2. The quest for prognostic biomarkers of HGSC 
 
In recent years there has been a significant expansion in data sets of 
gene expression analyses of HGSC. The Australian Ovarian Cancer 
Study (AOCS) lead by the laboratory of Prof David Bowtell in Melbourne 
is a collaborative project uniting scientific and clinical data to search for 
predictive biomarkers for earlier diagnosis, chemotherapy response and 
survival of HGSC patients. Tothill and colleagues (Tothill et al., 2008) 
used an unbiased clustering statistical analysis of microarray gene 
expression data to collate data from 285 HGSC and endometrioid 
biopsies into six molecular subtypes on the basis of patient clinical 
outcome and their response to chemotherapy. Four of those subtypes  
(C1, C2, C4 and C5) related to HGSC and collectively showed an up-
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regulation in pathways associated with a reactive stromal signature, 
such as cell signalling pathways, angiogenesis, mesenchymal 
expression markers, and extracellular matrix and cell adhesion proteins. 
The C1 and C2 subtypes expressed high levels of pro-inflammatory 
cytokines and chemokines of the described TNF (tumour necrosis factor) 
network; interleukin (IL)-6, TNF-α and CXCL12 (Kulbe et al., 2012). 
Biopsies of the C1 subtype related to a poor prognosis and response to 
chemotherapy, and expressed markers such as FAP (fibroblast 
activation protein) and α-SMA (smooth muscle actin). These C1 
subytype biopsies were also highly desmoplastic defined by excessive 
collagen deposition (Tothill et al., 2008). More recently the BRCA1 and 
BRCA2 mutated C2 molecular subtype was further annotated with 
increased T cell infiltrates and an immunoreactive signature (George et 
al., 2013).  
 
Interrogation of a further gene expression data set of more than 500 
HGSC ovarian cancer biopsies derived from The Cancer Genome Atlas 
(TCGA) (Cancer Genome Atlas Research, 2011), recently aided the 
formulation of the CLOVAR model (classification of ovarian cancer 
survival signatures)(Verhaak et al., 2013). Four described gene 
signature groups were identified on the basis of patient prognosis. 
Patients of HGSC with a mesenchymal and immunoreactive signature 
had the worst prognosis, with disease recurrence in less than six months 
from treatment and the development of resistance to platinum therapy. 
This highlights the relevance of the tumour microenvironment in disease 
severity. 
 
In a later study Yang J and colleagues generated a second model using 
the biopsies of the TCGA based on high throughput protein expression 
arrays, named the PRotein-driven index of OVARian cancer (PROVAR) 
model (Yang et al., 2013b). This model was composed of 9 protein 
markers that were predictive of progression free survival, and was more 
robust than the CLOVAR model. Similarly to the CLOVAR model, four 
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distinct protein clusters were identified that related to patient prognosis. 
These PROVAR model protein clusters correlated with the molecular 
subtypes of the CLOVAR model. High-risk patients with a poor 
prognosis as predicted by the PROVAR model, clustered and associated 
with the mesenchymal and immunoreactive gene signature subytpes as 
predicted by the CLOVAR model. Three of the protein markers found to 
be associated with poor prognosis STAT (signal transducer and activator 
of transcription) 5α, pPKC (protein kinase C) α and pMAP (mitogen 
activated protein) 2 kinase 1 were all in downstream signalling pathways 
of EGFR (epidermal growth factor receptor) involved in tumour cell 
proliferation, survival and invasion. 
 
1.1.1.3. Potential new therapeutic strategy for HGSC 
 
Women with a family history of breast or ovarian cancers carrying 
genetic mutations in the DNA repair molecules RAD51C and BRCA1/2 
fall within the high-risk group for developing HGSC (Vaughan et al., 
2011). Hence poly adenosine diphosphate ribose polymerase (PARP) 
inhibitors are one of the most promising new leads for advancing the 
treatment of HGSC patients. These molecular inhibitors take advantage 
of the inefficiency of BRCA1 and BRCA2 mutated HGSC cells to repair 
double-strand breaks in DNA (Banerjee et al., 2010). In primary cell 
cultures established from the ascites of 50 women, RAD51 positive 
nuclear foci were used as a marker of DNA double-strand break repair 
by homologous recombination (HR) (Mukhopadhyay et al., 2012). 96% 
of the cultures that were deficient in HR mechanisms were also sensitive 
to the PARP inhibitor rucaparib, compared with none of the HR 
competent cultures. In the patients that the cultures were derived from, 
HR deficiency also correlated with increased platinum sensitivity and 
improved overall survival.  
 
It was thought that acquired resistance to such PARP inhibitors might 
jeopardise the efficacy of subsequent treatments with platinum-based 
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chemotherapy. This was disproved in a recent retrospective study of 
patient responses (Ang et al., 2013). Therefore PARP inhibitors are still 
strong candidates for HGSC care. 
 
1.1.2. Clear cell ovarian carcinoma (CCC) 
 
Clear cell carcinoma, CCC, is the second most common subtype of 
ovarian cancers and responds poorly to current chemotherapeutic 
strategies. In advanced cases, it actually has a worse prognosis than 
HGSC (Goff et al., 1996). CCC often presents in younger women and is 
strongly associated with endometriosis (Kennedy et al., 1989). 
Approximately 50% of CCCs carry a mutation in the chromatin-
remodelling gene and tumour supressor ARID1A (AT-rich interactive 
domain containing protein 1A) (Jones et al., 2010; Wiegand et al., 2010). 
Pathologically CCC is rich in basement membrane components and 
glycogen. The latter is reflective of the enrichment in gene expression 
profile signatures associated with metabolic pathways that are distinctive 
to this subtype (Anglesio et al., 2011a). CCCs are also molecularly 
characterised by enrichment in cytokine signalling, oxidative stress and 
hypoxia driven pathways.  
 
CCCs present with activating mutations in PIK3CA, a regulator of the 
phosphoinositide (PI) 3 kinase pathway (Campbell et al., 2004). On a 
molecular level, CCCs are very similar to renal carcinomas, both 
showing an up regulation in HIF1A (hypoxia-inducible factor 1A) (Lee et 
al., 2007a) and EPAS1 (endothelial (Period circadian protein, Aryl 
hydrocarbon receptor nuclear translocator protein, Single-minded 
protein) domain-containing protein 1). Sunitinib is a tyrosine kinase 
inhibitor that targets angiogenesis through inhibition of VEGFR (vascular 
endothelial growth factor receptor), PDGFR (platelet-derived growth 
factor receptor) and KIT signalling pathways amongst others. The 
success of the anti-angiogenic drug sunitinib in renal cancers (Kumar et 
al., 2009) prompted an investigation involving sunitinib treatment in CCC 
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(Anglesio et al., 2011b). High IL-6 levels are also found in CCC and 
endometriosis, which activate STAT3, HIF and VEGFA (vascular 
endothelial growth factor A). Two sunitinib-treated CCC patients showed 
a significant decrease in tumour size with an associated reduction in 
monitored CA-125 (cancer antigen 125) levels suggesting that high IL-6 
levels drive early events in the development of CCC. 
 
In contrast to HGSCs, CCCs specifically express HNF1B (hepatocyte 
nuclear factor 1 homeobox B), which may be involved in the 
deregulation of apoptosis (Tsuchiya et al., 2003). CCCs also have no 
TP53 mutations and have a low frequency of BRCA1/BRCA2 mutations 
(Nik et al., 2014).  
 
These further supports the notions that the two subtypes of ovarian 
cancer are more distinct from one another than the term ‘subtype’ 
suggests, and are in fact completely different diseases. It is becoming 
increasingly important that we recognise this when considering 
treatments for these diseases. Given that the predominant proportions of 
ovarian cancer deaths are attributed to HGSC, this subtype is the focus 
of this thesis. The contribution of the microenvironment to tumour 
development and chemotherapy resistance is particularly important in 
HGSC (Vaughan et al., 2011; Verhaak et al., 2013). Given the malignant 
cells of HGSC are characterised by their clonal diversity and ability to 
quickly acquire resistance to therapies, the supporting cells of the 
microenvironment may be a favourable target for HGSC treatment. 
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1.2. Inflammatory cells of the tumour 
microenvironment 
 
The involvement of the immune system in malignant transformation and 
development is a well recognised hallmark of cancer progression 
(Cavallo et al., 2011). It is widely accepted that the presence of an 
inflammatory infiltrate within a tumour can often support its growth and 
metastasis (Erez and Coussens, 2011). The first observation of the 
presence of an immune infiltrate in cancers was noted by Rudolf 
Virchow in 1863 (Balkwill and Mantovani, 2001). The inflammatory 
infiltrate within malignant disease can switch from a tumour promoting 
response which is detrimental to patient survival to a tumour-targeted 
response that is beneficiary (Hanahan and Weinberg, 2011). Therefore 
the signature of inflammatory infiltrate may provide useful information as 
a prognostic marker, and also aid the design of more personalised 
therapies (Fridman et al., 2012). The roles of immune cell infiltrates 
studied in ovarian cancer are discussed in this chapter and summarised 
in table 1-2. 
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Immune cell infiltrate Patient prognosis Reference 
Neutrophils Poor (Carus et al., 2013) 
B cells Poor (Yang et al., 2013a) 
CD4+ FOXP3+ T 
cells 
Poor (Curiel et al., 2004) 
T Helper (TH) 1 & 
TH17 CD4+ T cells 
Good (Fridman et al., 2012) 
TH2 CD4+ T cells Poor (Fridman et al., 2012) 
CD8+ T cells Good (Fridman et al., 2012; 
Stumpf et al., 2009) 
Macrophages Poor (Kryczek et al., 2007; 
Vaughan et al., 2011) 
 
Table 1-2 The effect of immune cell infiltrates on ovarian cancer patient 
prognosis. 
Table summarising the role of immune cell infiltrates in ovarian cancer progression on 
the basis of their impact on patient prognosis when present in the tumour 
microenvironment at high densities. The associated references are also indicated. 
 
1.2.1. Neutrophils 
 
Neutrophils release reactive oxygen species that can contribute to 
malignant transformation by damaging DNA and deregulating the action 
of DNA repair, cell cycle control and apoptosis proteins (Schafer and 
Werner, 2008). Neutrophils can adopt an angiogenesis inducing pro-
tumorigenic role within the tumour microenvironment (Fridlender et al., 
2009; Polyak et al., 2009). Additionally and conversely ‘tumour entrained 
neutrophils’ (TENs) can be anti-metastatic. Granot et al demonstrated 
that hydrogen peroxide production by TENs at the metastatic site 
prevented metastasis to the lung in the 4T1 breast carcinoma in vivo 
model (Granot et al., 2011). 
 
In ovarian cancer patients increased numbers of neutrophils in the blood 
correlates with a poor response to chemotherapy (Carus et al., 
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2013)(Table 1-2). Recently in a randomised trial involving 964 ovarian, 
fallopian and peritoneal cancer cases, patients were treated with a 
constant or increasing dose of carboplatin. (Banerjee et al., 2013; 
Donskov, 2013). There was no significant improvement on survival. 
However within both arms of the study increased baseline neutrophil 
blood counts correlated with a reduced progression free survival, 
suggesting that these may be a useful prognostic marker. Tumour-
infiltrating neutrophils within the microenvironment of HGSC omental 
metastases were quantified by immunohistochemical analysis (Leinster 
et al., 2012). Conversely to the baseline blood counts the overall number 
of neutrophils in the microenvironment was relatively low in comparison 
with T cell and macrophage infiltrates. However there were no data 
linking HGSC infiltrating neutrophils with patient survival. 
 
1.2.2. B and T cell lymphocytes 
 
B and T cell lymphocytes of the adaptive immune system are also found 
within the tumour microenvironment (Balkwill et al., 2012). Classically B 
cells produce antibodies and the deposition of immune complexes can 
polarise macrophages to become tumour promoting (Balkwill et al., 
2013). B cells promoted tumour progression in a mouse model of skin 
carcinoma mediated by the recruitment of inflammatory cells and Fcγ 
receptor interactions on the surface of macrophages (Andreu et al., 
2010). B cells also had an immunosuppressive function on T cell activity 
through interactions with CD40 and secretion of IL-10 (Qin et al., 1998; 
Shah et al., 2005). Depleting B cell populations with the CD20 targeted 
antibody rituximab, is used for the treatment of Non-Hodgkin’s 
lymphoma and chronic lymphocytic leukaemia (CLL) (Balkwill et al., 
2013). However research into B cell activity in tumour progression is 
largely hindered through a lack of definitive B cell markers. A recent 
report correlated CD19 positive B cells with poor overall survival in a 
cohort of 49 omental metastases of HGSC (Yang et al., 2013a)(Table 1-
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2), but in general very little is known about the role of B cells in ovarian 
cancer.  
 
B cell-cell interactions with CD4 positive T cells together with TGF 
(transforming growth factor) β production stimulates the differentiation of 
the T cell into a regulatory T cell (Balkwill et al., 2013). Different T cell 
subsets can have either tumour-targeted cytotoxic effector functions, or 
regulatory functions that counteract and dampen the immune response 
to the developing tumour (Balkwill and Mantovani, 2012; Mantovani et 
al., 2008). CD3 positive T cells are broadly sub-categorised into CD4 
positive regulatory or memory T cells and CD8 positive cytotoxic T cells. 
T regulatory cells are generally associated with a poor prognosis in 
cancers (Bates et al., 2006; Hiraoka et al., 2006), and characterised by 
the expression of FOXP3 (forkhead box P3) and CD25 (Balkwill et al., 
2012). They promote tumour progression through preventing tumour cell 
interactions with cytotoxic T cells via blockade of the cytotoxic T-
lymphocyte antigen 4 (CTLA4). In some cases T regulatory cells can 
also hinder tumour growth. High levels of CXCL12 in cervical cancers, 
which correlated with a poor prognosis, repelled the infiltration of 
regulatory T cells (Jaafar et al., 2009). However in ovarian cancer an 
infiltrate of these cells rather impairs patient survival (Curiel et al., 
2004)(Table 1-2). 
 
Other CD4 positive T helper (TH2 and TH17) cells found in the tumour 
microenvironment are believed to promote tumour progression, but in 
some cases they correlate with a good prognosis (Balkwill et al., 
2012)(Table 1-2). Differences in the clinical response to CD4 positive T 
cell infiltrates across a panel of cancer types illustrates the complexity of 
the subpopulations within this group of inflammatory cells (Fridman et 
al., 2012). Using alternative CD4 positive T cell markers correlated with 
patient response will aid studying the role of these cells in different 
tumour microenvironments. 
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CD4 positive TH1 cells producing IL-2 and IFNγ support the activity of 
CD8 positive cytotoxic T cells. These CD8 positive inflammatory cells in 
the tumour microenvironment are overall associated with a good 
prognosis (Balkwill et al., 2012; Fridman et al., 2012). CD8 positive T 
cells can be found at both the invasive margin and core of the 
developing tumour. For example, a high infiltrate of CD8 positive T cells 
within the invasive margin of human colorectal cancer liver metastases 
correlated with an improved response to chemotherapy and increased 
patient survival (Halama et al., 2011).  
 
CD8 positive T cell infiltrates are also associated with an increased 
survival in ovarian cancer patients, which has been supported by many 
studies (Fridman et al., 2012; Hamanishi et al., 2007; Sato et al., 2005; 
Zhang et al., 2003). Investigation into the tumour infiltrating lymphocytes 
of one hundred stage III HGSC biopsies linked the presence of 
intraepithelial CD8 positive T cells with an improved overall survival in all 
cases, inclusive of patients whom had received chemotherapy (Stumpf 
et al., 2009)(Table 1-2).  
 
More recently Webb and colleagues associated CD8 positive T cells that 
were also positive for CD103 with an increased progression free survival 
compared with those that were CD103 negative (Webb et al., 2014). The 
epithelial regions of HGSCs in particular were rich in CD103 positive T 
cells, and it was thought that the proximity of the T cells with the 
epithelial cells was mediated by interactions between CD103 and E-
Cadherin.  
 
Furthermore, activation of the programmed cell death (PD)-1 receptor 
expressed on tumour infiltrating lymphocytes with its ligand PD-L1 has a 
tumour targeted immunosuppressive function (Duraiswamy et al., 2013). 
Antibody mediated inhibition of this pathway in the syngeneic ID8 
ovarian cancer mouse model caused tumour regression, which was 
related to an increased infiltrate, proliferation and function of CD8 
positive T cells. 
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1.2.3. Macrophages 
 
Given there is a focus on macrophage infiltrates in this thesis following 
the work described in chapter 3, more background information will be 
provided in this chapter about these inflammatory cells and their role in 
the tumour microenvironment. 
 
Monocytes can differentiate, according to the cues of chemokine and 
cytokine signalling within the microenvironment, to macrophages or 
dendritic cells. CD68 positive macrophages can also be divided into two 
broad groups. M1 or classically polarised macrophages are pro-
inflammatory, displaying markers such as CD40, CD80, and MHC (major 
histocompatibility complex) class II and releasing cytokines such as, 
interferon (IFN)-γ, TNF-α, IL-6 and IL-12. The pro-inflammatory 
properties of these macrophages are tumour-promoting, however the 
phagocytic functions of these macrophages can engulf tumour cells 
(Wynn et al., 2013). 
 
M2 polarised or tumour-associated macrophages (TAMs) release anti-
inflammatory cytokines such as IL-10, and express IL-4 and its receptor. 
TAMs support tumour growth and metastasis. One of the first studies to 
show that TAMs promote the development of cancer was in a mouse 
breast carcinoma model (Lin et al., 2001). Tumours grown in mouse 
models that had been genetically engineered to be completely depleted 
of macrophages failed to develop lung metastases. TAMs can increase 
the invasion and proliferation of malignant cells by the release of 
chemotactic and growth factors such as TGF-β and EGF (epidermal 
growth factor) (Bonecchi et al., 2011). They secrete VEGF promoting 
angiogenesis (Yang et al., 2004) and suppress the adaptive tumour-
targeted immune response including CD8 positive T cell activation 
(Mantovani et al., 2008; Sica and Bronte, 2007). Macrophages are also 
very important in the remodelling of the extracellular matrix (ECM) in 
tumours. Matrix metalloproteinase (MMP) production facilitates tumour 
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cell invasion and in addition TAMs regulate ECM stabilisation through 
promoting collagen fibrillogenesis (Pollard, 2008). 
 
1.2.3.1. Multiple macrophage subtypes and their origins 
 
The binary sub-classification of macrophages is really too basic. There is 
in fact a very complex transitional spectrum of intermediate phenotypes 
(Wynn et al., 2013). Gene expression profiles for tissue resident 
macrophages of different mouse organs have been established to 
identify unique molecular subytpes (Gautier et al., 2012). Efforts are 
currently underway to translate these studies in humans to better 
understand the mechanisms underpinning the transition between the 
subtypes. Frankenberger and colleagues identified distinct gene 
expression profiles for CD16 positive and negative monocyte 
populations in the blood, which are further unique to tissue resident 
macrophages (Frankenberger et al., 2012). The mononuclear phagocyte 
system (MPS) model hypothesised that monocytes circulating in the 
blood extravasate into tissues and differentiate according to localised 
molecular cues (Gomez Perdiguero and Geissmann, 2013). The model 
proposed that within the tissue the macrophages then contribute to 
inflammation, tissue remodelling and tumour progression. However the 
identification of macrophages in embryos, such as those in the 
peritonea, the microglia in the central nervous system, and the Kupffer 
cells in the liver negated this theory. A mouse model deficient for the 
transcription factor Myb revealed that the hematopoietic stem cell 
derived CD11b positive macrophage population found in the fetal liver 
was ablated (Schulz et al., 2012). F4/80 positive tissue resident 
macrophages were however still present suggesting a completely 
separate origin for these cells that were able to self-renew and were Myb 
independent. A normal number of macrophages were found in the yolk 
sac of these developing mice, proposing that this may be the origin of 
tissue resident macrophages, which unlike their bone marrow derived 
counterparts differ in function (Gomez Perdiguero and Geissmann, 
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2013). Tissue resident macrophages are thought to be less involved in 
inflammation, as they do not activate nuclear factor (NF)-κB, and do not 
secrete inflammatory cytokines, but they are more involved in tissue 
homeostasis.  
 
1.2.3.2. Macrophage targeted therapies 
 
Current therapeutic strategies, such as those targeting CCL2 aim to 
ablate macrophage recruitment to tumours (Qian et al., 2011; Wynn et 
al., 2013). Tumour cells secrete colony-stimulating factor (CSF) 1 which 
macrophages are responsive to through expression of the receptor on 
their cell surface. In a recent study involving a viral mammary tumour in 
vivo model, targeting the CSF1 receptor with a blocking antibody in 
combination with inhibition of CXCR4 signalling significantly reduced 
invasion and metastasis (Boimel et al., 2012). This work demonstrated 
that EGF stimulated breast cancer invasion and metastasis is co-
dependent upon macrophage infiltration and CXCR4 signalling. Agents 
targeting CSF1 and its receptor are in clinical trials (Hamilton and 
Achuthan, 2013). However such strategies affecting all macrophage 
subtypes deprive the tumour of their favourable phagocytic and antigen 
presentation functions that would stimulate a tumour-targeted immune 
response. 
 
Further genomics, transcriptomics and proteomics studies could herald 
the development of therapeutic strategies that could re-educate TAMs to 
a tumour-targeting phenotype that prolongs patient survival (Wynn et al., 
2013). For example, murine models of melanoma and neuroblastoma 
treated with an established regime of immunotherapy and chemotherapy 
that controlled tumour growth, gave promising indications of the re-
polarisation of infiltrating TAMs to a more classical phenotype 
(Buhtoiarov et al., 2011). 
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1.2.3.3. Macrophages in ovarian cancer 
 
Overall an infiltrate of macrophages in the ovarian cancer 
microenvironment correlates with a poor patient outcome (Kryczek et al., 
2007; Vaughan et al., 2011)(Table 1-2). This is also true of BRCA 
mutation positive ovarian cancers (Mhawech-Fauceglia et al., 2013). 
The release of pro-inflammatory cytokines by ovarian cancer cells 
induced the differentiation of M1 macrophages into the tumour 
associated M2 phenotype in in vitro co-culture assays (Hagemann et al., 
2006). The co-cultured ovarian cancer cells also showed an increase in 
their ability to invade. This was dependent on MMP activity and TNF-α 
induced activation of the transcription factor NF-κB and the MAP kinase 
pathway through JNK (Jun N-terminal kinase) (Hagemann et al., 2005). 
The role of macrophages in an in vivo model of ovarian cancer also 
further validated their ability to promote ovarian cancer invasion and 
metastasis (Robinson-Smith et al., 2007).  
 
IKKβ (IκB kinase β) is the activator of NF-κB, and targeting this in bone 
marrow derived macrophages or TAMs derived from ID8 tumour bearing 
mice reduced tumour cell invasion in in vitro co-culture assays 
(Hagemann et al., 2008). The co-cultured ID8 tumour cells showed 
increased caspase 3/7 activation and consequent increased apoptosis, 
mediated by macrophage tumoricidal activity. The IKKβ targeted 
macrophages reduced tumour burden in mice following adoptive transfer 
of the cells. Both in vitro and in vivo the macrophages showed reduced 
expression of IL-10, TNF-α and arginase 1, with associated increases in 
IL-12, nitric oxide (NO) and NO synthase 2. This work suggested that 
inactivation of IKKβ in macrophages within the ovarian cancer 
microenvironment could ‘re-educate’ the tumour-promoting inflammatory 
cells to switch their activities to those that are tumoricidal. This was 
linked to MyD88 (myeloid differentiation primary response gene) and IL-
1 receptor signalling, and IL-12 mediated recruitment of natural killer 
(NK) cells to the microenvironment.  
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A recent report describes how chemoresistance induced IL-6 signalling 
in ovarian cancer cell lines can promote the differentiation of monocytes 
to the M2 tumour-associated polarised macrophage in vitro (Dijkgraaf et 
al., 2013). This is suggestive of a link between macrophages in the 
ovarian cancer microenvironment and the development of resistance to 
therapies. Targeting the polarisation mechanisms of the macrophages 
such as IKKβ activation may therefore increase sensitivity of tumours to 
current chemotherapy treatments and reduce resistance. 
 
The concept of further intermediate macrophage phenotypes is 
supported in a recent study of TAMs isolated from the ascites of thirty 
HGSC patients (Reinartz et al., 2013). These TAMs expressed the ‘M2’ 
cell surface marker CD163. This correlated with a reduced relapse free 
survival, and increased levels of both the pro-inflammatory cytokine IL-6 
and the anti-inflammatory cytokine IL-10 in the ascitic fluids. In addition 
the gene expression profile of the CD163 positive TAMs carried no 
relationship to the “Beyer Signature” which has previously been used to 
distinguish ‘M1 and M2” macrophage phenotypes (Beyer et al., 2012). 
This work highlights a void in our understanding for the true 
transcriptional and molecular profile of ovarian cancer associated 
macrophages. 
 
1.2.3.4. Macrophage and adipocyte interactions 
 
More specific to the metastatic microenvironment of ovarian cancer is 
the abundance of adipocytes in the omentum. In a gene expression 
array of adipose tissues, in control and obese mice, 30% of the genes 
that correlated with an increased body mass were those associated with 
macrophages (Weisberg et al., 2003). The recruitment of macrophages 
to adipose tissues was confirmed in histopathology sections, including 
that of the mesentery. This recruitment initiated a positive feedback loop 
leading to an increase in adipose tissue mass and therefore further 
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macrophage recruitment (Sun et al., 2011). Adipose tissue macrophages 
isolated from obese mice expressed higher levels of the pro-
inflammatory cytokines TNF-α and IL-6, whereas from the control mice, 
the macrophages expressed increased anti-inflammatory IL-10 (Lumeng 
et al., 2007). These studies suggested that there is interplay between 
adipocytes and macrophages that regulates adipocyte function and 
macrophage polarisation. Tumour cell and adipocyte interactions have 
already been reported in ovarian cancer metastasis (Nieman et al., 
2011). They may be potential targets for future therapeutic intervention. 
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1.3. Cytokines and chemokines in cancer 
 
For almost 25 years cancers have been described as “wounds that do 
not heal” (Dvorak, 1986). During wound healing and pathogen 
stimulation, chemokines and cytokines released by the resident 
fibroblasts and damaged epithelial cells recruit inflammatory cells 
(Dranoff, 2004; Mantovani et al., 2008). Inflammatory cells release 
proteases and reactive oxygen species for anti-bacterial defence 
mechanisms (Schafer and Werner, 2008). Inflammatory cytokine and 
chemokine-mediated processes in their chronic form are mirrored in the 
development and progression of cancer. In the majority of solid tumours, 
associated chronic inflammation reduces the efficacy of chemotherapy 
(Grivennikov et al., 2010). 
 
The long-term usage of non-steroidal anti-inflammatory drugs reduces 
the risk of developing some cancers. For instance the daily use of 
aspirin minimised the risk of developing estrogen receptor (ER)-positive 
breast cancer (Gierach et al., 2008). Large-scale clinical trials where 
patients were treated with aspirin daily for 5 years or longer reduced the 
incidence (Rothwell et al., 2011) and the development of distant 
metastases (Rothwell et al., 2012) for many solid cancers. Death by 
colorectal cancers in particular was reduced by 30-40% (Rothwell, 
2013).  
 
1.3.1. Inflammatory cytokines 
 
Acute inflammation is a rapid response to pathogen stimulation. The 
work of the New York surgeon William Coley in the 19th century gave the 
first indication that microbial preparations and an induction of an acute 
inflammatory response can be used to treat cancer (Balkwill, 2009). The 
treatment of bladder cancer with Bacillus Calmette-Guerin (BCG); a 
vaccine for tuberculosis, is based on these ideas (Grivennikov et al., 
2010). 
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Chronic inflammation is also known to promote malignant transformation 
and metastasis (Balkwill and Mantovani, 2001). Many types of cancer 
are initiated by bacterial or viral infections that also induce long and 
sustained chronic inflammation. Helicobacter Pylori infections are 
involved in the development of gastric cancer, and the Hepatitis B virus 
(HBV) causes liver cancers (Cavallo et al., 2011). Vaccinations against 
the Human Papilloma Virus (HPV) are now routinely administered for the 
prevention of cervical cancer (Mesher et al., 2013).  
 
Many oncogenic mutations are also drivers of inflammatory signalling 
pathways. RET (rearranged during transfection) activation in thyroid 
carcinomas induced the expression of the pro-inflammatory cytokine IL-
1β and the angiogenesis inducing cytokine IL-8 (Grivennikov et al., 
2010; Mantovani et al., 2008). Similarly Myc expression induced under 
the insulin promoter in β-islet cells in a pancreatic cancer mouse model 
increased angiogenesis via IL-1β (Shchors et al., 2006). When 
supernatant from explanted islet cells were cultured with human 
umbilical vein endothelial cells (HUVECs), there was an increase in 
endothelial cell proliferation and tubule formation. This was 
accompanied by the release of VEGF-A that was redistributed in the 
tumours upon Myc activation. IL-1β was immediately up regulated in 
response to Myc activation and the release of ECM sequestered VEGF-
A and endothelial cell proliferation was significantly reduced when mice 
were treated with IL-1β neutralising antibodies. In addition Ras activation 
in human ovarian surface epithelial cells induced transformation and 
tumour growth in animal models that was coupled with an increase in 
cytokine production, including IL-1β, IL-6 and IL-8 (Liu et al., 2004). 
Furthermore tumour growth in xenograft models with induced Ras 
activation in cervical and lung cancer cells was reduced by 
approximately 60% when treated with IL-8 neutralising antibodies 
(Sparmann and Bar-Sagi, 2004). This was accompanied by a decrease 
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in endothelial cell recruitment, vascularisation and infiltration of 
macrophages and granulocytes. 
 
The malignant epithelial cells in tumours as well as the stromal cells 
produce cytokines and chemokines (Balkwill, 2002). Perturbed 
expression of these inflammatory mediators blocks the progression of 
cancer in experimental models. The deletion of the cytokine TNF-α or its 
receptor in mice prevented the development of DMBA (7, 12-
dimethylbenzanthracene) initiated skin carcinogenesis (Moore et al., 
1999). NF-κB regulates the transcription of inflammatory cytokines. The 
deletion of its activator IKKβ and inhibition of the NF-κB pathway in the 
epithelial cells of a colitis induced colon cancer model reduced the risk of 
tumour development (Greten et al., 2004). Targeting the same pathway 
in the myeloid subpopulation of leukocytes in this model also 
significantly reduced tumour growth. The importance of TNF-α and the 
downstream signalling pathways in cancer associated inflammation has 
lead to several phase I and II clinical trials with single agent antagonists 
and antibodies targeting TNF-α (Balkwill, 2009). 
 
1.3.1.1. The TNF network 
 
Kulbe et al (Kulbe et al., 2005) correlated high CXCR4 expressing 
ovarian cancer cell lines with the expression of TNF-α. TNF-α stimulated 
CXCR4 and CXCL12 expression in the malignant cells, which then fed 
back into an autocrine signalling loop. 
 
Malignant cell driven inflammatory cytokine networks maintain a tumour-
promoting microenvironment through both autocrine and paracrine 
signalling. The TNF network in ovarian cancer cells involves the 
autocrine-stimulated expression of other inflammatory cytokines and 
chemokines including IL-6 and the angiogenesis-inducing VEGF (Kulbe 
et al., 2007). This TNF network was described following gene set 
enrichment analyses of gene expression microarray data from the AOCS 
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(Kulbe et al., 2012). This and supporting immunohistochemistry on a 
tissue microarray (TMA) of 53 HGSC patients showed significant 
associations between the expression of TNF-α, IL-6 and CXCL12. 
Stable knock down of CXCR4 in the IGROV1 ovarian cancer cells 
reduced the secretion of these inflammatory cytokines and increased 
survival in a xenograft in vivo model. Targeting TNF-α with the antibody 
Infliximab produced the same results in vitro and in vivo. Supporting this 
further, treating the same xenograft model with the IL-6 targeted 
antibody Siltuximab inhibited IL-6 signalling and reduced tumour burden 
(Coward et al., 2011). This antibody in a Phase II clinical trial of eighteen 
ovarian cancer patients also reduced plasma levels of VEGF and 
CXCL12, whilst inducing disease stabilisation for seven patients and 
generating a partial response for one patient.  
 
Interestingly in all three cases, inhibition of the TNF network reduced the 
vasculature area and the macrophage infiltrate in vivo (Coward et al., 
2011; Kulbe et al., 2012). Comparing biopsies of the AOCS data set 
displaying high expression levels of the TNF network with those 
displaying low expression levels identified an enrichment in cell 
adhesion, cell cycle, NOTCH signalling, angiogenesis and immune cell 
signatures (Kulbe et al., 2012). Analysis of 21 human ovarian cancer 
biopsies derived from the AOCS revealed an increased CD68 positive 
macrophage population in the stromal areas of biopsies associated with 
high expression of the TNF network. VEGF itself increases the 
expression of CXCR4 in vascular endothelial cells and therefore 
CXCL12 may support VEGF-induced angiogenesis in ovarian cancers. 
CXCL12 alone increases angiogenesis in vivo, but only at 
concentrations that are much higher than what would naturally be seen 
in a tumour microenvironment (Kryczek et al., 2005). 
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1.3.2. Chemokines and receptors 
 
Inflammatory chemokines promote immune cell recruitment, activation 
and differentiation. Constitutively expressed homeostatic chemokines 
regulate and maintain the levels of inflammatory responses (Kucia et al., 
2004; Moser and Loetscher, 2001). In wound repair the signalling 
pathways that chemokines activate support the proliferation and survival 
of resident cells. 
 
The nomenclature for chemokines is derived from the location of 
conserved cysteine residues in their molecular structure. Chemokines 
induce their downstream effects by binding to G-protein coupled 
chemokine receptors on the cell surface. The numbers given to 
chemokine receptors denote the chronological order that they were 
discovered (Raz and Mahabaleshwar, 2009). Chemokine receptors have 
seven transmembrane domains, and chemokines will often bind to 
numerous chemokine receptors and vice versa. There are approximately 
50 different chemokines and 20 different receptors in humans offering to 
the complexity of their pathological roles (Kucia et al., 2004). 
 
Deregulated expression of chemokines can lead to the development of 
various inflammatory diseases and can also initiate and promote tumour 
development in over-reactive tissue (Kulbe et al., 2004; Schafer and 
Werner, 2008). The chemokines within the tumour microenvironment 
influences the described immune infiltrate (Coussens and Werb, 2002; 
Fridman et al., 2012). Chemokine receptors on the surface of malignant 
cells, allows them to utilise the downstream proliferative and cell survival 
signalling pathways. Exploitation of chemokine: receptor signalling 
allows CXCR4-expressing malignant cells to metastasise to CXCL12-
expressing sites (Muller et al., 2001). 
 
One of the aims of this thesis was to study chemokine signalling in 
ovarian cancer metastasis to the omentum. CXCR4 is the major 
chemokine receptor expressed on malignant epithelial cells in ovarian 
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cancer biopsies (Scotton et al., 2001). Therefore the literature review 
here focuses on the role of CXCR4 and its ligand CXCL12 in the ovarian 
cancer microenvironment.  
 
1.3.3. CXCR4 and CXCL12 signalling in the tumour 
microenvironment 
 
In the last twenty years research has significantly advanced around the 
biology of the chemokine receptor CXCR4. This is since the discovery of 
its role as an entry co-receptor with CCR5 for Human Immunodeficiency 
Virus (HIV) into CD4 positive T lymphocytes and macrophages (Feng et 
al., 1996). Epithelial and stromal cells, including leukocytes, secrete its 
ligand CXCL12. Under normal conditions, the generated concentration 
gradient regulates the homing of CXCR4-expressing leukocytes and 
haematopoietic progenitor cells to sites of inflammation (Aiuti et al., 
1997; Tchernychev et al., 2010), and controls cell migration in 
embryogenesis (Doitsidou et al., 2002; Raz and Mahabaleshwar, 2009). 
It has later been elucidated as a key player in angiogenesis, tumour 
development and metastasis (Murdoch, 2000). Hypoxic conditions up 
regulate the expression of CXCL12 within the core of a tumour and its 
receptor CXCR4 on infiltrating immune cells, endothelial cells and 
metastasising malignant cells (Schioppa et al., 2003). It is potentially an 
attractive therapeutic target for cancer treatment as its sole ligand 
CXCL12 interacts only with CXCR4 (Balkwill, 2004). Following its 
discovered involvement in HIV infection, there was a boom in production 
of receptor targeted molecular inhibitors and antibodies, that have since 
been readily available for experimentation in cancer models and clinical 
trials (Domanska et al., 2013). 
 
CXCR4 is expressed by a number of different malignant cells, for 
example in haematopoietic, glioma, colorectal, prostate, renal (Burger 
and Kipps, 2006), lung and breast cancers, and generally not expressed 
by their normal counterparts. Integrin-mediated cell adhesion is 
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increased by CXCR4 signalling. It has been suggested that CXCR4 
induced integrin signalling may confer the development of resistance to 
chemotherapeutic agents in lung cancers (Hartmann et al., 2005).  
 
1.3.3.1. CXCR4 expression in the early transformation events of 
ovarian cancer 
 
Immortalised ovarian surface epithelial cells that spontaneously 
transformed when grown in soft agar acquired TP53 mutations typical of 
those seen in HGSC, and also genomic amplification of the CXCR4 
receptor (Archibald et al., 2012). The transformed cells demonstrated 
increased CXCR4 dependent growth and migration, and showed 
epigenetic silencing of the chemokine receptor’s ligand CXCL12. This 
work suggests that increased CXCR4 expression on ovarian surface 
epithelial cells may be important in the early stages of their 
transformation to a malignant phenotype. Their silencing of CXCL12 
expression may sensitise their evasion potential from the ovarian 
epithelium into the chemokine rich peritoneal fluids. Given the recent 
advances in our understanding of the origins of HGSC, it would be 
interesting to investigate the amplification of CXCR4 in the early 
transformation events of the surface epithelial cells of the fimbria 
(section 1.1.1.1). 
 
1.3.3.2. CXCR4 expression in ovarian cancer cell lines 
 
Supporting this work, Son and colleagues recently studied a panel of 
ovarian cancer cell lines covering wild type, null and mutant TP53 
statuses. Cell lines with low level expression or mutated TP53 showed 
increased mRNA (messenger ribonucleic acid) expression of CXCR4 
and pro-inflammatory cytokines including TNF-α (Son et al., 2012). 
Either restoring TP53 status in the null or mutant cell lines, or 
stabilisation of the protein with Nutlin-3 in the low expressors, reduced 
NF-κB promoter activity and expression of the pro-inflammatory 
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cytokines. This together with the work of Archibald and colleagues 
(Archibald et al., 2012) suggests that the TP53 mutations typical of 
HGSC may drive cancer-associated inflammation. 
 
The ovarian cancer cell lines IGROV1 and CAOV-3 migrated towards a 
CXCL12 chemokine gradient (Scotton et al., 2001). Activation of the 
receptor sent signals through the MAP kinase and PI3 kinase pathways, 
promoting cell adhesion, survival, proliferation and invasion, (Kulbe et 
al., 2005; Kulbe et al., 2007; Scotton et al., 2002), which were inhibited 
by the CXCR4 antagonist AMD3100 (Scotton et al., 2002). 
 
1.3.3.3. CXCR4 expression in ovarian cancer metastasis and its 
clinical significance 
 
When the SKOV3 ovarian cancer cells were transfected with CXCR4, 
they showed increased metastasis to the peritoneum in in vivo models 
compared to controls (Balkwill, 2004). In a xenograft in vivo model of 
HGSC, short hairpin RNA (shRNA) interference of the receptor reduced 
tumour burden and delayed the angiogenic switch. However it did not 
alter tumour cell attachment to the bowel mesentery (Leinster et al., 
2012). The nature of ovarian cancer metastasis may exclude the 
processes of intra- and extravasation, unlike other cancers such as 
breast cancer (Muller et al., 2001). This might therefore suggest that 
CXCR4 expression does not play such a pivotal role in targeting ovarian 
cancer cells to the peritoneum per se, but becomes of greater 
importance for the development of metastases once in situ. This is 
perhaps supported by a recent report that investigated copy number 
variations in matched ovarian primary tumours and peritoneal 
metastases of nine patients (Malek et al., 2011). Gene set enrichment 
analysis highlighted a role for the JAK/STAT and cytokine signalling 
pathways when comparing the two groups. For example many CC 
cytokines and their receptors were deleted in the primary tumours, but 
expressed in the metastases. Conversely, many CXC chemokines, 
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including CXCL12 were amplified in the primary tumour but not in the 
metastases. These data were validated with that of the TCGA (Cancer 
Genome Atlas Research, 2011) and this highlighted the concerning 
issue that the majority of chemotherapy targets are amplified in the 
primary tumours but not in the metastases. Given that the major clinical 
problem of ovarian cancer is the spread to the peritoneum, it is important 
to identify druggable targets amplified in the metastases. 
 
Both paracrine and autocrine signalling are responsible for the 
downstream effects of CXCL12. CXCL12 is largely sourced from the 
surrounding stroma but is, in fact, also produced by the malignant cells 
(Kajiyama et al., 2008b; Kulbe et al., 2007). Immunohistochemical 
analysis of ovarian cancer biopsies showed CXCL12 expression in the 
malignant cells and a weak expression in the surrounding stromal 
fibroblasts (Scotton et al., 2002). In a more recent study, 20% of a cohort 
of 289 ovarian cancer biopsies expressed CXCL12 in the cytoplasm of 
the tumour cells (Popple et al., 2012). 69% of the biopsies were serous 
carcinomas. Increased levels of CXCL12 in this cohort correlated with a 
poor overall patient survival, and patient biopsies negative for CXCL12 
benefited a 51-month survival advantage. 
 
1.3.3.4. Inhibition of CXCR4 signalling 
 
AMD3100 is a small molecular inhibitor of CXCR4 and was identified as 
a useful agent for HIV-1 entry blockade (Donzella et al., 1998). It is also 
used to mobilise hematopoietic progenitor cells for transplants (Liles et 
al., 2003). As a potential cancer treatment, AMD3100 has been 
predominantly assessed for its efficacy in acute promyelocytic leukemia. 
It was shown to sensitise these malignant cells to chemotherapeutic 
agents through mobilising them away from the protective 
microenvironment of the bone marrow and into the peripheral blood 
stream (Nervi et al., 2009). In solid cancers not only has the inhibitor 
been shown to minimise invasion and tumour burden (Domanska et al., 
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2013), it has also been utilised as an imaging tool. Coupled with the 
radioactive Copper-64, it offered its potential for visualising solid tumours 
expressing CXCR4 in positron emission tomography (PET) scans 
(Jacobson et al., 2009). In December 2008, the Food and Drug 
Administration (FDA) agency approved the use of the inhibitor for 
medical purposes (Pusic and DiPersio, 2010). In a recent publication 
Salomonnson and colleagues showed that in a combination therapy with 
cisplatin, AMD3100 decreased tumour burden in an in vivo model of 
ovarian cancer greater than either treatment alone (Salomonnson et al., 
2013). 
 
Infiltration of immune cells and the expression of inflammatory mediators 
within the microenvironment promote tumour growth and metastasis. 
Evidence suggests that intervention of the molecular pathways that 
regulate tumour-associated inflammation can increase patient survival 
and improve their response to chemotherapy. The aims of this thesis 
were to study these processes in HGSC. The following sections of this 
review discuss available experimental models of HGSC with a particular 
focus on 3-dimensional (3D) cell culture assays. 
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1.4. Models of HGSC 
 
1.4.1. In vitro models of human HGSC ovarian cancer 
 
1.4.1.1. Cell line models of HGSC ovarian cancer 
 
The subtype of ovarian cancer under question (section 1.1) must be 
reflected in the models we use to study the disease. Experiments on cell 
lines often formulate baseline ideas and hypotheses that are later tested 
in animal models and clinical trials. In recent years there has been huge 
emphasis on short tandem repeat (STR) profiling of cell lines due to 
identified discrepancies within and between laboratory cell line banks. 
Therefore researchers need to employ extra caution when working with 
these models. Also commonly used cell lines were established and 
characterised before the detailed study of cancer genomes revealed 
specific genetic types and subtypes.  
 
In respect of this Domcke and colleagues recently evaluated the 
genomic profiles of 47 ovarian cancer cell lines from the Broad-Novartis 
Cell Line Encyclopedia with those of approximately 500 HGSC ovarian 
cancer biopsies studied in the TCGA (Domcke et al., 2013). The cell 
lines were ranked by their resemblance to the HGSC ovarian cancer 
biopsies, notably revealing that the SKOV3, A2780 and IGROV1 ovarian 
cancer cells that were originally thought to be HGSC cell lines, are not 
representative of HGSC tumours at all. The strength of the resemblance 
was based upon the presence of a TP53 mutation, the absence of other 
subtype related mutations, a low frequency of non-synonymous 
mutations and a correlation between chromosomal copy numbers. It is 
concerning that these cell lines in particular are amongst those that have 
been most frequently cited in publications. 
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Later work by Anglesio and colleagues (Anglesio et al., 2013) reported 
the use of an established calculator of subtype prediction (COSP) 
algorithm (Kalloger et al., 2011) to create a reliable panel of CCC cell 
lines from 32 tested lines. The group assessed the expression of nine 
markers by immunohistochemistry, the presence of common mutations, 
the chromosomal copy number variations and the transcriptomic profiles 
of the 32 cell lines. ARID1A mutations typical of CCC produce a 
truncated protein, which cannot be detected by immunohistochemistry. 
Most of the cell lines previously annotated as CCC were negative for this 
marker by immunohistochemistry and closely resembled primary 
tumours of CCC. For the interests of this thesis the TOV21G cells were 
representative of CCC, but the RMG1 cells line were unclassified by this 
group’s methods. Many cell lines with TP53 mutations previously used to 
model HGSC also had ARID1A mutations, with an 
immunohistochemistry profile of endometrioid carcinomas. This was true 
for the IGROV1 cell line. Consistent with the work of Domcke et al 
(Domcke et al., 2013), Anglesio and colleagues also classified the 
SKOV3 cells as non-HGSC, owing to their mutations in ARID1A and 
PIK3CA, despite their positive expression for HGSC related 
immunohistochemistry markers (Anglesio et al., 2013). The message of 
this work is that the subtype of ovarian cancer that cell lines represent 
must be clearly defined at the onset of any experiments. Without this 
inaccurate conclusions regarding targeted therapy efficacies will be 
relayed through translational studies and clinical trials. What is also 
important to consider is that cell lines cultured particularly in 2D (2-
dimensional) are subject to adverse changes through a lack of normal 
cell-cell and cell-matrix interactions. 
 
Recently optimised methods were established to isolate and culture 
epithelial ovarian cancer cells from the ascites and solid tumours with a 
91% success rate (O Donnell et al., 2014). These primary cultures were 
positive for ovarian cancer cell markers such as pan-cytokeratin, 
EpCam, CA-125 and vimentin. Using primary cell cultures such as this 
will better represent the heterogenecity of ovarian cancer and also 
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allows the performance of experimental assays that could not otherwise 
be reproduced on paraffin or frozen tissue sections. 
 
1.4.1.2. Ovarian cancer cell spheroid formation in vitro 
 
One frequently used in vitro 3D model for ovarian cancer is spheroid 
formation (Lengyel et al., 2013). The drop assay allows gravity to bring 
ovarian cancer cells together for adhesion and compaction into spheroid 
aggregates (Kelm et al., 2003). This is appropriate for modelling the 
aggregates that are free-floating in the peritoneal cavity of HGSC 
patients. However it is unknown whether these have detached from the 
primary tumour as multicellular aggregates or whether they have formed 
from single cells in the peritoneal fluids (Lengyel, 2010; Pease et al., 
2012). A clustering antibody for αVβ1 integrin and its ligand fibronectin 
encouraged spheroid development. (Casey et al., 2001). Some cell lines 
are unable to form spheroids, and this is due to defects in actinomysin 
contractility. Cell lines that do grow into spheroids have myofibroblast 
characteristics with increased expression of TGFβ1 regulated genes 
(Sodek et al., 2009). Cell lines that form more compact spheroids also 
have a greater ability to invade collagen matrices. Recently fluidic forces 
that would naturally be experienced by metastasising ovarian cancer 
aggregates increased expression of EGF and drove an epithelial–
mesenchymal transition (EMT) (Rizvi et al., 2013), perhaps making the 
cells more viable for survival in spheroid formation. EMT is a process 
that normally occurs during embryonic development, where a loss of 
epithelial intercellular adhesion and polarisation transitions the cell to a 
migratory mesenchymal state (Wan et al., 2013). Cancer cells utilise this 
transition for invasion and metastasis, supporting the development of 
chemoresistance. Regulated by the transcription factors Slug, Snail and 
Twist, EMT was also driven in a pancreatic cancer mouse model by 
inflammation (Rhim et al., 2012). Dexamethasone treatment reduced 
EMT and dissemination of the tumour. However EMT is a phenomenon 
under huge debate, since it is especially difficult to capture cells in transit 
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particularly in clinical samples. Rizvi and colleagues observed a 
reduction in E-Cadherin expression in ovarian cancer spheroids, which 
is characteristic of EMT (Rizvi et al., 2013), but not so typical in the 
development of chemoresistance in the aggregates (Green et al., 2004). 
 
Multicellular aggregates of ovarian cancer express matrix interacting 
receptors that prepare them for metastasis to the peritoneum and 
omentum. For example, they express α2, α5 and α6β1 integrins (Figure 1-
2) that bind to collagen type IV, fibronectin and laminin respectively 
(Lengyel, 2010). These are the most abundant matrix proteins of the 
sub-mesothelial layer (Witz et al., 2001). Before interacting with these 
underlying matrix proteins, the ovarian cancer cells must negotiate the 
protective mesothelial cell layer. MMP2 expression in the malignant cells 
potentiates adhesion to the mesothelial layer through proteolysis of the 
ECM proteins fibronectin and vitronectin. These cleavage reactions 
expose the binding sites for αVβ1 and αVβ3 integrins on the surface of 
the malignant cells (Kenny et al., 2008). 
 
1.4.2. Multicellular culture models of HGSC ovarian cancer 
 
1.4.2.1. 2D multicellular culture models 
 
Early in vitro models incorporating cell-cell interactions involved culturing 
ovarian cancer cells on 2D mesothelial cell monolayers (Lengyel et al., 
2013) (Figure 1-3a). For example such a model was used to describe 
the contractile nature of mesothelial cells to give clearance of the sub-
mesothelial matrix to invading ovarian cancer spheroids (Figure 1-2) 
(Iwanicki et al., 2011). Iwanicki and colleagues used time-lapse video 
microscopy of fluorescently labelled ovarian cancer spheroids and 
immortalised mesothelial cells from the lung mesothelium to 
demonstrate that the ovarian cancer cells spread on the surface of the 
mesothelial cells before penetrating beneath them. This observed 
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localised de-adhesion of the mesothelial cells occurred when they were 
cultured on glass or fibronectin-coated polyacrylamide gels. Short-
interfering RNAs targeting myosin II expression in the ovarian cancer 
cells reduced mesothelial cell clearance. Talin I dependent interactions 
connected the myosin network to the fibronectin receptor αVβ1 integrin. 
Antibodies blocking the function of this receptor also reduced 
mesothelial cell clearance. Fluorescently labelled fibronectin fibrils on 
the surface of the mesothelial layer revealed the detachment and 
reorganisation of these fibrils around invading spheroids. Interactions 
between the myosin network, talin I and αVβ1 integrin were all required 
to exert the maximal strain energy on the extracellular matrix as 
determined by displacement of fluorescent beads within the matrix. 
Collectively this work identified molecular mechanisms relevant to 
ovarian cancer metastasis to the peritoneum. However further work is 
required to investigate the cues that drive migration of the mesothelial 
cells away from the invading ovarian cancer cells. 
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Figure 1-2 Ovarian cancer cell aggregate development and interactions with 
HPMC layers. 
Spheroid development and compaction is promoted by TGFβ stimulated epithelial-
mesenchymal transition (EMT) and actinomysin contractility (Sodek et al., 2009). 
Ovarian cancer cell aggregates express the β1 integrin receptors (α2, αV and α6) for 
interactions with the extracellular matrix (ECM) proteins collagen (Col) IV, fibronectin 
(FN) and laminin (Lam) in the sub-HPMC (human primary mesothelial cell) 
compartment (Lengyel, 2010). Spheroids induce localised clearance (yellow arrows) of 
the HPMCs for invasion into the ECM (Iwanicki et al., 2011). 
 
 
 
 
 
Chapter 1 - Introduction 
 60 
1.4.2.2. 3D multicellular culture models 
 
Despite our increasing awareness of the impact of a 3D matrix 
microenvironment on tumour cell survival and differentiation (Levental et 
al., 2009), the repertoire of 3D organotypic models that have been 
utilised for studies into ovarian cancer tumourigenesis has been rather 
limited. Some earlier 3D organotypic models have co-cultured murine 
embryonic fibroblasts with human ovarian cancer cells in a collagen 
matrix (Guruswamy et al., 2001). These models have often been raised 
on a metal mesh platform within a culture dish or well to generate an air-
medium interface (Gregoire et al., 1998) (Figure 1-3b). This not only 
mixed cells of different species origin, but also more closely resembled a 
skin carcinogenesis model with an air-medium interface than an ovarian 
cancer model that should have exposure to medium recapitulating the 
peritoneal fluids. 
 
More recently the work of Kenny and colleagues (Kenny et al., 2007) 
advanced the complexity of 3D in vitro models available for research into 
ovarian cancer metastasis. Human primary fibroblasts (HPFs) and 
mesothelial cells (HPMCs) isolated from human omentum removed at 
surgery, were co-cultured in and on the surface of a collagen I matrix 
respectively (Figure 1-3c). This omentum-mimicking microenvironment 
formed the substrate on which to culture ovarian cancer cells to monitor 
their stromal interactions. 
 
Cai et al (Cai et al., 2012) used the 3D omental model established by 
Kenny and colleagues to show the importance of cell-cell interactions in 
the stimulation of MMP2 expression in the omental fibroblasts. They 
illustrated the role of TGFβ1 signalling in omental fibroblast activation 
and measured the invasion of HGSC cells through the ECM. 
 
Subsequent to its establishment, the Kenny et al 3D omental model has 
further offered insights into the role of α5 integrins (Kenny et al., 2008; 
Sawada et al., 2008) in the early adhesion events of ovarian cancer 
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metastasis. Undoubtedly there is a void in our understanding of these 
early events due to the absence of accurate genetic mouse models and 
the late stage presentation of patients in the clinic. However in none of 
the studies carried out thus far has anyone ventured to maintain these 
cultures for longer time periods than five days.  
 
The Kenny et al 3D omental model also offered the opportunity to 
experiment with novel therapies. Zillhardt et al (Zillhardt et al., 2011) 
utilised the 3D omental model to test the effect of a clinically available 
oral multikinase inhibitor of c-Met and VEGFR2, which reduced the 
adhesion and invasion of the ovarian cancer cell line SKOV3ip1. 
However this work in particular highlighted one of the limitations of the 
model as it currently stands. VEGFR2 is a regulator of angiogenesis, the 
synthesis of new blood vessels. The study described by Zilhardt et al 
could not effectively test the inhibition of VEGFR2 in the 3D omental 
model, due to the absence of endothelial cells in the co-culture system. 
The potential to introduce further cell types to the model provides huge 
opportunity to develop its complexity and increase its likeness to the 
microenvironment of the human omentum as it is in situ. 
 
1.4.3. Prospects for further developing 3D cell culture models of 
ovarian cancer 
 
The tumour microenvironment of ovarian cancer includes many cell 
types including adipocytes (Nieman et al., 2011). The abundance of 
lipids serves as a fuel source for ovarian cancer cell proliferation and 
adipokines are direct drivers of cancer cell invasion. Recently a 3D cell 
culture model of breast cancer has been described incorporating 
adipose stem cells (ASCs) (Delort et al., 2013). Culturing the ASCs with 
fibroblasts for three weeks led to the development of an adipose 
substrate. Breast cancer cells were then cultured on the surface for a 
week before being raised to an air-medium interface for a further two 
weeks. In comparison with keratinocyte and non-malignant mammary 
Chapter 1 - Introduction 
 62 
epithelial control cell lines, the breast cancer cells induced differentiation 
of the ASCs to adipocytes as measured by oil red staining. Following 
culture on the model, the surface epithelial cells were subjected to a 
thermolysin treatment to selectively remove them from the surface of the 
substrate. Quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) analysis on the epithelial cells revealed a role for the 
adipose microenvironment in promoting cell cycle, anti-apoptotic, 
angiogenesis and cytokine signalling pathways (Delort et al., 2013). 
Despite the microenvironment having no significant effect on aromatase 
expression, it was postulated that the increase in inflammatory cytokines 
TNF-α and IL-6 may stimulate aromatase activity leading to promoted 
androgen conversion to estrogen. This was hypothesised because the 
basal breast cancer cell line MDA-MB-231 that is ER negative, was less 
responsive to the adipose microenvironment than the luminal ER 
positive cell line MCF7. The MCF7 cells demonstrated increased 
invasive capacity in the 3D model. Kenny and colleagues are currently 
working to introduce adipocytes to their previously established 3D 
omental model of ovarian cancer (Figure 1-3d) (communications with 
Prof Ernst Lengyel). 
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Figure 1-3 The development of 3D cell culture models of ovarian cancer. 
a) Early 2D cell culture models involved culturing ovarian cancer cells on mesothelial 
cell layers (Lengyel et al., 2013). b) Early organotypic models cultured ovarian cancer 
cells on raised fibroblast embedded collagen gels (Gregoire et al., 1998). c) The most 
advanced current 3D cell culture model mimics ovarian cancer metastasis to the 
omentum and includes the growth of primary mesothelial cells and fibroblasts on the 
surface and within a collagen matrix respectively (Kenny et al., 2007). d) Developing 
3D models of ovarian cancer will involve introducing further cell types normally present 
within the ovarian cancer microenvironment including adipocytes, leukocytes, 
adipocyte (ASC) and mesenchymal (MSC) stem cells (Lengyel et al., 2013; Nieman et 
al., 2011; Touboul et al., 2013). 
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Instead of reassembling an artificial tumour microenvironment methods 
have been employed involving ex vivo tissue explant cultures. Kahn and 
colleagues maintained murine ex vivo omentum cultures for ten days, 
and demonstrated the potential for human ovarian cancer cells to 
colonise areas of the tissue rich in inflammatory cells and proliferate 
(Khan et al., 2010b). More recently human ovarian cancer cell line 
spheroids adhered to and infiltrated a human amniotic membrane 
scaffold over a course of 72 hours (Touboul et al., 2013). This 
demonstrated enhanced interactions with mesenchymal stem cells, 
mediated by IL-6 signalling. The limitations of such ex vivo culture 
models do however lie in the duration that they can be maintained in the 
absence of a blood supply and the variability of microenvironmental 
elements between tissue explants (Lengyel et al., 2013). 
 
The inflammatory infiltrate in ovarian cancer is yet to be modelled in a 
3D cell culture system (Lengyel et al., 2013) (Figure 1-3d). A newly 
improvised breast cancer model co-cultured tumour spheroids of the 
MDA-MB-231 basal cell line with in vitro polarised peripheral blood 
derived monocytes (PBMCs). This work demonstrated that tumour cell 
conditioned medium educated the PBMCs to stimulate the invasive 
capacity of the breast cancer cell spheroids, but these PMBCs also 
retained the ability to respond to tumour antigen targeted phagocytosis 
cues (Grugan et al., 2012). Therefore the influx of infiltrating 
macrophages in the tumour microenvironment could potentially be 
monopolised for their maintained tumouricidal activity with tumour 
antigen targeted monoclonal antibody therapies. The impact of the 
immune cells on ovarian cancer progression is well documented (section 
1.2), and a 3D cell culture model mimicking this could further delineate 
their multivariate interactions within the metastatic microenvironment. 
Ultimately the aim for the development of in vitro models of human 
ovarian cancer is to incorporate all components of the tumour 
microenvironment (Figure 1-3d), and this is the long-term endeavour of 
the newly established CANBUILD project team in the Balkwill laboratory 
of Barts Cancer Institute, London (YouTube video web reference). 
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1.4.4. Animal models of HGSC ovarian cancer 
 
1.4.4.1. Xenograft models 
 
Modelling metastasis for most tumour types necessitates tumour cell 
entry into a vascular or lymphatic system, and the development of 
metastases in distant organs. This can only be reproduced in animal 
models. The nature of ovarian cancer metastasis however removes the 
requirement to recreate tumour cell intra- and extravasation. Most 
ovarian cancer cells are thought to metastasise via the ascitic fluids to 
exposed surfaces of the peritoneal cavity, where they invade to the 
surrounding organs and eventually to the lymphatic vasculature. 
Therefore mouse models of late stage ovarian cancer can be created by 
intraperitoneal injection of malignant cells to generate xenografts. The 
first xenograft model was developed approximately thirty years ago with 
the drug resistant human ovarian cancer cell line NIH-OVCAR-3 
(Hamilton et al., 1984). In more recent times patient-derived aggregates 
of fibroblasts, tumour and immune cells were engrafted in the ovary, 
omentum, pancreas and liver of intraperitoneal injected mice. These 
later developed ascites and corresponding increments in CA-125 levels 
both in the peritoneal fluids and serum (Bankert et al., 2011), however 
the patient-derived cells did not survive for long. Unfortunately, xenograft 
models require the use of mouse strains with an impaired adaptive 
immune system to prevent xenograft rejection. This limits investigating 
the role of immunity and other microenvironment interactions in tumour 
progression. 
 
1.4.4.2. Syngeneic mouse models 
 
Mouse ovarian surface epithelial cells (MOSECs) were isolated by 
gentle trypsinisation of the ovaries from five adult C57BL/6 mice (Roby 
et al., 2000). These isolated cells were transformed by more than twenty 
passages in vitro in the presence of EGF. The ID8 cells were one of ten 
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clones established from these MOSECs. Intraperitoneal injection of the 
ID8 cells in immunocompetent mice caused tumour growth throughout 
the peritoneal cavity including the omentum, and the production of 
ascites. However this syngeneic model of ovarian cancer was not 
representative of HGSC since the ID8 cells were wild type for TP53 
(unpublished data). 
 
1.4.4.3. Genetically engineered mouse models 
 
At the beginning of the work for this thesis there was no genetically 
engineered mouse model available that displayed true HGSC 
characteristics, including high rates of TP53 mutations and genomic 
instability (Cancer Genome Atlas Research, 2011). The existence of 
such a model will greatly benefit research into the early development 
stages of HGSC ovarian cancer. Generating models has previously 
been problematic due to difficulties finding the precursor lesions of 
HGSC and a lack of tissue specific promoters.  
 
The first transgenic mouse model of ovarian cancer was generated 
using expression of the viral SV40 Tag (Simian virus 40 T antigen) 
protein under the promoter region of the Müllerian inhibiting substance 
receptor (MISR) type II gene (Connolly et al., 2003). The MISRII gene is 
expressed and involved in the development of the female reproductive 
tract and is also expressed in ovarian cancer (Masiakos et al., 1999). 
The SV40 TAg protein transforms cells through perturbing the function of 
tumour-suppressors such as TP53 and Retinoblastoma (Rb) protein 
(DeCaprio et al., 1988; Garson et al., 2012; Hahn et al., 1999; Kierstead 
and Tevethia, 1993). The transgenic mice in this model developed 
ovarian epithelial tumours that gave rise to ascites and metastases in 
the peritoneum. However the mice developed tumours too quickly and 
did not survive long. 
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To remove the need for tissue specific promoters, cells can be 
genetically manipulated with viral vector transported Cre recombinase 
inserted transgenes (Wang et al., 1996). These can be injected directly 
into the tissue of preference. However different cell types can have 
variable infection efficiencies and the virus can stimulate an immune 
response (Garson et al., 2012). Recently transgenic mice expressing 
Cre recombinase under the MISRII promoter were crossed with 
transgenic mice bearing LoxP sites flanking the genes Dicer and PTEN 
(phosphatase and tensin homolog). The resultant mouse was a double 
knock–out for the miRNA synthesis gene and the negative regulator of 
PI3K gene respectively. All the mice developed tumours in the fallopian 
tube that closely resembled HGSC seen in patients (Kim et al., 2012). 
The tumours generated ascites, peritoneal metastases, and elevated 
levels of CA-125; currently the most reliable serum marker of HGSC 
(Bast, 2003). Deregulated PI3K pathway activation is frequent (45% of 
cases) in HGSC, however PTEN deletion is not so, occurring in 2% of 
cases (Cancer Genome Atlas Research, 2011). In addition, despite low 
expression levels of the TP53 protein, the tumour in this model did not 
have a TP53 mutation. Kim and colleagues argue that the role of TP53 
mutations as drivers of HGSC tumourigenesis is unknown (Kim et al., 
2012). Nevertheless we cannot deny the 96% frequency rate of these 
mutations in this disease (Cancer Genome Atlas Research, 2011), and 
therefore the current gap in the field for a more appropriate genetic 
mouse model of HGSC. 
 
The TCGA provides publically available exomic sequencing data for 
more than 500 HGSC ovarian tumours (Cancer Genome Atlas 
Research, 2011). Interrogation of these data and an shRNA screen of 25 
ovarian cancer cell lines identified PAX8 (paired box gene 8) as an 
essential gene for cell survival (Cheung et al., 2011). Under normal 
circumstances PAX8 is a transcription factor involved in the 
organogenesis of the thyroid, kidney and müllerian system, whereby 
expression in the latter is specifically in the epithelial cells of the fimbria 
(Bowen et al., 2007). The Drapkin laboratory of the Harvard Cancer 
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Centre, United States (US) have recently developed a genetic mouse 
model of HGSC (Perets et al., 2013). The group first generated a model 
that used a reverse tetracycline-controlled transactivator under the 
promoter of PAX8 to express Cre-recombinase. The expression of a 
LacZ transgene in this model confirmed specificity of the driver to the 
fallopian tube. This model was then crossed with models mutant for 
BRCA2 and TP53, and negative for PTEN. Following induced 
expression with doxycycline, the resultant models developed STICs in 
the fallopian tubes that were characterised by increased secretory cell 
proliferation, loss of polarity and structural abnormalities. The developing 
tumours metastasised to the ovaries and the peritoneum and expressed 
markers typical of HGSC, such as PAX2 and WT-1 (Wilms tumour 1). 
The tumours were also positive for nuclear TP53. Omental metastases 
were not any more frequent than those in other areas of the peritoneum. 
Interestingly however, the performance of oophorectomies following the 
induction of tumour development reduced peritoneal metastases, 
suggesting that hormones secreted by the ovaries are important for 
metastasis. A comparative genomic hybridisation array confirmed that 
the tumours had high genomic copy number alterations that correlated 
with those seen in the human TCGA data set. Colleagues in the Balkwill 
laboratory have been endeavouring to produce the same genetic mouse 
model (unpublished data). This mouse model represents and mimics 
HGSC as seen in human patients with far greater accuracy than any 
other that is currently available, and will be an essential tool for research 
particularly benefiting earlier detection of the disease. 
 
The value of mouse models here for research into HGSC cannot be 
negated, but like all models, they have their limitations. Despite the 
remarkable similarities between the mouse and human genome (Mural 
et al., 2002) there are unquestionably anatomical and biochemical 
differences between the two. The phenotype of murine models can be 
greatly affected by the method employed to generate the model, the 
productivity of potential heterozygotes, and the strain of the mouse used 
(Garson et al., 2012). Therefore this can affect the translation of animal 
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experiments to clinical trials. Results from mouse models ideally need to 
be complimented with human in vitro 3D model systems. 
 
The Drapkin animal model of HGSC was published very recently (Perets 
et al., 2013). Prior to this there were no animal models available that 
accurately represented HGSC. Therefore for the work of this thesis, the 
3D cell culture model mimicking HGSC metastasis to the omentum, 
established by Kenny and colleagues (Kenny et al., 2007) was 
constructed and developed. The model was used to investigate the role 
of the chemokine CXCL12 and macrophages in HGSC progression. 
Advancements to this model system will later support the drug discovery 
process for identifying novel therapies for HGSC treatment. 
 
 
Thesis aims 
 70 
Thesis aims 
 
I. Characterise the immune infiltrate of HGSC metastasis to the 
omentum. 
 
II. Establish and optimise a 3D primary cell culture model 
mimicking ovarian cancer metastasis to the omentum. 
 
III. Test the efficacy of a neutralising antibody targeting CXCL12 on 
the growth of ovarian cancer cell lines on the 3D omental model. 
 
IV. Validate the association between CXCL12 and ECM gene 
expression in HGSC omental metastasis. 
 
V. Investigate the effect of introducing an immune cell subtype to 
the pre-established 3D omental metastasis model.  
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Chapter 2 
2. Materials and Methods 
 
2.1. Cell culture 
 
The SKOV3ip1-cGFP (green fluorescent protein) human ovarian cancer 
cell line (a kind donation from Prof Ernst Lengyel, The University of 
Chicago), the PA1 human cancer cell line, and the human breast 
carcinoma cell line MCF7 were cultured in DMEM, High Glucose (4.5g/L) 
with L-Glutamine, (PAA, E15-810), 10% Fetal Bovine Serum (FBS; PAA, 
A15-104) and 1X Penicillin/Streptomycin (PS; PAA, P11-010, 100X). 
The AOCS1 (a kind donation from Prof. David Bowtell, Peter MacCallum 
Cancer Centre, Australia), TOV21G-GFP (kindly donated by Dr Michael 
Salako) and RMG1 human ovarian cancer cell lines, the ICRF27 human 
embryo fibroblasts (HEFs), and all the primary cells isolated were 
cultured in RPMI-1640 with L-Glutamine, (PAA, E15-840), 10% FBS, 
and 1X PS.  
 
The THP1 monocytic cell line were cultured in suspension in RPMI-1640 
with L-Glutamine, 10% FBS, 1X PS and 0.05mM β–mercaptoethanol 
(Sigma, M-6250). The THP1 cells were differentiated in 5ng/mL phorbol 
12-myristate 13-acetate (PMA) (Sigma, P-8139).  
 
PBMC-derived macrophages were differentiated in RPMI 1640, 
Glutamax I (Invitrogen, 61870), 10% FBS (HI/GI) (SAFC Biosciences, 
12006C), 1% PS (Invitrogen, 15140) and 100ng/mL macrophage colony-
stimulating factor M-CSF (R&D Systems, 216-MC). 
 
All cultures were kept under standard conditions at 37oC and 5% CO2. 
Adherent cells were passaged after washing in Dulbecco’s phosphate 
Chapter 2 – Materials and methods 
 72 
buffer solution (PBS) without Ca & Mg, (PAA, H15-002) and detachment 
with 0.1%/0.04% Trypsin-EDTA in PBS, (PAA, L11-003, 0.5%/0.2%). 
 
2.2. Human omental metastasis sample processing 
 
All human omentum samples were collected from surgery on ovarian 
cancer patients at St. Bartholomew’s hospital. All samples were taken 
under the guidelines of the Human Tissue Authority Act 2004 and only 
from patients whom had given prior consent under the Research Ethical 
Committee Project reference 10/H0304/14. Samples were transported in 
sterile PBS back to the laboratory. On arrival this PBS was centrifuged 
at 1500rpm for five minutes, and the pelleted cells were re-suspended in 
full medium and plated in a T75 flask, (Corning, 430641). Photographs 
of the samples in a 150mm dish petri dish (Corning, 430599) were taken 
before they were processed. In an additional 20mL of PBS, the tissue 
was cut with a scalpel to give an approximately 20mm x 20mm piece to 
fix in Formal Saline Solution (equivalent to 4% formaldehyde; Adams 
Healthcare, 416479) and be embedded in paraffin. Four 10mm x 10mm 
sections were cut each to be embedded in O.C.T. Compound, (Tissue-
Tek, 4583) and to prepare snap frozen samples. The tissue was stored 
in a bijoux and placed directly on to dry ice for snap freezing. OCT 
blocks and snap frozen samples were stored at -80oC. All human 
omentum samples were stored under the Barts Gynae Tissue Bank. The 
20mL PBS was centrifuged at 1500rpm for five minutes, and the pelleted 
cells were resuspended in full medium and plated in a T75 flask. 
 
2.3. Human primary fibroblast and mesothelial cell 
isolation 
 
The human omental tissue remaining from processing was cut into 
approximately 5mm x 5mm pieces and a maximum of 5mL volume of 
tissue was placed into a single 50mL centrifuge tube (Falcon, Becton 
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Dickinson). The number of centrifuge tubes required was dependent on 
the size of the tissue received. To each tube, 15mL of PBS was added 
to the tissue together with 15mL of 0.25%/0.1% Trypsin-EDTA. The 
tissue was then agitated at 200rpm at 37oC for 15 minutes. The solution 
was passed through a cell strainer and centrifuged at 1500rpm for five 
minutes. The pelleted cells were re-suspended in full medium and plated 
in a T75 flask. Cells were cultured for approximately four days, when 
10mL of fresh medium was added to each flask. After a total of one 
week in culture the entire medium was discarded and complete fresh 
medium was added to the cultures. The cells were further cultured until 
confluent. Note that on average I obtained primary tissue at a rate of 
approximately one every two weeks. 
 
2.4. Peripheral blood monocytic cell (PBMC) 
preparation 
 
PBMCs were prepared by density gradient centrifugation (Figure 2-1). 
Approximately 6-8mL of whole blood was diluted in PBS to a total 
volume of 25mL. The diluted blood was slowly layered on top of 15mL of 
Ficoll-Paque Plus (GE Healthcare, 17-1440-03) in a 50mL centrifuge 
tube (Falcon, Becton Dickinson). This was immediately centrifuged at 
2600rpm, 18oC for 20 minutes without braking. The supernatant was 
discarded to the level of 20mL in the centrifuge tube, and the ring of cells 
containing the PBMCs was gently aspirated and transferred to a new 
50mL centrifuge tube. The total volume of PBMCs was made to 50mL 
with PBS and centrifuged at 1600rpm, 18oC for ten minutes with 
maximal brake. The pelleted PBMCs were re-suspended in PBS and 
viable cells were counted with Trypan blue (Sigma, 93595) exclusion 
staining. The PBMCs were then seeded in 40mL of RPMI 1640 without 
supplements at a density of 2 x 106 cells/mL in T175 flasks. The 
monocyte population within the preparation were allowed to adhere for 
one hour at 37°C, 5% CO2 in a humidified incubator. The non-adherent 
cells were then removed and the monocytes were washed in RPMI 1640 
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before allowed to differentiate in complete medium supplemented with 
100ng/mL M-CSF (R&D Systems, 216-MC) for one week. 
 
PBMC-derived macrophages were dissociated from the flask before 
inclusion into the 3D omental model with accutase (PAA Laboratories, 
L11-007). The PBMC preparations were performed at MedImmune, 
Cambridge. 
 
 
 
Figure 2-1 Peripheral blood monocytic cell preparation by density gradient 
centrifugation. 
 
2.5. 3D Omental model construction 
 
A collagen mix was made up on ice constituting one part 10X RPMI-
1640 (powder dissolved in distilled water and Sodium Bicarbonate; 
Sigma, R6504), one part 0.33M Sodium Hydroxide, (Sigma, S-8045), 
one part FBS, and seven parts Rat-tail Collagen, Type 1, (BD 
Biosciences, 354236). 50µL of the mix was added to each well of a 24 
well Corning Transwell-Clear, plate 12 inserts, 3µm pore size, 6.5mm 
diameter, (Fisher, TKT-525-090R), and allowed to set for 30 minutes. 
50,000 HEFs or HPFs were mixed into 50µL of the collagen mix per well, 
and allowed to set on top of the pre-set layer. 500µL and 100µL of full 
medium were placed in the bottom and top part of the transwell 
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respectively and left in culture for 24 hours. 20,000 HPMCs were then 
seeded in 100µL of full medium to the top part of each transwell and left 
to culture for 24 hours. 50,000 ovarian cancer cells were then seeded in 
100µL of full medium to the top part of each transwell and left to culture 
for a further 24 hours. The top and bottom compartment of each 
transwell was washed in PBS, and full medium was placed in the bottom 
compartment and serum-free medium was placed in the top 
compartment to generate a serum concentration gradient. The models 
were left in culture for 14 days. 
 
2.6. Histopathology 
 
All human tissue and 3D model gels were fixed in formal saline solution 
(Adams Healthcare, 416479) at room temperature over night, and 
dehydrated in 30%, 50% and 70% Ethanol, (VWR, 10107EP) series. 
Samples were then stored in 70% Ethanol at 4oC. The samples were 
embedded in paraffin, sectioned and stained with hematoxylin and eosin 
by the staff in the Barts Cancer Institute (BCI) Histopathology 
department.   
 
2.7. Antibodies 
 
All human antibodies were monoclonal and of mouse origin unless 
indicated. 
 
Monoclonal Rabbit Anti-CD3, (Labvision, RM-9107-S) 
Anti-CD4, Clone 1F6, (Novocastra, NCL-CD4-368) 
Anti-CD68, Clone KP1 (Dako, M0814) 
Anti-CD8, Clone C8/144B, (Dako, M7103) 
Anti-CXCR4 (Fusin), Clone 44716, (R&D Systems, MAB172) 
Polyclonal Rabbit Anti-Pan-Cytokeratin (Dako, Z0622) 
Monoclonal Rabbit Anti-Cytokeratin 8, (Epitomics, 2032-1) 
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Polyclonal Rabbit Anti-GFP, (Invitrogen, A11122) 
Anti-Ki67 Antigen clone MIB-1 (Dako, M7240) 
Anti-Vimentin, (Dako, M0725) 
 
John McCafferty in Cambridge (under a Cancer Research UK Discovery 
committee grant) kindly provided a lead compound, single chain variable 
fragment antibody to neutralise CXCL12. The antibody was denoted as 
114_3H1. 
 
2.8. Flow cytometry 
 
For flow cytometry cells were detached with enzyme-free PBS-based 
cell dissociation buffer (Gibco, Invitrogen, 13151-014). 500,000 cells 
were pelleted and washed twice in buffer (PBS, 2% BSA (Albumin from 
bovine serum, Cohn V fraction, Sigma, A4503), 2mM EDTA (Ambion, 
AM9262)). All antibodies and dyes were diluted in buffer. The cells were 
incubated in the primary antibody for 45 minutes on ice. The cells were 
pelleted and washed twice again in buffer. The cells were then incubated 
in a secondary 546nm Alexa Fluor antibody (Invitrogen) diluted 1:1000 
for a further 45 minutes on ice. The cells were then pelleted and washed 
twice in buffer before incubation in Fixable Viability Dye eFluor 450 
(eBioscience, 65-0863). The cells were washed twice and finally fixed in 
20% Formal Saline Solution (Adams Healthcare, 416479). The cells 
were analysed on the FACS (fluorescence activated cell sorting) Calibur 
in the Barts Cancer Institute FACS suite, having compensated with FITC 
and PE labelled anti-mouse Ig Comp beads (BD Biosciences, 552843). 
These data were processed with the FlowJo 9.4.11 software. 
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2.9. Immunofluorescence 
 
Cells on 13mm glass cover slips were washed once in PBS and fixed in 
formal saline solution for one hour at room temperature. They were then 
washed twice with PBS and made permeable with a ten minute 
incubation in 0.5% Triton X-100 in PBS. The cells were washed twice 
again with PBS and once with PBS, 1% BSA, 2% FBS. This solution 
was further used to dilute all the antibodies. The cells were incubated 
with the primary antibody for one hour at room temperature.  
 
3D model paraffin embedded sections were prepared for 
immunofluorescence staining by initially deparaffinising and rehydrating 
the sections. This was carried out by two five-minute incubations in 
Xylene, (Fisher Scientific, X620017) followed by two two-minute 
incubations in each of 100%, 95%, 70% and 50% ethanol series. The 
sections were then washed twice for two minutes in distilled water. 
Boiling the sections for nine minutes in the microwave in a solution 
containing 2.5mL of Antigen Unmasking Solution, (Vector, H-3300) in 
250mL of distilled water was carried out for antigen retrieval. The 
sections were allowed to cool for 15 minutes and then washed three 
times for three minutes in PBS. A PAP hydrophobic pen was used to 
mark around the sections, and they were blocked for one hour at room 
temperature in a humidified chamber with 5% Goat Serum, (Invitrogen, 
Gibco, 16210072), 2.5% BSA, in PBS. After removal of the block 
solution, the sections were left to incubate in the primary antibodies 
diluted in the same blocking solution over night at 4oC.  
 
The cells or sections were washed three times with PBS and incubated 
with the appropriate secondary Alexa Fluor antibody (Invitrogen) diluted 
1:1000 for one hour at room temperature. The cells/sections were then 
washed twice with PBS and incubated in Hoechst diluted 1:200 for 30 
minutes at room temperature. The cells/sections were washed three 
times in PBS. The cover slips were dipped three times in distilled water 
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before mounting on to a frosted glass slide with 5µL Mowiol (1% Mowiol 
4.88, Calbiochem, 475904, one part Citifluor, Electron Microscopy 
Services, AF1-17970-25, one part distilled water, two parts 200mM Tris-
HCl (pH 8.5)). The cover slips were sealed with clear nail varnish and 
stored at 4oC before analysis. Sections were mounted with 10µL of 
Mowiol under a square glass cover slip and also stored at 4oC. The cells 
or sections were visualised and photographed on the Zeiss LSM 510 
META laser scanning confocal microscope in the Barts Cancer Institute 
imaging suite.  
 
2.10. Immunohistochemistry 
 
For immunohistochemistry, sections were deparaffinised and rehydrated 
as above. Sections were also incubated with the primary antibody over 
night at 4oC after antigen retrieval and blocked for one hour at room 
temperature. The sections were then washed three times in PBS, and 
incubated in the appropriate biotinylated secondary antibody diluted 
1:200 for 45 minutes; Goat Biotinylated Anti-Rabbit, (Vector, BA-1000), 
Goat Biotinylated Anti-Mouse, (Vector, BA-9200). The sections were 
then washed twice in PBS and endogenous peroxidase activity was 
blocked in a solution containing Methanol, (Fisher, M4000PC17) and 
Hydrogen peroxide 30% w/v, (Fisher, BPE2633-500) in a ratio 50:1 for 
20 minutes at room temperature. Vectastain ABC Kit, Standard, (Vector, 
PK-6100) was diluted by manufacturer’s instructions in 0.5M Sodium 
Chloride, (Sigma, S3014), and allowed to sit on ice for 30 minutes before 
use. Following blocking endogenous peroxidase activity, the sections 
were washed three times in PBS and were incubated in the ABC 
solution for 30 minutes at room temperature. One DAB tablet and one 
Tris/Peroxide tablet FAST 3,-3’-Diaminobenzidine Tablet, (Sigma, 
D4418) was dissolved in 15mL of distilled water, and after washing the 
sections three times in PBS, the sections were developed in the DAB 
solution for 3 – 5 minutes. The sections were then washed twice in 
distilled water and counterstained with Hematoxylin Solution, Gill No. 3, 
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(Sigma, GHS316) for 30 seconds. The sections were washed again in 
distilled water and dunked ten times in an acid differentiating solution of 
750µL Ammonium Hydroxide, (Sigma, A6899) in 250mL of distilled 
water. The sections were then dunked twenty times in 100% isobutanol, 
(Fisher, B/5100/PB17) and then incubated in isobutanol for four minutes, 
and twice in Xylene for two minutes at room temperature. The sections 
were mounted in General Purpose Grade DPX mounting medium, 
(Fisher, D/5319/05) under a square glass cover slip and left flat until dry. 
 
2.11. Automated Immunohistochemistry 
 
Sections of human omental tissue were stained for the 
immunohistochemical markers CD68, CD3, CD4 and CD8 using a Dako 
Autostainer Plus with a Super Sensitive Polymer-HRP DAB (Launch 
Diagnostics Ltd, QD430-XAKE). 
 
2.12. Immunohistochemistry Analysis 
 
Quantification of the tumour-infiltrating inflammatory cells and Ki67 
positive tumour cells was determined using the Ariol computer-controlled 
microscope and image analysis software (Leica Microsystems). 
 
2.13. Measurement of growth on the 3D omental model 
 
Confocal or bright field images were taken across the paraffin embedded 
centre cross-section of each gel at 20x magnification. On average two 
images were taken per immunofluorescence section and up to ten 
images were taken of each H & E stained section respectively. This was 
performed for triplicate gels in each treatment group. The images were 
made binary using the Image J software, and the area covered by any 
visible fibroblasts was omitted from the image. The software was then 
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used to calculate the area covered by the growing tumour cells in µm2. 
The average tumour cell area per image was calculated for each gel. 
This average tumour cell area was then used as a measure of tumour 
growth. 
 
2.14. Calculation of Invasion Index in the 3D omental 
model 
 
The average tumour cell area was calculated as described in section 
2.13. As previously published (Nystrom et al., 2005), the cells sitting on 
the surface of the gels were then omitted from the binary images within 
the Image J software. The software was used to analyse the number of 
invading particles greater than 1µm2. Measurements of the distance 
invaded by the particles were taken at three different points across the 
image and the average distance invaded was calculated. The product of 
the distance invaded, the number of invading particles and the total 
tumour cell area was calculated to give an Invasion Index. 
 
2.15. Enzyme-linked immunosorbent assay (ELISA) 
 
The assay procedure was carried out as advised by manufacturer’s 
instructions. All reagents were provided in the Quantikine Human 
CXCL12/SDF-1α ELISA kit, (R & D Systems, DSA00). 
 
2.16. Bioinformatics 
 
Protocols provided by Dr Probir Chakravarty at the London Research 
Institute who conducted all of the bioinformatics analyses for this thesis: 
 
The cohort of 285 ovarian cancer biopsies from the Australian Ovarian 
Cancer Study (AOCS) was selected as a second data set to confirm the 
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CXCL12 and extracellular matrix-remodelling link initially identified in the 
GSE 6008 and 3149 data set. The NCBI GEO (Gene Expression 
Omnibus web reference) accession number for the AOCS arrays was 
GSE 9891. Raw CEL files were downloaded and analysed using 
Bioconductor 1.9 (Gentleman et al., 2004) running on R 2.6.0 (Statistical 
computing text book reference). Probe set expression measures were 
calculated using the Affymetrix package's Robust Multichip Average 
(Gautier et al., 2004) default method. All samples were ranked on the 
normalised expression of CXCL12 [probe set ID: 209687_at] from 
highest expression to the lowest expression. The 50 highest CXCL12-
expressing biopsies were compared with the 50 lowest CXCL12-
expressing biopsies with an eBayes t-test from the limma package 
(Limma package text book reference). Amongst these two groups of 50 
biopsies, more than 95% of the biopsies were from HGSC, and the 
remaining biopsies were from endometrioid ovarian cancers. A total of 
5167 genes were differentially expressed between the two groups. Each 
gene was identified with multiple probes. Only probe sets with p values 
equal to or less than a multiple testing corrected (Multiple testing text 
book reference) p value of 0.05 were considered differentially 
expressed. There was no filtering based on fold change. 
 
The biological processes enriched in the 5167 differentially expressed 
genes were elucidated using the Metacore Pathway Analysis software 
(Metacore Analysis web reference). This process used a hyper-
geometric test to look for enrichment of genes within a gene list relative 
to a background list, which in this case were all genes present on the 
Affymetrix Human Genome U133 plus2 Array. 
 
Gene set signatures defining macrophage and other immune cell 
infiltrates (Abbas et al., 2005) were used to interrogate the differentially 
expressed genes associated with high levels of CXCL12. 
 
The function GeneSetTest from the limma package was used to assess 
whether the t-statistic from the high CXCL12 versus low CXCL12 
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comparison had a tendency to be associated with an up or down-
regulation of members of each immune cell signature. The function 
employed Wilcoxon's t test to generate p values. 
 
2.17. RNA Extraction 
 
Omental metastases samples were lysed in 1mL of lysis buffer and 10µL 
of β–mercaptoethanol (Sigma, M-6250). The tissue was homogenised in 
a gentle MACS tube (MACS Miltenyi Biotec, 130-093-236). The 
homogenised tissue was centrifuged at 1200rpm for five minutes, and 
the supernatant was centrifuged through a QIAShredder column 
(Qiagen, 79654) as advised by the manufacturer’s instructions.  
 
Two 3D omental model gels were lysed in 0.5mL of lysis buffer and 5µL 
of β–mercaptoethanol by vortexing.  
 
350µL of the lysed tissue samples or gels were mixed with an equal 
volume of 70% ethanol. The two solutions were mixed by pipetting, not 
vortexing. The total 700µL final volume was then transferred to a RNA 
binding column. The columns and lysis buffer are both provided in the 
RNeasy Mini kit (Qiagen, 74104). The remainder of the RNA extraction 
was performed as advised by the kit manufacturer’s instructions. An on-
column DNA digest was carried out using Qiagen’s RNase-Free DNase I 
set (Qiagen, 79254). The resultant concentration of the eluted RNA was 
measured on the Nanodrop. The RNA was then stored at -80oC. 
 
2.18. cDNA Synthesis 
 
Up to 2µg of RNA can be reverse transcribed in a single reaction, and 
the final reaction volume was made up to 20µL. A master mix of the 
appropriate volumes of the required reagents was generated containing 
1X concentration of first strand buffer (Invitrogen, 18064-014), 10mM 
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dithiothreitol (DTT) (Invitrogen, 18064-014), 0.5mM dNTP 
(deoxyribonucleotide triphosphate) (Promega, U1240), 12.5ng/µL 
random hexamers (Promega, C1181), 6.25 ng/µL oligo dT 15 mers 
(Promega, C1101), 1U/µL RNasin (Promega, N2111) and 5U/µL 
SuperScript II reverse transcriptase (Invitrogen, 18064-014). 8.75µL of 
master mix was added to 11.25µL of the diluted RNA in PCR tubes or a 
96 well PCR plate. The tubes or plate were placed in to a PCR machine 
and subjected to the program of one hold at 25oC for ten minutes, 42oC 
for 60 minutes, 90oC for five minutes, and then continuously held at 4oC. 
The cDNA was then stored at -20oC. 
 
2.19. TaqMan gene expression assays 
 
All TaqMan gene expression assays were purchased from Applied 
Biosystems, 4331182. 
 
IFNγ (Hs00989291_m1), TNFα (Hs01113624_g1), IL-12 
(Hs01073447_m1), IL-10 (Hs00961622_m1), IL1-β (Hs01555410_m1), 
IL-6 (Hs00985639_m1), IL-8 (Hs00174103_m1), VEGF 
(Hs00900055_m1), CXCL12 (Hs00171022_m1), ACTB 
(Hs01060665_g1), YWHAZ (Hs03044281_g1), TBP (Hs00427620_m1), 
HPRT1 (Hs02800695_m1), POSTN (Hs00170815_m1), VCN 
(Hs00171642_m1), LUM (Hs00929860_m1), DCN (Hs00754870_s1), 
COL6a3 (Hs00365098_m1), THBS1 (Hs00962908_m1). 
 
2.20. Quantitative Real-time PCR (qRT-PCR) 
 
The cDNA was diluted to a concentration that corresponded to 
0.625ng/µL of RNA. A master mix of the appropriate volumes of the 
required reagents was generated containing 1X TaqMan Universal PCR 
master mix (Applied Biosystems, 4318157), 1X target gene Fam labelled 
gene expression array (Applied Biosystems, 4331182) and 1X 18S Vic 
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labelled gene expression assay (Applied Biosystems) or water if the 
second Vic labelled primer was not required. 8µL of the diluted cDNA 
was added to 11.25µL of the master mix per reaction in a MicroAmp 
Fast Optical 96-well reaction plate (Applied Biosystems, 4346906). The 
plate was covered with MicroAmp optical adhesive film (Applied 
Biosystems, 4311971), and centrifuged at 1500rpm for one minute. The 
quantitative real-time PCR was then run on a StepOnePlus Real-Time 
PCR system (Applied Biosystems). 
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Chapter 3 
3. Characterising the tumour microenvironment  
of HGSC metastases 
 
3.1. The omentum 
 
The omentum is a fold in the peritoneal lining that overlies and physically 
protects the stomach and bowels. A monolayer of mesothelial cells 
creates a non-abrasive, non-adhesive surface between the adipose-rich, 
well-vascularised tissue of the omentum and the peritoneal cavity.  These 
mesothelial cells regulate the transfer of solutes between the two 
compartments, and elicit a defensive barrier against invading pathogens 
(Khan et al., 2010a). Just below the mesothelial cells there is a layer of 
fibroblasts, which are likely to contribute significantly to collagen and 
fibronectin synthesis in the sub-mesothelial compartment (Kenny et al., 
2007). The omentum is the area of the peritoneal cavity that is most 
dominantly colonised by disseminated HGSC cells during metastasis 
(Sehouli et al., 2009). At the beginning of the project a tissue bank of 
human omental metastases of HGSC was started and established, and 
the microenvironment of these metastatic deposits was characterised. 
 
3.2. Collection of human omental metastases specimens 
 
After 3-4 cycles of neoadjuvant chemotherapy, ovarian cancer patients 
undergo interval-debulking surgery to remove as much of the tumour as 
possible before the next cycle of chemotherapy. For the purpose of this 
thesis, I collected a total of 112 samples of human omentum removed 
during this surgery on ovarian cancer patients at St. Bartholomew’s 
hospital. For patient confidentiality purposes, each sample was given an 
anonymous code. The letter ‘G’ denoted this code followed by a number 
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representing the order that the samples were collected in. Therefore the 
first sample collected was given the anonymous G-code ‘G1,’ and this 
continued to the final sample collected which was G-coded ‘G112.’ During 
2011, 18 out of the total 44 (41%) samples collected that year were from 
HGSC patients. The majority of the patients had received on average 3 
cycles of carboplatin and paclitaxel before surgery. The majority of the 
patients were between 50 and 70 years of age. The samples ranged from 
relatively non-involved samples (Figure 3-1a) to predominantly metastatic 
disease (Figure 3-1b). Omenta with metastatic lesions are often termed 
‘omental cake,’ describing the increase in mass and density of the tissue 
as the malignant cells promote a huge stromal reaction and monopolise 
the normal adipose tissue. Approximately 20% of the samples I have 
collected were colonised by tumour deposits, as determined by the 
hematoxylin and eosin (H & E) stained sections (Figure 3-2 & Figure 3-3). 
Ten HGSC diseased samples were selected to investigate the degree of 
inflammatory infiltrate in these omental metastases. All of these ten 
patients had received chemotherapy. The relevant clinical information for 
these samples is recorded in Table 3-1. 
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Anon. 
Code 
Collection 
Date 
Age Histotype Grade Stage Treatment prior to 
biopsy 
G9 09/08/2010 59 SP HG 3 23/07/2010 – C & P 
G11 23/09/2010 70 SP HG 3 April 2010 - C 
G15 11/01/2011 73 SP HG 3 6 cycles: incomplete 
debulking 
G17 10/03/2011 62 SP HG 3  
G20 17/03/2011 46 SP HG 4 22/12/10 - C & P 
G33 28/06/2011 70 SP HG 3 03/2011 - C & P 
G34 30/06/2011 63 SP HG 3 22/2/11 – C & P. Post 
surgery C & T 07/2011. 
G73 21/08/2012 67 SP HG 3 4 cycles, first 3 
including AVASTIN 
G75 30/08/2012 47 SP HG 3  
G77 13/09/2012 66 SP HG 3  
 
Table 3-1 Clinical information for disease colonised biopsies 
Each patient was identified with an individual anonymous code as denoted in the first 
column. The table shows for each patient the date the biopsy was collected, the 
patient’s age at collection, and the histopathology (SP – Serous Papillary), grade (HG – 
High Grade) and stage of the disease. Information is also given about the treatment the 
patient received before the biopsy was taken. All the biopsies received were interval-
debulking specimens. If known, the date the patient started chemotherapy and the 
combination of chemotherapy (C – Carboplatin, P – Paclitaxel) they received is 
recorded. 
 
 
Chapter 3 – Human omental metastases 
 88 
 
 
Figure 3-1 Human omentum is removed during routine de-bulking surgery on 
ovarian cancer patients. 
Human omentum tissue samples were collected from ovarian cancer patients. Samples 
were taken for paraffin-embedded and frozen sections, snap freezing, and isolation of 
human primary mesothelial cells and fibroblasts. a) Normal omentum and b) diseased 
omentum. Tissue is photographed in a 150mm dish. 
 
Representative H & E images of non-involved (Figure 3-2) and diseased 
(Figure 3-3) omentum samples from four different patients are shown. 
The non-involved omental samples are largely adipose tissue and highly 
vascularised. They are covered in a monolayer of mesothelial cells as 
illustrated in Figure 3-2a. Figure 3-2b shows fibrous septa in the 
omentum that can be exploited by invading malignant cells following 
adhesion to the mesothelial cell surface to invade deeper into the tissue. 
Surrounding the tumour deposits within the omentum one can identify 
infiltrating leukocytes, as well as a dense fibroblastic and vascularised 
stroma that engulfs the normal adipose tissue (Figure 3-3a). Figure 3-3b 
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indicates the presence of calcium deposits known as psammoma bodies 
that are found within the stroma of the omental metastases. It has been 
suggested that the presence of these psammoma bodies, which is 
particularly characteristic of HGSC, is associated with an increased 
overall survival. It is argued that the formation of these psammoma 
bodies is a result of the deposition of crystallised calcium during 
apoptosis, and the production of osteopontin by infiltrating CD68 positive 
macrophages (Motohara et al., 2010). 
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Figure 3-2 Histopathology of normal human omentum. 
Hematoxylin and eosin histochemical staining of 5µm thick paraffin-embedded 
omentum sections. a) Normal omentum characterised by an abundance of adipose 
tissue (A) covered by a monolayer of mesothelial cells (MC) (indicated by arrow). b) 
Arrow indicates a fibrous septum passing through adipose tissue (A). 10x 
magnification, black bar = 200µm. 
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Figure 3-3 Histopathology of human omental metastases of HGSC.  
Hematoxylin and eosin histochemical staining of 5µm thick paraffin-embedded 
omentum sections. a) Diseased omentum characterised by the presence of tumour 
deposits (T) surrounded by a leukocyte infiltrate (L), blood vessels (BV) (indicated by 
arrow) and stroma (S). b) Arrows indicate the location of psammoma bodies, which are 
calcium deposits found in ovarian cancer metastases. 10x magnification, black bar = 
200µm. 
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3.3. Characterisation of the microenvironment of the 
omental metastases 
 
To develop an overview of immune cell infiltrate involvement in HGSC 
metastasis to the omentum, the localisation and the percentage of 
macrophages and T cells within the human omental metastatic lesions 
was investigated by immunohistochemistry analysis. The tumour 
deposits in the entire tissue section of the ten individual biopsies were 
scanned using a computer-operated microscope, and analysed with the 
Leica Ariol software. The number of positively stained cells was 
quantified and illustrated as a percentage of the total number of cells in 
the deposits determined by the hematoxylin nuclear counterstain. The 
quantification of the immune cell infiltrates was represented as a 
percentage so the number of immune cells to be introduced to the 3D 
omental model later in chapter 7 could be calculated. 
 
3.3.1. Predominant macrophage and T cell infitrate in human 
omental metastases 
 
CD3 positive T cells surrounded the tumour deposits within the omentum 
and CD68 positive macrophages infiltrated within the tumour deposits 
(Figure 3-4 & 3-5). T cells and macrophages were the most prominent 
inflammatory infiltrate in these omental metastases of those analysed 
here, comprising 9.4% and 11.3% of the tumour volume respectively 
(Figure 3-6). These data were included in a paper I co-authored 
(Leinster et al., 2012)(Appendix II). 
 
It has been shown that neutrophils can both promote tumour-associated 
angiogenesis (Fridlender et al., 2009; Polyak et al., 2009), but can also 
prevent tumour metastasis (Granot et al., 2011). Neutrophils were rarely 
observed in the human omental metastases of HGSC accounting for 
less than 1% of the total tumour volume (Leinster et al., 2012). 
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Figure 3-4 CD3 positive T cell infiltrate in human omental metastases of HGSC. 
Representative immunohistochemical staining of CD3 positive T cells in paraffin-
embedded sections of human omental metastases from two patients, G11 and G15. 
Human tonsil is used as a positive control. 10x magnification, black bar = 200µm. 
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Figure 3-5 CD68 positive macrophage infiltrate in human omental metastases of 
HGSC. 
Representative immunohistochemical staining of CD68 positive macrophages in 
paraffin-embedded sections of human omental metastases from two patients, G11 and 
G15. Human tonsil is used as a positive control. 10x magnification, black bar = 200µm. 
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Figure 3-6 Immune cell infiltrate in human omental metastases of HGSC.  
Quantification of the immune cell infiltrate in a) ten of the disease involved omentum. 
Tumour deposits within entire consecutive tissue sections of biopsies analysed by 
computer-aided microscopy and Leica Ariol software. Values are the percentage of 
positively stained cells in relation to the hematoxylin nuclear counterstain. b) Summary 
of data. All values represent mean and standard deviation. 
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3.3.2. The effect of the immune cell infiltrate on malignant 
epithelial cell proliferation 
 
Figure 3-7 shows the proliferating population of malignant epithelial and 
stromal cells in the human omental metastases detected by Ki67 
positivity. Using the Leica image analysis software the tumour deposit 
areas were carefully drawn around and selected (Figure 3-7). 
Undoubtedly stromal cells were found infiltrating the selected tumour 
deposit areas, however the majority of the cells within these areas were 
epithelial cells. Within these selected areas the software quantified the 
number of Ki67 positive and hematoxylin counterstained cells. The sum 
of these values was used determine the total number of cells within the 
designated areas. The percentage of Ki67 positive cells relative to the 
total cell count in these selected areas was then calculated for each 
omental specimen. To investigate the hypothesis that the balance of 
inflammatory cell infiltrate can influence tumour growth, the number of 
CD68 positive macrophages and CD3 positive T cells was correlated 
with the percentage of Ki67 positive cells in each of the omental 
metastases (Figure 3-8). 
 
Figure 3-8a shows there was a significant positive correlation between 
tumour-infiltrating macrophages and tumour cell proliferation, where as 
there was no significant correlation between T cell infiltrate and tumour 
cell proliferation (Figure 3-8b). The Shapiro-Wilk normality test defined 
both data sets to form parametric distributions and therefore the Pearson 
rank correlation coefficient was employed to test the strength of the 
correlations. This is therefore supportive of the argument that an infiltrate 
of macrophages in ovarian cancer can promote tumour growth and 
correlate with a poor patient outcome (Kryczek et al., 2007; Vaughan et 
al., 2011). 
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Figure 3-7 Ki67 positive cells in human omental metastases of HGSC. 
Representative immunohistochemical staining of Ki67 positive epithelial cells in 
paraffin-embedded sections of human omental metastases from two patients, G73 and 
G77. 10x magnification, black bar = 200µm. G73 Ariol view shows a screen shot from 
the Leica image analysis software when a zoom factor of 0.23 was used to view the 
section. Purple lines indicate the enclosed tumour deposit areas analysed. 
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Figure 3-8 The correlation between CD68 positive macrophage and CD3 positive 
T cell infiltrates with tumour cell proliferation in human omental metastases of 
HGSC. 
Correlation between Ki67 positive tumour cells with a) CD68 positive macrophages and 
b) CD3 positive T cells in disease involved omenta. Tumour deposits within entire 
tissue sections of biopsies analysed by computer-aided microscopy and Leica Ariol 
software. Values are the percentage of positively stained cells in relation to the 
hematoxylin nuclear counterstain. r = Pearson rank correlation coefficient. ns = not 
significant. 
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A further analysis was performed by Dr Steffen Boehm in the laboratory 
investigating the relationships between CD4 and CD8 positive T cell 
infiltrates with tumour cell proliferation in omental metastases of HGSC. 
This study utilised a tissue microarray (TMA) of the omental metastases 
that he established after my study was completed. Figures 3-9 and 3-10 
(images kindly provided by Dr Anne Montfort and Dr Steffen Boehm) 
illustrate the infiltrate of CD4 and CD8 positive T cells respectively 
surrounding the tumour deposits within the TMA cores of the biopsies. 
 
The same patient derived samples were analysed in the TMA for CD4 
and CD8 positive T cell infiltrates as with the whole sections studied for 
CD68 positive macrophages and CD3 positive T cells (Table 3-1). The 
Shapiro-Wilk normality test defined the data sets to form non-parametric 
distributions. Therefore the Spearman rank correlation coefficient was 
employed to test the strength of the correlations between CD4 (Figure 3-
11a) and CD8 (Figure 3-11b) positive T cell infiltrates with the 
percentage of Ki67 positive tumour cells. Of the specimens studied here 
in this chapter there were no significant correlations between either T 
cell subsets and tumour cell proliferation. 
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Figure 3-9 CD4 positive T cell infiltrate in human omental metastases of HGSC. 
Representative immunohistochemical staining of CD4 positive T cells in paraffin-
embedded tissue microarray cores of human omental metastases from two patients, 
G11 and G15. Human tonsil is used as a positive control. 10x magnification, black bar 
= 200µm. Images provided by Dr Anne Montfort and Dr Steffen Boehm. 
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Figure 3-10 CD8 positive T cell infiltrate in human omental metastases of HGSC. 
Representative immunohistochemical staining of CD8 positive T cells in paraffin-
embedded tissue microarray cores of human omental metastases from two patients, 
G11 and G15. Human tonsil is used as a positive control. 10x magnification, black bar 
= 200µm. Images provided by Dr Anne Montfort and Dr Steffen Boehm. 
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Figure 3-11 The correlation between CD4 and CD8 positive T cell infiltrates with 
tumour cell proliferation in human omental metastases of HGSC. 
Correlation between Ki67 positive tumour cells with a) CD4 and b) CD8 positive T cells 
in disease involved omenta. Tumour deposits within tissue microarray cores of biopsies 
analysed by computer-aided microscopy and Leica Ariol software. Values are the 
percentage of positively stained cells in relation to the hematoxylin nuclear 
counterstain. r = Spearman rank correlation coefficient. ns = not significant. Data 
collected and provided by Dr Steffen Boehm. 
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Ki67 is expressed in cells in all phases of the cell cycle, but not in 
quiescent cells. It seems controversial as to whether Ki67 scoring can be 
predictive of patient prognosis (Dowsett et al., 2011). All of the human 
omental metastases described in this chapter were removed from 
patients whom had received chemotherapy prior to surgery (Table 3-1). 
At the time of writing this thesis, the omental metastases tissue bank 
was four years old. Survival rates are usually based upon five-year 
intervals following diagnosis (Cancer Research UK). Therefore 
information regarding patient survival and response to treatment was not 
available. Consequently a correlation between the CD68 positive 
macrophage infiltrate and chemoresistance or overall survival could not 
be determined directly here, but a relationship with the proliferation index 
in the omental metastases can be considered indicative of macrophages 
supporting a tumour-promoting microenvironment.  
 
3.4. Summary 
 
• The omentum is a common site for HGSC metastasis. 
• Interactions with the mesothelial cells and fibroblasts of the omentum 
potentiates malignant cell invasion. 
• Of the ten patient samples studied, all of the patients had received 
chemotherapy prior to the removal of the omentum during interval 
debulking surgery. 
• In the samples studied there was a prominent infiltrate of CD3 positive 
T cells (9.4% of total cells) and CD68 positive macrophages (11.3% of 
total cells). 
• An increase in CD68 positive macrophages in the omental deposits 
significantly correlated with an increase in tumour cell proliferation (r = 
0.835, p = 0.003), whereas the extent of the CD3, CD4 and CD8 positive 
T cell infiltrate did not correlate with tumour cell proliferation. 
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3.5. Discussion 
 
At the time of writing this thesis many points raised by the preliminary 
data presented in this chapter have been followed up. Dr Steffen 
Boehm, a Clinical Research Fellow in The Centre for Cancer and 
Inflammation generated a TMA with the omental metastases of 47 
patients (11 pre-treatment, and 36 post-treatment unmatched samples). 
This was complimented also with a TMA of the primary ovarian tumour 
masses of 15 patients (seven pre-treatment, and eight post-treatment 
unmatched samples). The same analyses into the immune infiltrate 
carried out here was applied to the TMAs, but the CD3 positive T cell 
population was sub-divided and the CD4 and CD8 positive populations 
were analysed separately. This showed significant positive correlations 
between CD68 positive macrophages and Ki67 (Pearson rank 
correlation coefficient r = 0.81, p = 0.002), and also CD4 positive T cells 
and Ki67 (Pearson rank correlation coefficient r = 0.72, p = 0.012) in the 
primary tumour TMA but not in the omental metastases TMA. In the 
omental metastases, only a significant negative correlation was 
identified between the CD8 positive cytotoxic T cells and Ki67 (Pearson 
rank correlation coefficient r = -0.52, p = 0.027) (Boehm S manuscript in 
preparation).  
 
Dr Steffen Boehm was also able to access pre and post chemotherapy 
matched patient paraffin embedded omental biospies, and again applied 
the same analyses into the immune infiltrate to those samples. These 
preliminary data suggest a decrease in the percentage of CD68 positive 
macrophages following chemotherapy and a significant increase in CD3 
positive T cells post treatment. Correlation of these data with Ki67 
positive epithelial cells indicated an increase in tumour cell proliferation 
in the presence of CD68 positive macrophages also in the pre-treatment 
samples (Boehm S manuscript in preparation).  
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These data from this chapter informed the next stage of this project 
which was to establish a 3D in vitro model of ovarian cancer metastasis 
to the omentum. The primary aim was to use malignant cells, fibroblasts 
and mesothelial cells in the model, with a further aim to introduce 
macrophages since the association between these cells and malignant 
cell proliferation. 
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Chapter 4 
4. A 3D cell culture model that mimics ovarian 
cancer metastasis to the omentum   
 
4.1. The 3D omental cell culture model 
 
Approximately 80% of all women that present with HGSC have 
metastases in the omentum (Nieman et al., 2011). Consequently it is 
clear that ovarian cancer omental metastasis is not a random process. 
There are molecular and cellular cues specific to the microenvironment 
of the omentum that attracts the tumour cells there. Kenny et al (Kenny 
et al., 2007) established a 3D cell culture model that incorporated both 
cell-cell and cell-matrix interactions, and recapitulated the human 
omental microenvironment better than any other experimental in vitro 
model previously described. 
 
I first set out to establish and optimise the model described by Kenny 
and colleagues. A panel of two HGSC ovarian cancer cell lines (AOCS1 
and SKOV3ip1) and two CCC cell lines (TOV21G and RMG1) were 
originally chosen for establishment of the model in the laboratory. 
However, since this work was completed a study comparing the genomic 
profiles of cell lines with HGSC biopsies revealed that the SKOV3ip1 
ovarian cancer cells are not comparable to HGSC (Domcke et al., 2013). 
The TOV21G cell line was confirmed to be CCC in this study. In an 
additional study, a panel of nine markers was used to test the 
resemblance of 32 cell lines to CCC, and this again confirmed the 
TOV21G cells as CCC cell line, but the RMG1 cells were unclassified 
(Anglesio et al., 2013). The AOCS1 ovarian cancer cells were kindly 
donated to the laboratory from Prof David Bowtell in Australia. These 
cells were not evaluated in the recent publication by Domcke and 
colleagues (Domcke et al., 2013), however Dr Carla Milagre in the 
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laboratory recently confirmed that they carry a W146* mutation in TP53, 
and TP53 mutations are characteristic of HGSC (section 1.1.1.1). 
 
Therefore the cell lines cultured on the 3D omental model throughout 
this thesis were the HGSC cell line AOCS1, the CCC cell line TOV21G, 
and the unclassified cell lines SKOV3ip1 and RMG1. For brevity the 
term ‘ovarian cancer cell lines’ was used to collectively describe them.  
 
4.2. 3D Omental cell culture model construction 
 
Figure 4-1a shows how the 3D omental cell culture model was 
constructed. The HPMCs classically had a cobblestone appearance in 
culture (Figure 4-1b) and the HPFs had a mesenchymal spindle-like 
morphology (Figure 4-1c). The HPFs were cultured in a collagen I 
matrix, with a monolayer of HPMCs on the surface. Ovarian cancer cell 
lines were then cultured on top of the 3D omental model for two weeks, 
and their growth and invasion into the matrix was analysed. A serum 
gradient was applied to the model to mimic the nutrient rich 
microenvironment of the well-vascularised omentum relative to the 
peritoneal fluids that are in contact with its surface. 
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Figure 4-1 Omental 3D cell culture model construction.  
a) Within a well of a 24 transwell plate ovarian cancer cells were seeded on to a 3D 
rat tail collagen I gel containing HPFs covered in a monolayer of HPMCs. b) 
Cobblestone morphology of HPMCs. c) Spindle morphology of HPFs. 20x 
magnification. Bar = 200 µm. Primary cells were isolated from human omentum 
removed during the debulking surgical treatment of ovarian cancer patients. 
 
 
 
 
 
 
 
Chapter 4 – 3D Omental cell culture model 
 109 
4.3. Human primary fibroblast and mesothelial cell 
characterisation 
 
HEFs were utilised as a non cancer-associated fibroblast in the 3D 
omental model. These cells were positive for the expression of the 
intermediate filament protein vimentin that is expressed by 
mesenchymal cells (Figure 4-2a), and negative for the expression of 
cytokeratin 8/18 that is expressed by cells of epithelial origin. The human 
breast carcinoma cell line MCF7 served as a control for the negative 
expression of vimentin and the positive expression of cytokeratin 8/18 
(Figure 4-2b). The HPFs mirrored the expression profile of the HEFs 
(Figure 4-2c), but the cell populations were not always pure and often 
contaminated with HPMCs. The HPMCs were characterised by their 
positive expression of both vimentin and cytokeratin 8/18 (Figure 4-2d) 
(Kenny et al., 2007). 
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Figure 4-2 Molecular characterisation of human primary mesothelial cells and 
fibroblasts by Vimentin and Cytokeratin expression.  
Immunofluorescence staining of cells cultured on glass cover slips. a) HEF b) MCF7 
c) HPFs with contaminating HPMCs d) HPMC. Blue = Hoechst nuclear stain, Green = 
Vimentin, Red = Cytokeratin 8/18. 40x magnification, bar = 50 µm. 
 
 
The percentage of vimentin and cytokeratin 8/18 positive cells was 
measured to determine the purity of a number of different cell 
populations taken from different patients (Figure 4-3). The cell 
populations were initially classified as HPF (Figure 4-3a) or HPMC 
(Figure 4-3b) by assessment of the cell morphology at confluency. On 
average the percentage of vimentin positive cells in the HPF populations 
was higher than the percentage of cytokeratin 8/18 positive cells 
(96.44% vimentin positive, st dev 4.834, 70.33% cytokeratin 8/18 
positive, st dev 34.13, Mann-Whitney test p = 0.010), and the reverse 
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was true for the HPMC populations (75.67% vimentin positive, st dev 
31.25, 98.54% cytokeratin 8/18 positive, st dev 2.975, Mann-Whitney 
test p = 0.009). However there were still a high number of cytokeratin 
8/18 positive cells in the HPF populations (Figure 4-3a), suggestive that 
despite their mesenchymal morphology, a good proportion of these cells 
were epithelial cells. These may have been activated HPMCs. There are 
reports that HPMCs can differentiate into mesenchymal derived lineages 
(Lansley et al., 2010), and it is quite possible that their culture on plastic 
may initiate this. Likewise in the HPMC populations where the cells were 
supposed to be equally positive for both cytokeratin 8/18 and vimentin, 
there were a number of populations that expressed lower levels of 
vimentin (Figure 4-3b). In these particular cases the observed difference 
may have been indicative of contamination with other cells in the 
omentum with epithelial origins, such as endothelial cells or invading 
tumour cells.  
 
In HPF and HPMC cell populations extracted from three different 
patients; G18, G20 and G34, the purity of the populations was 
determined with increasing passage number (Figure 4-3). In most cases 
the relative percentage of cytokeratin 8/18 positive cells declined and the 
percentage of vimentin positive cells increased. This may represent the 
differentiation of cells in culture as previously mentioned or the 
monopolisation of the culture with contaminating fibroblasts. 
 
Absence of appropriate and specific cell surface markers for both the 
HPF and HPMCs meant that cell sorting by FACS or magnetic beads 
was not feasible for improving the purity of the cell populations. Given 
the reassurance that there was no significant difference between the 
vimentin expression in HPF versus HPMC populations (Mann-Whitney 
test p = 0.053) and the cytokeratin 8/18 expression was significantly 
higher in the HPMCs versus the HPFs (Mann-Whitney test p = 0.002) it 
was concluded that the best approach to using the primary cells in the 
3D omental model would be to base the cell type on the cell 
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morphology at confluency. Experiments would be conducted primarily 
with the HEFs, and repeated with HPFs where possible. 
 
 
 
Figure 4-3 Assessment of human primary mesothelial cell and fibroblast culture 
purification determined by Vimentin and Cytokeratin expression. 
Quantification of the percentage of cytokeratin 8/18 (red bars) and vimentin (green 
bars) positive cells in a) HPF and b) HPMC cultures from the omentum of different 
patients (G-coded) at varying culture passage numbers (p1-3). The number of positive 
stained cells was quantified from four fields of view at 40x magnification. 
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4.4. Optimisation of the growth of ovarian cancer cell 
lines on the 3D omental model 
 
Kenny and colleagues maintained the 3D omental models in culture for 
up to five days. For this thesis long-term cultures of two weeks were 
developed to allow sufficient time for true tumour-stroma interactions 
and to better represent the established omental metastases of ovarian 
cancer. 24 well transwell inserts were utilised to maximise the number 
of experimental conditions that could be tested with limited numbers of 
primary cells. 
 
The aim of this chapter was firstly to optimise the culture conditions for 
four ovarian cancer cell lines on the 3D omental model. Secondly the 
purpose of the experiments was to investigate the effects of the 
fibroblasts, the mesothelial cells and ascitic fluids on the growth and 
invasion of the ovarian cancer cell lines on the 3D omental model. For 
simplicity throughout this thesis, ‘K’ has been used to denote 1,000 
cells where cell titrations have been performed. 
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These data collected in this chapter are summarised in the two tables 
below. 
 
 
  Increase in growth 
Cell line No. tumour cells HEF/HPF HPMCs Ascitic fluids 
AOCS1 200K ns 10.5 p=0.002** 1.9 p=0.026* 
SKOV3ip1 50K ns 1.7 p=0.029* ns 
TOV21G 50K No data No data No data 
RMG1 50K ns ns ns 
 
Table 4-1 Table summarising the growth of ovarian cancer cell lines on the 3D 
omental model 
The ovarian cancer cell lines AOCS1, SKOV3ip1, TOV21G and RMG1 were cultured 
on the 3D omental model for two weeks. The number of ovarian cancer cells (K=1000) 
seeded on the model was optimised for each cell line. The effect of increasing numbers 
of HEFs, HPFs and HPMCs as well as the presence of ascitic fluids was assessed on 
ovarian cancer cell growth. No data were available for cell lines that did not grow 
collectively on the surface of the model. Statistically significant fold changes in growth 
are denoted with the associated p-values. ns = not significant. 
 
 
 
 
Table 4-2 Tables summarising the invasion of ovarian cancer cell lines in the 3D 
omental model 
The ovarian cancer cell lines AOCS1, SKOV3ip1, TOV21G and RMG1 were cultured 
on the 3D omental model for two weeks. The effect of increasing numbers of HEFs, 
HPFs and HPMCs as well as the presence of ascitic fluids was assessed on ovarian 
cancer cell invasion. No data were available for cell lines that were non-invasive. 
Statistically significant fold changes in invasion are denoted with the associated p-
values. ns = not significant 
. 
 
 
 Increase in invasion 
Cell line HEF/HPF HPMCs Ascitic fluids 
AOCS1 No data No data No data 
SKOV3ip1 ns From zero to 
61.8 p=0.027* 
5.3 p=0.032* 
TOV21G 534.9 
p=0.035* 
1466.5 
p=0.0004*** 
ns 
RMG1 No data No data No data 
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The number of each of the ovarian cancer cell lines to be seeded on to 
the 3D omental models was first optimised (Table 4-1). 
 
To measure growth, confocal or brightfield images were taken across 
the expanse of the cross-section of each 3D omental model. The 
average area covered by the tumour cells in the images was calculated 
using the image-processing program ImageJ. 
 
4.4.1. Statistical analyses of data 
 
To analyse these data where there were two test conditions, a non-
parametric Mann-Whitney test (two-tailed) was applied. Due to the intra-
experimental variation given by the impurity of primary cell cultures, a 
parametric distribution of these data could not be assumed. 
 
To compare more than two given test conditions a non-parametric 
Kruskal-Wallis One-Way Analysis of Variance (ANOVA) was utilised (as 
advised by Dr Shah-Jalal Sarker, Lecturer in Biostatistics, Barts Cancer 
Institute). The One-Way ANOVA test reduces the potential for 
generating false positive results (Type I error) that would occur through 
applying multiple t tests across a single data set. A 95% confidence 
interval was applied for the calculation of all p values and a Dunns post-
test was used to compare all experimental conditions following the 
Kruskal-Wallis test. 
 
Each experiment was conducted with primary mesothelial cells 
extracted from patient samples. Intratumoral heterogeneity and patient 
differences for example, age (Table 3-1), proliferative capacity of 
tumour bulk (Figure 3-8 & 3-11), and response to chemotherapy etc, 
created significant variation between samples. This generated huge 
inter-experimental variation, and so actual values from one experiment 
could not be collated with the repeated experiment for statistical 
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analysis. Therefore each measurement was normalised to the average 
of the control measurements for each experiment. These values across 
repeated experiments were pooled for statistical analyses. 
 
4.4.2. The effect of fibroblasts on the growth of ovarian cancer 
cell lines on the 3D omental model 
 
Within a tumour microenvironment fibroblasts are recruited and activated 
to secrete an abundance of chemotactic and growth factors (Bhowmick 
et al., 2004). Therefore the effect of these fibroblasts on ovarian cancer 
cell growth and invasion in the 3D omental model was investigated.  
 
There was no significant increase in ovarian cancer cell growth with 
increasing numbers of fibroblasts (Table 4-1). 
 
4.4.3. The effect of mesothelial cells on the growth of ovarian 
cancer cell lines on the 3D omental model 
 
Mesothelial cells are the first line of contact for metastasising HGSC 
cells. It was therefore asked whether HPMCs would influence the growth 
of the ovarian cancer cell lines on the 3D omental model. Figure 4-4 
shows H & E photographs of the 3D omental model cross sections, 
when the HGSC cell line AOCS1 was grown with increasing numbers of 
HPMCs. There was a significant increase (p = 0.002) in ovarian cancer 
cell growth as the number of HPMCs increased from 0 to 40,000 (Figure 
4-4a, b & c) followed by a slight drop in growth where 80,000 HPMCs 
were seeded (Figure 4-4d & e). This drop is perhaps indicative of the 
HPMCs eliciting too much of a defensive barrier for the tumour cells to 
break for attachment to the underlying ECM. 
 
It has been reported that the tumour cells can induce contractile forces 
within the HPMCs via integrin and talin signalling which drives clearance 
of the HPMCs away from the invading tumour cells, so that they can 
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access the underlying matrix (Iwanicki et al., 2011). It is clear that these 
cell-cell interactions are critical in activating the signalling cascades 
necessary for tumour cell metastasis to the omentum, and this proved to 
be modelled in the 3D omental co-culture system. It was concluded that 
40,000 HPMCs (Figure 4-4c) would be used in future experiments to 
maximise these cell-cell interactions, without exhibiting the potential to 
block tumour cell attachment with as many as 80,000 HPMCs (Figure 4-
4d & e). Additionally, the numbers of HPFs and HPMCs used in 
experiments were kept as low as possible because of their limited 
supply. 
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Figure 4-4 The effect of increasing numbers of HPMCs on the growth of the 
ovarian cancer cell line AOCS1 on the 3D omental model. 
The ovarian cancer cell line AOCS1 was cultured on the 3D omental model for two 
weeks. Representative H & E stained images of 5 µm thick cross sections of the 3D 
models when a) 0K, b) 20K, c) 40K and d) 80K HPMCs were grown on each model. 
20x magnification, bar = 100 µm. e) Graph illustrating the growth of the AOCS1 cells 
in the presence of increasing numbers of HPMCs and co-cultured with HEFs. 
Photographs of H & E stained sections were taken across the whole section of each 
model. Each treatment group was tested with triplicate models. The tumour area (µm2) 
on each photograph was quantified as a measure of tumour growth. Bars indicate the 
means and standard deviations across all measurements. Collective data from two 
experiments. p = 0.002** 
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Similarly, increasing numbers of HPMCs within the 3D omental culture 
model had a significant effect (p = 0.029) on the growth of the ovarian 
cancer cell line SKOV3ip1 when co-cultured with HEFs (Figure 4-5). 
There was no significant increase in the growth of the RMG1 ovarian 
cancer cell line with increasing HPMCs. No data were collected on the 
growth of the TOV21G cells since they were invasive in the model and 
did not grow on the surface of the model as the other three cell lines did 
(Table 4-1).  
 
 
 
Figure 4-5 The effect of increasing numbers of HPMCs on the growth of the 
ovarian cancer cell line SKOV3ip1 on the 3D omental model. 
Graph illustrating the growth of the ovarian cancer cell line SKOV3ip1 in the presence 
of increasing numbers of HPMCs and co-cultured with HEF. Tumour cells were 
cultured on the 3D omental model containing zero to 80K HPMCs for two weeks. 
Photographs of H & E stained sections were taken across the whole section of each 
model. Each treatment group was tested with triplicate models. The tumour area (µm2) 
on each photograph was quantified as a measure of tumour growth. Bars indicate the 
means and standard deviations across all measurements. Data from one experiment. 
p = 0.029* 
 
 
 
Chapter 4 – 3D Omental cell culture model 
 120 
4.4.4. The effect of ascitic fluids on the growth of ovarian cancer 
cell lines on the 3D omental model 
 
Ascites is an excessive production of peritoneal fluids produced in 
response to the developing tumour. Ascitic fluid is drained from patients 
prior to surgery and the fluid carries metastatic free-floating tumour cells 
and immune cells. The fluid also contains a host of growth factors (Mills 
et al., 1990) and pro-inflammatory cytokines (Moradi et al., 1993). To 
further mimic the microenvironment of omental metastases within the 3D 
cell culture model, I set out to test the effect of ascitic fluid on the growth 
of the tumour cells in the model. Experiments were conducted with 
pooled ascitic fluid from six patients and with low numbers (20,000 per 
model) of HPMCs so that conditions were sub-optimal. 
 
Figure 4-6 shows these data collected when the ovarian cancer cell line 
AOCS1 was co-cultured on the 3D omental model, and the serum-free 
medium in the top compartment of the transwell was substituted with 
50% ascitic fluid. The ascitic fluids caused a significant increase in 
tumour growth (p = 0.026). 
 
Figure 4-7 illustrates the effect of the ascitic fluid on the growth of the 
AOCS1 3D omental models together with a titration in HPMC numbers. 
There was a trend increase (data not statistically significant) in tumour 
growth with lower numbers of HPMCs, but when this was increased 
beyond 40,000 HPMCs per well, the growth of the AOCS1 ovarian 
cancer cells was reduced (data not statistically significant) in the 
presence of ascitic fluid. It is possible that the ascitic fluid may have 
been a source of cellular waste products from carrying the free-floating 
malignant cells and immune cells within the peritoneal cavity. This in the 
presence of increasing numbers of cells in the cultures may result in the 
concentration of the cellular waste products becoming toxic for cell 
growth. 
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Figure 4-6 The influence of ascitic fluid on the growth of the ovarian cancer cell 
line AOCS1 on the 3D omental model. 
Graph illustrating the growth of the ovarian cancer cell line AOCS1 in the absence and 
presence of human ascitic fluid. Co-cultured with HEFs, tumour cells were cultured on 
the 3D omental model for two weeks. Photographs of H & E stained sections were 
taken across the whole section of each model. Each treatment group was tested with 
triplicate models. The tumour area (µm2) on each photograph was quantified as a 
measure of tumour growth. Bars indicate the means and standard deviations across all 
measurements. Collective data from three experiments. p = 0.026* 
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Figure 4-7 The influence of ascitic fluid together with the HPMCs on the growth 
of the ovarian cancer cell line AOCS1 on the 3D omental model. 
Graph illustrating the growth of the ovarian cancer cell line AOCS1 in the absence and 
presence of human ascitic fluid when co-cultured with HEFs and increasing numbers of 
HPMCs from zero to 80K. Tumour cells were cultured on the 3D omental model for two 
weeks. Photographs of H & E stained sections were taken across the whole section of 
each model. Each treatment group was tested with triplicate models. The tumour area 
(µm2) on each photograph was quantified as a measure of tumour growth. Bars 
indicate the means and standard deviations across all measurements. Data from one 
experiment. Data not statistically significant. 
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The growth of the ovarian cancer cell line SKOV3ip1 on the 3D omental 
model was not significantly altered when treated with ascitic fluid (Figure 
4-8). 
 
 
 
Figure 4-8 The influence of ascitic fluid on the growth of the ovarian cancer cell 
line SKOV3ip1 on the 3D omental model. 
Graph illustrating the growth of the ovarian cancer cell line SKOV3ip1 in the absence 
and presence of human ascitic fluid and co-cultured with HEFs. Tumour cells were 
cultured on the 3D omental model for two weeks. Photographs of H & E stained 
sections were taken across the whole section of each model. Each treatment group 
was tested with triplicate models. The tumour area (µm2) on each photograph was 
quantified as a measure of tumour growth. Bars indicate the means and standard 
deviations across all measurements. Collective data from two experiments. Data not 
statistically significant. 
 
 
Similarly, there was no significant increase in the growth of the RMG1 
ovarian cancer cell line in the presence of ascitic fluid. Again, no data 
were collected on the growth of the TOV21G cells since they were 
invasive in the model and did not grow on the surface of the model as 
the other three cell lines did (Table 4-1). 
 
Overall it was concluded that higher numbers of HPMCs in the 3D 
omental model were advantageous with regard to the cell-cell and cell-
matrix interactions. The presence of ascitic fluids under these conditions 
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did not consistently promote ovarian cancer cell growth on the model 
(Table 4-1). For future work it would perhaps be beneficiary to titrate the 
ascitic fluid concentration in the 3D omental model to better investigate 
its impact on tumour cell growth. It is possible that lower concentrations 
would reduce the toxicity of the cellular waste products present in the 
cultures, but would have enough cytokines and growth factors to 
stimulate proliferative signalling pathways and promote tumour cell 
growth. 
 
4.5. Optimisation of the invasion of ovarian cancer cell 
lines in the 3D omental model 
 
Invasion is a complex process. Conditions within the tumour 
microenvironment regulate a plethora of cell-matrix and cell-cell 
interaction proteins to allow the migration of the tumour cells through the 
surrounding ECM (Friedl and Alexander, 2011). Fibroblasts and TAMs 
release chemokines and growth factors that form gradients to which the 
corresponding receptors on the surface of the tumour cells are 
responsive to (Schioppa et al., 2003) (Bonecchi et al., 2011). MMP 
production by the tumour cells, fibroblasts and TAMs facilitates the 
remodelling of the surrounding ECM structures to develop tracks for 
tumour cell migration (Hagemann et al., 2005; Pollard, 2008). 
Dependent upon the pattern of ECM remodelling and cell-matrix 
interactions, tumour cells can either invade collectively or as single cells 
(Friedl and Gilmour, 2009; Friedl and Wolf, 2010). This is mediated by 
Rho and Rac signalling pathways that regulate the dynamics of the cell 
cytoskeleton, and which can induce either an amoeboid or mesenchymal 
form of migration (Sanz-Moreno and Marshall, 2010). 
 
Nystrom and colleagues developed a method of image analysis for 
quantifying invasion in 3D organotypic models which incorporates the 
growth, depth and dissemination of the invasion within the model 
(Nystrom et al., 2005). The output is an invasion index which taken from 
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the images analysed is an arbitrary factor of the tumour cell area, the 
average invasion depth, and the number of invading particles. Therefore 
the common component between the measurements of tumour growth 
and invasion used in this thesis is the tumour cell area, and those 
distinguishing them are the measurements of the number of invading 
particles and the invasion distance. I applied this method of analysis to 
the 3D omental model. Of the four cell lines tested, only the ovarian 
cancer cell lines SKOV3ip1 and TOV21G showed invasion into the 
matrix of the model (Figure 4-9, Figure 4-11, Table 4-2). 
 
Given the known role of cancer-associated fibroblasts in promoting 
tumour cell invasion (Wan et al., 2013), the effect of increasing the 
number of fibroblasts in the 3D omental model was tested on the 
invasive capacity of the ovarian cancer cell line SKOV3ip1. Increasing 
the number of fibroblasts in the 3D omental model had no significant 
effect on the invasion of the tumour cells (Table 4-2).  
 
Interestingly however tumour cell invasion increased (p = 0.027) when 
the ovarian cancer cell line SKOV3ip1 were co-cultured in the 3D 
omental model with increasing numbers of HPMCs. Figure 4-9 illustrates 
the collective cell invasion exhibited by the green fluorescent protein 
(GFP)-labelled SKOV3ip1 cells in the model. It is clear that there was no 
tumour cell invasion in the absence of HPMCs (Figure 4-9), but there 
was a significant (p = 0.027) increase in invasion in the presence of 
80,000 HPMCs (Figure 4-9b – e). This result reinforced the importance 
of tumour cell interactions with the HPMC layer to allow invasion into the 
underlying matrix as described in section 4.4.3. 
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Figure 4-9 The effect of increasing numbers of HPMCs on the invasion of the 
ovarian cancer cell line SKOV3ip1 in the 3D omental model. 
The GFP labelled human ovarian cancer cell line SKOV3ip1 was cultured on the 3D 
omental model for two weeks. Representative immunofluorescence images of 5 µm 
thick cross sections of the 3D models when a) 0K, b) 20K, c) 40K and d) 80K HPMCs 
were grown on each model. Blue = Hoechst nuclei stain, Green = GFP. 20x 
magnification, bar = 200 µm. e) Graph illustrating the invasion index of the SKOV3ip1 
cells in the presence of increasing numbers of HPMCs and co-cultured with HEFs. 
Photographs of immunofluorescence stained sections were taken across the whole 
section of each model. Each treatment group was tested with triplicate models. The 
invasion index is a factor of the number of invading particles, tumour area (µm2) and 
invasion distance (µm). Bars indicate the means and standard deviations across all 
measurements. Data from one experiment. p = 0.027* 
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Despite the ascitic fluid treatment having no effect on tumour growth in 
the SKOV3ip1 3D omental models (Figure 4-8), it did cause a significant 
increase (p = 0.032) in tumour cell invasion (Figure 4-10). This 
highlighted how tumour growth and tumour cell invasion are independent 
of one another, but also proved the strength of the model where both 
processes can be monitored simultaneously.  
 
 
 
Figure 4-10 The influence of ascitic fluid on the invasion of the ovarian cancer 
cell line SKOV3ip1 in the 3D omental model. 
Graph illustrating the invasion index of the ovarian cancer cell line SKOV3ip1 in the 
absence and presence of human ascitic fluid and co-cultured with HEFs. Tumour cells 
were cultured on the 3D omental model for two weeks. Photographs of 
immunofluorescence stained sections were taken across the whole section of each 
model. Each treatment group was tested with triplicate models. The invasion index 
from each photograph was determined. The invasion index is a factor of the number of 
invading particles, tumour area (µm2) and invasion distance (µm). Bars indicate the 
means and standard deviations across all measurements. Collective data from two 
experiments. p = 0.032* 
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Conversely to the SKOV3ip1 cells, the ovarian cancer cell line TOV21G 
displayed the single-cell invasion in the 3D omental model, which is 
illustrated in Figure 4-12. Increasing the number of HPFs co-cultured in 
the model (Figure 4-11) caused a significant increase (p = 0.035) in 
TOV21G cell invasion. 
 
 
 
Figure 4-11 The effect of increasing numbers of fibroblasts on the invasion of 
the ovarian cancer cell line TOV21G in the 3D omental model. 
Graph illustrating the invasion index of the ovarian cancer cell line TOV21G in the 
presence of increasing numbers of HPFs. Tumour cells were cultured on the 3D 
omental model containing zero to 500K HPFs for two weeks. Photographs of 
immunofluorescence stained sections were taken across the whole section of each 
model. Each treatment group was tested with triplicate models. The invasion index 
from each photograph was determined. The invasion index is a factor of the number of 
invading particles, tumour area (µm2) and invasion distance (µm). Bars indicate the 
means and standard deviations across all measurements. Collective data from two 
experiments. p = 0.035* 
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Increasing the numbers of HPMCs co-cultured in the 3D omental model 
with the ovarian cancer cell line TOV21G also reproducibly caused an 
increase (p = 0.0004) in tumour cell invasion (Figure 4-12). The most 
significant promotion of invasion was observed when 80K HPMCs were 
co-cultured in the 3D omental model (Figure 4-12d & e). There were 
really no signs of invasion in the absence of these cells (Figure 4-12a & 
e). 
 
The effect of ascitic fluid on TOV21G cell invasion was inconclusive 
(Table 4-2). 
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Figure 4-12 The effect of increasing numbers of HPMCs on the invasion of the 
ovarian cancer cell line TOV21G in the 3D omental model. 
The GFP labelled human ovarian cancer cell line TOV21G cultured on the 3D omental 
model for two weeks. Representative immunofluorescence images of 5 µm thick cross 
sections of the 3D models when a) 0K, b) 20K, c) 40K and d) 80K HPMCs were grown 
on each model. Blue = Hoechst nuclei stain, Green = GFP. 20x magnification, bar = 
200 µm. e) Graph illustrating the invasion index of the TOV21G cells in the presence of 
increasing numbers of HPMCs and co-cultured with HPFs. Photographs of 
immunofluorescence stained sections were taken across the whole section of each 
model. Each treatment group was tested with triplicate models. The invasion index is a 
factor of the number of invading particles, tumour area (µm2) and invasion distance 
(µm). Bars indicate the means and standard deviations across all measurements. 
Collective data from three experiments. p = 0.0004*** 
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4.6. Concluding remarks 
 
4.6.1. Summary of the growth and invasion of ovarian cancer cell 
lines in the 3D omental model 
 
4.6.1.1. Primary cell characterisation 
 
Cultures of HPFs and HPMCs from several patients have been 
characterised by cytokeratin 8/18 and vimentin expression. The HPF 
populations contained a high percentage of cytokeratin 8/18 positive 
cells. The original publication for the establishment of the 3D omental 
model distinguished between the HPFs and HPMCs by the expression 
of the collagen synthesising enzyme prolyl-hydroxylase. They did not 
however show that their HPF populations were negative for cytokeratin 
8/18 ((Kenny et al., 2007) and it can be argued that describing isolated 
fibroblasts only by their ability to produce collagen is insufficient. Due to 
the lack of specific cell surface markers to separate the two cell 
populations however, and due to the low cell yields, it was deduced that 
the most efficient means of identifying the cells would be by examining 
cell morphology at confluency. Arguably the potential for activated 
HPMCs to differentiate in to mesenchymal cells (Lansley et al., 2010) 
suggested that cell morphology was perhaps also not the best method 
for distinguishing the primary cell types. This in essence was the reason 
for predominantly performing experiments with the non tumour-
associated HEFs. 
 
4.6.1.2. Longevity of culture 
 
3D omental cell culture models of a group of four ovarian cancer cell 
lines have been established. Previously no laboratories had cultured 
ovarian cancer cells on the model for longer periods than five days, but 
for this thesis the malignant cells were grown on the 3D model for at 
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least 14 days. Other publications describing work with this particular 
model (Cai et al., 2012; Kenny et al., 2008; Kenny et al., 2007; Zillhardt 
et al., 2011) only culture the models for 72 hours to study early tumour 
cell adhesion and invasion events. For the purpose of this thesis it was 
important to establish a long-term cell culture model that increases the 
interactions between the tumour cells and the cells of the tumour 
microenvironment. This was successfully done. 
 
4.6.1.3. Tumour cell line variations 
 
The optimal number of each of the ovarian cancer cell lines to be 
seeded on the 3D omental model for growth and invasion was 
established (Table 4-1). There was a significant level of variation in the 
pattern of growth and invasion in the 3D omental model between ovarian 
cancer cell lines. For example the TOV21G cell line demonstrated a 
single cell invasion pattern where as the SKOV3ip1 cells demonstrated 
collective cell invasion. The AOCS1 and RMG1 cell lines did not invade 
at all. The TOV21G cells were confirmed to be representative of the 
CCC subtype of ovarian cancer (Anglesio et al., 2013; Domcke et al., 
2013). CCC is characterised by increased activation of cytokine, 
oxidative stress and hypoxia driven pathways, as well as the PI3K 
pathway (Jones et al., 2010), all of which may support the survival of 
single cells disseminated in a matrix. Comparably the SKOV3ip1 cells 
may not have an enrichment in these survival signalling pathways and 
therefore require more cell: cell contact for survival in a novel 
environment, encouraging them to invade collectively. 
 
4.6.1.4. Fibroblasts 
 
Fibroblasts had no effect on the growth of the tumour cells on the model 
as measured by tumour area, but the fibroblasts stimulated the invasion 
of the ovarian cancer cell line TOV21G. The release of chemokines, 
growth factors and MMPs from fibroblasts in the collagen matrix was 
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likely to be responsible for this stimulated invasion. 50,000 cells per 
model were optimal for cell growth, but 250,000 cells were optimal for 
invasion. 
 
4.6.1.5. Mesothelial cells 
 
Mesothelial cells were important for both the growth and invasion of 
ovarian cancer cell lines on the model. Induced HPMC contractility and 
clearance on the surface of the omentum by metastasising tumour cells 
has been reported to allow tumour cell access to the underlying matrix 
(Iwanicki et al., 2011). The HPMC titrations in the 3D omental model 
reinforced the importance of this cell: cell contact for tumour cell 
metastasis to the omentum, however excessive numbers of HPMCs in 
the co-culture also highlighted their capacity to form a physical defensive 
barrier to invading cells or pathogens from the peritoneal cavity. 40,000 
cells per model were optimal for cell growth and invasion.  
 
4.6.1.6. Ascitic fluid 
 
Ascitic fluid from HGSC patients could stimulate the growth and invasion 
of the ovarian cancer cell lines in the model, but had minimal effect in 
the presence of more HPMCs. Ascitic fluid is rich in growth factors and 
inflammatory cytokines that potentially supported pro-survival signalling 
in the tumour cells, particularly in cells that displayed low autocrine 
inflammatory cytokine signalling. Cytokine signalling has been shown to 
stimulate cell contractility via the JAK (Janus kinase) pathway (Sanz-
Moreno et al., 2011), which may have potentially attributed to the 
increase in tumour cell invasion in the 3D omental model in the presence 
of ascitic fluid. It was also possible that any detrimental effects of ascitic 
fluid on tumour cell growth and invasion observed was a consequence of 
an increased localised concentration of cellular waste products in the co-
culture system. 
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4.6.2. Overall scope for 3D omental model development 
 
One of the strengths of the 3D omental model was its ability to subject 
the tumour cells to a multicellular microenvironment, where the stromal 
cells were sourced from the actual human tissue that it set out to mimic. 
It was multi-dimensional and offered potential to assess several 
processes simultaneously, such as tumour cell adhesion, growth and 
invasion. There are multiple signaling pathways that regulate these 
processes (Hanahan and Weinberg, 2011). PI3 kinase and Akt signaling 
mediate tumour cell adhesion and survival. Growth factor signaling 
activates the MAP kinase pathway supporting cell proliferation. Tumour 
cell invasion is associated with EMT, which can also be stimulated by 
growth factor signaling. The reported interactions between CSF1 and 
EGF signaling promoting breast cancer invasion is an example of the 
role of growth factor signaling in tumour cell invasion (Boimel et al., 
2012). Similarly the cytokine activated JAK-STAT3 signaling pathway 
promotes both proliferation and invasion (Coward et al., 2011; Sanz-
Moreno et al., 2011). Therefore therapeutic agents that target these 
signaling pathways are desirable since they affect multiple processes 
involved in cancer progression. The 3D omental model would be an 
ideal model for testing these therapeutic agents since these processes 
can be measured concurrently.  
 
Both RNA and protein could be extracted from the 3D omental models 
for qRT-PCR and western blot analysis respectively. Once cells had 
been cultured in the model they could also be re-extracted from the 
collagen matrix with collagenase treatment and separated by FACS for 
further analysis. Hence the model could be applied to studies into the 
effect of the tumour cells on the stroma and vice versa. 
 
The normal omentum can be described as a fatty pad of tissue that lies 
from the stomach and over the bowels. Nieman el at (Nieman et al., 
2011) recently described how the monopolisation of the adipocyte-rich 
tissue by the invading tumour cells is stimulated by adipokines such as 
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IL-8, and how the direct transfer of lipids from the adipocytes to the 
tumour cells provides the tumour cells with an energy source for 
proliferation. This suggests that the adipocytes in the omentum are a key 
cellular component in driving HGSC metastasis to this site. 
Communications with Prof Ernst Lengyel revealed that omentum 
sourced adipocytes have now been introduced to the established 3D 
omental cell culture model. 
 
This highlights the most exciting challenge for the development of this 
3D omental model. The tumour microenvironment contains many 
different cell types (Balkwill et al., 2012), including the malignant cells, 
the immune cells, fibroblasts, mesenchymal stem cells and endothelial 
cells. Incorporating additional cell types in the 3D omental model will 
bring the microenvironment even closer to the microenvironment found 
in vivo, which will not only reduce the need for animal experiments, but 
will generate results that will recapitulate the disease situation in patients 
with greater accuracy. 
 
4.6.3. Conclusion 
 
The major clinical problem with HGSC is late stage diagnosis and 
presentation with heavily spread tumour burden throughout the 
peritoneal cavity. Research into earlier diagnosis is critical, however 
difficult when patients are rarely seen at an early stage. There is 
therefore a demand for models to study the early events in HGSC 
metastasis. The 3D omental model has already proved its worth in 
studying these early events (Kenny et al., 2008) and may lead to 
improved therapies to reduce tumour cell attachment to areas of the 
peritoneal lining. Combinational therapies are though also critical when 
targeting HGSC. Cells that might become resistant to a single line of 
therapy may still colonise the peritoneal lining and develop to form 
significantly sized metastatic deposits. The fibroblasts and mesothelial 
cells are of course present at the early stages of HGSC metastasis, but 
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as the deposits develop there is an influx of infiltrating inflammatory cells 
(Leinster et al., 2012).  
 
The aim of the next chapter was to use the 3D omental model to study 
the role of the chemokine CXCL12 in the development of metastatic 
deposits of ovarian cancer. Following this the accompanied influx of 
macrophages was further modelled and investigated within the in vitro 
system established in this chapter. 
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Chapter 5 
5. Using the 3D omental model to test the 
efficacy of a neutralising antibody targeting 
CXCL12 
 
Collaborative work with John McCafferty in Cambridge as a part of a 
Cancer Research UK Discovery committee grant provided our lab with 
an antibody, denoted 114_3H1 that targeted human CXCL12. The role 
of the CXCR4/CXCL12 signalling pathway in ovarian cancer is well 
established (Kulbe et al., 2012). CXCR4 signalling has been shown to 
promote tumour cell proliferation, survival and migration (Balkwill, 2004; 
Scotton et al., 2001; Scotton et al., 2002). These cellular responses can 
be measured in the established 3D omental model as described in 
chapter 4. Therefore I used this 3D omental model to test the efficacy of 
the antibody and the targeting of this pathway in ovarian cancer 
metastasis. 
 
5.1. CXCL12 expression in the 3D omental model 
 
The levels of secreted CXCL12 in the supernatant of the 3D omental 
models were measured by ELISA. The supernatants of the 3D omental 
models were collected and the models were fixed after two weeks in 
culture. The number of positive hematoxylin nuclear stained cells in each 
section was quantified using a computer-operated microscope and the 
Leica Ariol software, as previously described in chapter 3. These 
hematoxylin nuclear cell counts were then used as reference figures for 
normalisation of CXCL12 concentrations in the supernatant relative to 
one million cells (Figure 5-1). 
 
These data collected showed that higher levels of CXCL12 were 
secreted from the SKOV3ip1 and TOV21G ovarian cancer cell lines on 
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the 3D omental model than the AOCS1 and RMG1 ovarian cancer cell 
lines (Figure 5-1). Interestingly these two cell lines were the most 
invasive of the four tested in the 3D omental model. When the ovarian 
cancer cells were cultured on plastic, negligible levels of CXCL12 can be 
detected from the supernatants (data not shown). 
 
 
 
Figure 5-1 CXCL12 levels in the 3D omental model supernatants 
Quantification of CXCL12 levels in cell culture supernatants measured by ELISA. 
CXCL12 concentrations (pg/mL) normalised per million cells as quantified from cross-
sections of the 3D omental models with the Leica Ariol image analysis software. Data 
from a single experiment when a panel of ovarian cancer cell lines AOCS1, SKOV3ip1, 
TOV21G and RMG1 were co-cultured for two weeks with the 3D omental model. 
 
5.2. Targeting CXCL12 in the 3D omental model 
 
The expression of the CXCR4 receptor on the ovarian cancer cell lines 
was first confirmed by flow cytometry analysis after culture on plastic 
(Figure 5-2). All of the ovarian cancer cells were positive for the receptor 
relative to the isotype controls. The TOV21G and RMG1 cell lines 
(Figures 5-2 c & d) displayed a broader spectrum of high and low 
expressing cells within the population than the AOCS1 and SKOV3ip1 
cell lines (Figures 5-2 a & b). It is possible that the spectrum of low and 
high CXCR4 expressing cells in Figures 5-2 c & d may be representative 
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of the higher levels of internalisation of the receptor in response to ligand 
binding. 
 
 
 
Figure 5-2 CXCR4 receptor expression on the surface of the ovarian cancer cell 
lines 
Histograms of CXCR4 positive PE labelled cell populations as analysed by flow 
cytometry. CXCR4 expression profile of the cell lines a) AOCS1, b) SKOV3ip1, c) 
TOV21G and d) RMG1. All cells positive for the FVD450 viability stain were excluded 
from the analysis and due to the GFP positivity of the SKOV3ip1 and TOV21G cells, all 
analyses were compensated with FITC and PE labelled beads. Green = CXCR4 
antibody, Blue = igG2B isotype control, Red = no primary antibody, secondary antibody 
only. 
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Figure 5-3 CXCR4 receptor expression on the surface of the fibroblasts and 
mesothelial cells 
Histograms of CXCR4 positive PE labelled cell populations as analysed by flow 
cytometry. CXCR4 expression profile of the a) HEFs and b) HPMCs from patient G90. 
c) The ovarian teratocarcinoma cell line PA1 was used as a negative control cell line. 
All cells positive for the FVD450 viability stain were excluded from the analysis. All 
analyses were compensated with FITC and PE labelled beads. Green = CXCR4 
antibody, Blue = igG2B isotype control, Red = no primary antibody, secondary antibody 
only. 
 
 
The HEFs used in the 3D omental model were also positive for cell 
surface expression of CXCR4 subsequent to their culture on plastic 
(Figure 5-3a). During flow cytometry analysis the HPMCs displayed a 
high level of auto fluorescence and had a high affinity for the isotype 
control, therefore the expression status of the HPMCs for CXCR4 here 
was inconclusive (Figure 5-3b). General CXCR4 expression in HPMCs 
could be further studied by qRT-PCR and western blotting analysis. The 
localisation of the receptor could be identified by immunofluorescence 
and confocal microscopy. Immunofluorescence analysis could potentially 
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be affected by auto fluorescence, but could be informative of the 
intracellular trafficking of the cell surface receptor following ligand 
activation. However, it has previously been reported that omentum 
derived HPMCs express CXCR4 as analysed by western blot (Kajiyama 
et al., 2008a). Kajiyama and colleagues also showed that the HPMCs 
secreted higher levels of CXCL12 than their panel of epithelial ovarian 
cancer cell lines. In addition stimulation of the HPMCs with TGFβ1 
increased the HPMC’s migratory potential and also induced 
differentiation from that of cobblestone morphology to a mesenchymal 
morphology.  
 
The ovarian teratocarcinoma cell line PA1 that was known to be 
negative for CXCR4 expression was used as an internal negative control 
(Figure 5-3c). 
 
The expression of the chemokine CXCL12 in ovarian cancer was 
mimicked in the 3D omental cell culture model (Figure 5-1). Hugh 
Kikuchi, a research assistant in the laboratory previously utilised 
transwell migration assays to identify the concentration of the 114_3H1 
antibody that optimally inhibited migration of the TOV21G ovarian cancer 
cell line. On the basis of Hugh Kikuchi’s experiments, the 3D omental 
models were treated with 10µg/mL of 114_3H1. This was controlled with 
an equal concentration of an anti-lysozyme IgG2 isotype control 
antibody. The results of the 3D omental model experiments are 
summarised in the table below (Table 5-1). 
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Cell line Decrease 
in growth 
Ki67 Decrease 
in invasion 
ELISA Control 
(pg/mL) 
ELISA anti-
CXCL12 (pg/mL) 
AOCS1 0.7 
p=0.012* 
ns No data 659.1 7356.7 
SKOV3ip1 ns ns No data 3654.9 3749.8 
TOV21G No data No data 0.6 
p=0.029* 
2834.9 8614.3 
RMG1 ns No data No data 801.4 2435.0 
 
Table 5-1 Results summary of 114_3H1 antibody treated 3D omental models 
Table summarising the effects of 10µg/mL of the CXCL12 neutralising antibody 
114_3H1 on ovarian cancer cell growth, proliferation (Ki67) and invasion in the 3D 
omental model. Four ovarian cancer cell lines were co-cultured on the model and 
treated with the antibody for two weeks. Experiments were controlled with equal 
concentrations of an IgG2 isotype control. No data were available for cell lines that did 
not grow collectively on the surface of the model or those that were non-invasive. 
Statistically significant fold changes in growth and invasion are denoted with the 
associated p-values. ns = not significant. ELISA measured CXCL12 concentrations 
(pg/mL) in the supernatants of the control and antibody treated 3D omental models are 
also summarised. 
 
 
Figure 5-4 shows that the CXCL12 targeted antibody significantly 
reduced tumour growth of the AOCS1 ovarian cancer cells on the 3D 
omental model. The antibody had no significant effect on the tumour 
growth of the SKOV3ip1 and RMG1 (Table 5-1) ovarian cancer cell lines 
on the 3D omental model. The TOV21G ovarian cancer cell line does 
not display accumulative cell growth on the surface of the model, but is 
invasive. Therefore measuring tumour growth was not applied to this cell 
line (Table 5-1). 
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Figure 5-4 The effect of CXCL12 targeted antibody treatment on the growth of the 
AOCS1 ovarian cancer cell line on the 3D omental model 
Graph illustrating the growth of the ovarian cancer cell line AOCS1 on the 3D omental 
model when treated with 10µg/mL of the CXCL12 targeted antibody 114_3H1. Control 
groups were treated with an equal concentration of an IgG2 isotype control. The 3D 
omental models were cultured for two weeks. Photographs of H & E stained sections 
were taken across the whole section of each model. Each treatment group was tested 
with triplicate models. The tumour area (µm2) on each photograph was quantified as a 
measure of tumour growth. Bars indicate the means and standard deviations across all 
measurements. Collective data from three experiments. p = 0.012* 
 
 
Ki67 positive epithelial cells in the 3D omental models were quantified 
with the aid of the computer-operated microscope and the Leica Ariol 
image analysis software. Where a significant reduction in AOCS1 
tumour cell growth with CXCL12 targeted antibody treatment was 
observed (Figure 5-4), there was no associated reduction in tumour cell 
proliferation (Figure 5-5). This therefore suggests that CXCL12 is more 
implicated in the survival of the AOCS1 ovarian cancer cells in this 3D 
omental model than in the proliferation of the cells. In addition targeting 
CXCL12 had no significant effect on the proliferation of the SKOV3ip1 
ovarian cancer cells in the 3D omental model (Table 5-1). 
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Figure 5-5 The effect of CXCL12 targeted antibody treatment on the proliferation 
of the AOCS1 ovarian cancer cell line in the 3D omental model 
Quantification of the proliferation indices in the 3D omental models co-cultured with the 
ovarian cancer cell line AOCS1 in the presence of 10µg/mL of the CXCL12 targeted 
antibody-denoted 114_3H1 or equal concentrations of an IgG2 isotype control. Tumour 
cells were cultured on the 3D omental model for two weeks. Three 3D omental model 
cross-sections from each experiment were analysed by computer-aided microscopy 
and Leica Ariol software. Values are the number of Ki67 positively stained cells in 
relation to the haematoxylin nucleus counterstain. Bars indicate the means and 
standard deviations across all measurements. Collective data from three experiments. 
p = 0.4 Data not statistically significant. 
 
 
Given the reported role of the chemokine CXCL12 as a chemoattractant 
for CXCR4 positive metastasising cells (Muller et al., 2001), the effect of 
the CXCL12 targeted antibody on invasion of CXCR4 receptor bearing 
ovarian cancer cells in the 3D omental model was then investigated. 
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Figure 5-6 The effect of CXCL12 targeted antibody treatment on the invasion of 
the ovarian cancer cell line TOV21G in the 3D omental model 
Graph illustrating the quantified invasion index of the ovarian cancer cell line TOV21G 
in the presence of 10µg/mL of the CXCL12 targeted antibody-denoted 114_3H1 or 
equal concentrations of an IgG2 isotype control. Tumour cells were cultured on the 3D 
omental model for two weeks. Photographs of H & E stained sections were taken 
across the whole section of each model. Each treatment group was tested with 
triplicate models. The invasion index from each photograph was determined. The 
invasion index is a factor of the number of invading particles, tumour area (µm2) and 
invasion distance (µm). Bars indicate the means and standard deviations across all 
measurements. Collective data from two experiments. p = 0.029*. 
 
 
The invasion of the ovarian cancer cell line TOV21G was tested in the 
presence of the CXCL12 targeted antibody relative to the isotype control 
(Figure 5-6). The treated 3D omental models demonstrated a significant 
decrease in invasion. The antibody had no significant effect on the 
invasion of the SKOV3ip1 ovarian cancer cells in the 3D omental model 
(Table 5-1). 
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Figure 5-7 The effect of CXCL12 targeted antibody treatment on the CXCL12 
levels in the 3D omental model supernatants 
Quantification of CXCL12 levels in cell culture supernatants measured by ELISA. 
CXCL12 concentrations (pg/mL) normalised per million cells as quantified from cross-
sections of the 3D omental models with the Leica Ariol image analysis software. Data 
from a single experiment when a panel of ovarian cancer cell lines AOCS1, SKOV3ip1, 
TOV21G and RMG1 were co-cultured for two weeks with the 3D omental model and 
treated with 10µg/mL of the CXCL12 targeted antibody-denoted 114_3H1 or equal 
concentrations of an IgG2 isotype control. 
 
 
The supernatants from SKOV3ip1 3D omental cultures had relatively 
high levels of CXCL12 in comparison with the other cell lines of the 
panel tested (Figure 5-1). When treated with the CXCL12 targeted 
antibody there was no reduction in CXCL12 supernatant levels (Figure 
5-7). Unexpectedly treatment of the remaining ovarian cancer cell lines 
in the panel on the 3D omental models appeared to increase the levels 
of CXCL12 in the cell culture supernatant (Figure 5-7). This could have 
been a result of the antibody sequestering the ligand in the culture and 
preventing its degradation. Alternatively it could have been a 
consequence of the cells secreting more CXCL12 as a compensatory 
mechanism for the lack of signalling.  
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5.3. Concluding comments 
 
Overall the chemokine receptor CXCR4 and its ligand CXCL12 are 
expressed in both the malignant and stromal compartments of ovarian 
cancer omental metastases, therefore targeting the chemokine network 
would implicate both the tumour cells themselves and the supporting 
tumour microenvironment. The stroma is a more favourable target due to 
its greater genomic stability in relation to the highly adaptable malignant 
cells. Targeting the chemokine network may have a greater impact on 
the survival of tumour cells that do not so highly and inherently express 
a chemokine driven network (Jones et al., 2010; Wiegand et al., 2010), 
and that are more dependent on stromal cues. However tumour cells 
that do express high levels of the chemokine network facilitating single 
cell invasion through the ECM may also be impacted through inhibition 
of the pathway due to dependencies on chemokine gradients. 
 
When the ovarian cancer cell lines were cultured on plastic very little 
CXCL12 could be detected in the supernatant in comparison to when 
they were cultured on the 3D omental model. It is impossible to know 
from the ELISA data collected in this chapter which cell types were the 
source of the CXCL12 in the 3D omental models. However the variable 
levels of CXCL12 secretion induced by different ovarian cancer cell lines 
in the model, emphasises the importance of the tumour-stroma 
interactions for chemokine production. This therefore highlights the 
significance of using this 3D model when studying inflammatory 
mediators in HGSC metastasis. 
 
A broader titration of the antibody concentrations would need to be 
tested in the 3D omental model across a larger panel of ovarian cancer 
cell lines to consolidate this work. Chemokines are often sequestered on 
matrix proteins (Sorokin, 2010; Vaday and Lider, 2000), and therefore it 
would also be necessary to consider the penetrance of the therapeutic 
agent into the collagen matrix of the model. 
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In this chapter, the 3D omental model was used to test the efficacy of a 
therapeutic agent that generated statistically significant results. This 
therefore supports the potential for the use of this assay in future 
therapeutic studies. However the antibody tested here showed no 
efficacy in in vivo subcutaneous pancreatic cancer models or xenograft 
models of ovarian cancer (experiments performed by research assistant 
Lily Keane in the Cancer & Inflammation laboratory). Targeting an 
inflammatory mediator in models deficient or absent of immune cells 
such as xenograft in vivo models or the 3D omental model respectively, 
may render such models insufficient for the given experiment. 
 
In parallel to the work of this chapter the potential association between 
CXCL12 and the up regulation of ECM genes was investigated in the 
HGSC omental metastases. The aim was to use the antibody targeting 
CXCL12 in the established 3D omental model as an in vitro system to 
further interrogate the CXCL12 and ECM gene expression link.  
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Chapter 6 
6. Investigating the association between 
CXCL12 and extracellular matrix remodelling in 
HGSC omental metastases 
 
6.1. Extracellular matrix remodelling in the tumour 
microenvironment 
 
Stabilisation of the ECM provides an anchoring substrate for cellular 
adhesion to support cell survival, and for chemokines to generate 
suitable concentration gradients for chemotaxis. The ECM is also a 
physical scaffold for tissue regeneration and angiogenesis (Cox and 
Erler, 2011; Lopez-Novoa and Nieto, 2009).   
 
Tissue desmoplasia and fibrosis describes an over-production, 
deposition and cross-linking of ECM proteins and is a key feature of 
inflammation and wound repair. Advanced solid tumours are 
characterised by a reactive stromal signature within a dense matrix 
(Erler and Weaver, 2009; Paszek et al., 2005). An increase in ECM 
density supports malignant and stromal cell survival and differentiation 
through an increase in focal adhesions and integrin signalling (Levental 
et al., 2009). MMPs cleave ECM proteins to aid malignant cell invasion 
(Kenny and Lengyel, 2009) and mediate growth factor and chemokine 
bioavailability (Kessenbrock et al., 2010).   
 
Breast cancer development is associated with an increased ‘stiffness’ of 
the surrounding stroma (Butcher et al., 2009; Erler and Weaver, 2009; 
Paszek et al., 2005). 3D acini culture of the non-malignant MCF-10A 
mammary epithelial cells in increasing stiffened collagen gels disrupted 
the polarisation of the cells and their ability to form lumen. An increase in 
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the concentration of ECM proteins within the cellular microenvironment 
provides an abundance of substrate for cell adhesion. Within the acini 
culture, incremental tensional force on the cellular spheroid development 
drove the formation of focal adhesions, integrin signalling, and EGF-
dependent ERK (extracellular signal related-kinase) activation (Levental 
et al., 2009). 
 
The stability of the surrounding ECM can therefore positively regulate 
cell de-differentiation, growth and survival, supporting malignant 
transformation and chemoresistance. An Affymetrix Gene Expression 
Array of four drug resistant MCF-7 breast carcinoma cell lines identified 
25 ECM genes with a two-fold or more up-regulation compared with the 
drug sensitive parental line (Iseri et al., 2010). Similarly a proteomic 
analysis of the cisplatin resistant COC1 ovarian cancer cell line 
compared with the parental control identified extracellular matrix proteins 
as one of the eight groups of differentially expressed proteins (Li et al., 
2010).  
 
6.2. ECM remodelling in ovarian cancer 
 
Osteopontin is an ECM protein that is significantly over-expressed in 
ovarian clear cell carcinoma compared with the other histological 
subtypes (Matsuura et al., 2010). Osteopontin integrates with and up-
regulates the expression of its receptors alpha V, alpha 5, beta 1, 3 and 
5 integrins particularly in the ovarian carcinoma cell lines TOV21G and 
RMG-1. It has been found to promote matrix invasion of these cell lines. 
 
In contrast to the increasingly developed argument that extracellular 
matrix proteins promote the acquisition of chemoresistance during 
malignant transformation, some ECM proteins are thought to elicit the 
opposite effect. The presence of the TGFβ-induced protein (TGFBI) in 
ovarian carcinomas was associated with paclitaxel cytotoxicity. The 
mechanism of this was established by the re-sensitisation of paclitaxel 
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resistant cells when they were treated with TGFBI. It is thought that 
TGFBI stabilises the microtubules of the resistant cells (Ahmed et al., 
2007). However more recent work suggests that mesothelial cell 
interactions with ovarian cancer cell lines increases the expression of 
TGFBI, and promotes ovarian cancer cell motility, adhesion and invasion 
(Ween et al., 2011). Not only is tumour progression mapped by the 
balance of ECM degradation and stabilisation, but the ECM composition 
is also equally important, whereby proteins that may be crucial at earlier 
stages of cell attachment and invasion, may in fact be detrimental to 
tumour growth in a more established microenvironment. 
 
In an analysis of gene expression in 285 ovarian cancer biopsies Tothill 
et al found that ECM remodelling processes correlate with poor overall 
patient survival (Tothill et al., 2008). The deposition of ECM proteins has 
also been identified as a possible mechanism for the development of 
chemoresistance in ovarian carcinomas (Etemadmoghadam et al., 
2009). Serial analysis of gene expression in the A2780 ovarian cancer 
cell line compared with cisplatin resistant derived clones identified an up-
regulation in both collagen 6 α3 and decorin (Sherman-Baust et al., 
2003). Growth of the parental cell line on collagen 6 α3 increased their 
resistance to cisplatin in a colony-formation assay. Cytoplasmic and 
extracellular staining was observed in a TMA of ovarian cancer biopsies, 
and expression associated with tumour grade. Collagen 6 α3 expression 
was however more variable in HGSC compared with other subtypes, 
and further analysis was required to associate expression with 
chemotherapy response. 
 
Overall there are very few reports describing the role of the extracellular 
matrix in HGSC metastasis. Very recently however a similar study to the 
work described in this chapter identified an ECM gene signature 
associated with poor survival in HGSC (Cheon et al., 2014). The ten 
genes were regulated by TGFβ1 and included periostin and versican. 
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The gene signature was also up regulated in the metastases in 
comparison with the primary tumours. 
 
6.3. ECM remodelling and cell-matrix interaction 
processes are associated with high levels of CXCL12 
expression in ovarian carcinoma. 
 
Pathway and process enrichment analysis of an Affymetrix gene 
expression array of 245 ovarian cancer biopsies (GSE 6008 and 3149 
sourced from the National Center for Biotechnology Information’s (NCBI) 
Gene Expression Omnibus (GEO) (Barrett and Edgar, 2006)) suggested 
an association between CXCL12 mRNA expression and ECM 
remodelling and cell-matrix interactions (Kulbe H, unpublished data). 
The aim of this chapter was to confirm this link in a second data set, and 
validate correlations between CXCL12 and ECM remodelling gene 
expression in the human omental metastases by qRT-PCR. 
 
Dr Probir Chakravarty at the London Research Institute conducted all of 
the bioinformatics analyses for this chapter. The gene selection and 
expression validation was completed in the Cancer and Inflammation 
laboratory. The cohort of 285 ovarian cancer biopsies from the 
Australian Ovarian Cancer Study (AOCS) was selected as a second 
data set to confirm the CXCL12 and extracellular matrix-remodelling link. 
The AOCS data set was interrogated by ranking the biopsies by their 
levels of CXCL12 expression. The 50 highest CXCL12-expressing 
biopsies were compared with the 50 lowest CXCL12-expressing 
biopsies with an eBayes t-test. Amongst these two groups of 50 
biopsies, more than 95% of the biopsies were from HGSC, and the 
remaining biopsies were from endometrioid ovarian cancers. A total of 
5167 probes for genes were differentially expressed between the two 
groups. Genes were identified with multiple probes. Only probe sets with 
p values equal to or less than 0.05 were considered differentially 
expressed.  
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The biological processes enriched in the 5167 differentially expressed 
probes were elucidated using the Metacore Analysis software (Figure 6-
1). Processes expected to be associated with CXCL12 signalling such 
as inflammation, development and chemotaxis for example were 
enriched in high CXCL12 – expressing ovarian cancers. The processes 
of cell-matrix interactions and ECM remodelling were also enriched and 
associated with high levels of CXCL12. This confirmed the preliminary 
data that generated the hypothesis to be investigated in this chapter. 
 
 
 
Figure 6-1 Gene set enrichment in high CXCL12 expressing ovarian cancer 
biopsies.  
Pie chart generated by interrogation of the microarray gene expression data from the 
285 ovarian cancer biopsies of the Australian Ovarian Cancer Study data set.  The 
biopsies were ranked by their levels of CXCL12 mRNA expression and the top 50 
CXCL12 - expressing biopsies were compared by an e-Bayes t-test with the 50 lowest 
CXCL12 - expressing biopsies. Metacore analysis of the differentially expressed genes 
elucidated the processes enriched in high CXCL12 expressing biopsies. 
 
 
These two main category processes were sub-divided into seven more 
specific processes. Five sub-category processes were more definitively 
associated with cell adhesion (Cell-matrix interactions, Integrin-mediated 
cell-matrix adhesion, Glycoconjugates, Integrin priming, Attractive and 
repulsive receptors) and two sub-category processes were associated 
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with proteolysis (Connective tissue degradation, ECM remodelling). Most 
of the genes denoted by these seven processes were up regulated in 
the high CXCL12 - expressing biopsies (Figure 6-2). 
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Figure 6-2 Extracellular matrix remodelling and cell-matrix interaction genes are 
up regulated in high CXCL12 – expressing biopsies. 
Heat map generated by interrogation of the microarray gene expression data from the 
285 ovarian cancer biopsies of the Australian Ovarian Cancer Study data set. 
Representation of the genes up regulated in ovarian cancers with associated high 
levels of CXCL12 expression in two of the seven enriched ECM remodelling and cell-
matrix interaction processes; Cell adhesion_Cell-matrix interactions (80 genes), and 
Proteolysis_ECM remodelling (36 genes). p value ≤ 0.05. Green denotes low 
expression and red denotes high expression. Heat map kindly generated by Probir 
Chakravarty at the London Research Institute. 
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6.4. ECM remodelling and cell-matrix interaction gene 
selection for validation 
 
The seven sub-category defined processes included a total of 201 genes 
out of the total 5167 (3.89%) differentially expressed probes for genes 
that were finally characterised as cell-matrix interactions and ECM 
remodelling genes associated with high levels of CXCL12. It was 
established that 89 of these 201 genes had a fold change in expression 
greater than two. The differential expression of genes was more likely to 
be detected by subsequent qRT-PCR analysis when there was a fold 
change in expression greater than two as determined by the 
bioinformatics analysis. 
 
This work was repeated in the GSE 6008 and 3149 data set of the 245 
ovarian cancer biopsies. The characterised cell-matrix interactions and 
ECM remodelling genes associated with high levels of CXCL12 from the 
AOCS and the GSE 6008 and 3149 data sets were then compared. 48 
differentially expressed genes were found to be common to the two 
independent data sets (Tables 10-1 & 2 in Appendix I). The common 
genes within each data set were then ranked by their fold change values 
and the twenty common genes with the highest fold change values from 
each data set were subsequently compared. Table 6-1 details the top 
twenty common genes in each data set and highlights those that appear 
in the top twenty in both data sets.  
 
The majority of genes listed in Table 6-1 encode for extracellular matrix 
proteins, suggesting that high levels of CXCL12 may associate with the 
deposition and establishment of the matrix. Five genes were selected for 
validation by qRT-PCR in the human omental metastases of HGSC. 
Decorin and collagen VI α3 were selected on the basis that they 
appeared in the top twenty common genes in both data sets. In addition 
these two genes were up regulated in a cisplatin resistant ovarian 
cancer cell line relative to the parental line (Sherman-Baust et al., 2003).  
Chapter 6 – CXCL12 and ECM gene expression 
 157 
AOCS data set Fold change GSE 6008 & 3149 data 
set 
Fold change 
collagen X α 1 11.780 lumican 11.558 
lumican 9.110 collagen V α 2 8.694 
collagen III α 1 7.558 fibronectin 1 6.404 
decorin 7.176 SPARC (osteonectin) 6.351 
versican 6.290 collagen III α 1 6.240 
TIMP metallopeptidase 
inhibitor 3 
6.205 collagen I α 1 6.137 
collagen V α 1 6.186 TIMP metallopeptidase 
inhibitor 3 
6.060 
collagen V α 2 6.032 collagen V α 1 5.635 
collagen I α 1 5.942 vascular cell adhesion 
molecule 1 
5.264 
vascular cell adhesion 
molecule 1 
5.742 fibrillin 1 5.057 
cartilage oligomeric 
matrix protein 
5.407 thrombospondin 1 5.045 
fibrillin 1 4.912 decorin 4.923 
actin, alpha 2, smooth 
muscle, aorta 
4.825 collagen VI α 3 4.581 
fibronectin 1 4.823 actin, alpha 2, smooth 
muscle, aorta 
4.410 
thrombospondin 1 4.775 matrix metallopeptidase 2 
(type IV collagenase) 
4.197 
plasminogen activator, 
urokinase 
4.769 matrix metallopeptidase 
11 (stromelysin 3) 
4.193 
SPARC (osteonectin) 4.229 serpin peptidase inhibitor, 
clade E (nexin, 
plasminogen activator 
inhibitor type 1), member 
1 
3.556 
collagen VI α 3 4.192 collagen XVI α 1 3.498 
collagen I α 2 3.928 cartilage oligomeric 
matrix protein 
3.280 
matrix 
metallopeptidase 11 
(stromelysin 3) 
3.839 
 
nidogen 2 (osteonidogen) 3.190 
 
Table 6-1 The twenty genes up regulated in high CXCL12 expressing biopsies 
common to two independent data sets. 
Table listing the twenty cell-matrix interactions and ECM remodelling genes with the 
greatest fold change values, when comparing their expression in the 50 highest versus 
the 50 lowest CXCL12 expressing ovarian cancer biopsies. The genes listed here are 
those common to the AOCS and the GSE 6008 and 3149 affymetrix gene expression 
array data sets. Those highlighted appear in the top twenty for both data sets. Fold 
change values are averaged from each gene probe set. p value ≤ 0.05. 
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Decorin is a member of the small leucine rich proteoglycan family and 
interestingly actually more renowned for its tumour growth inhibitory 
effects in many cancers through blockade interactions with EGFR (Sofeu 
Feugaing et al., 2013). Lumican was also one of the top twenty common 
genes in both data sets, and also falls within the same family of matrix 
proteins (Iozzo and Sanderson, 2011).  
 
Versican is within the proteoglycan family and appeared in the top 
twenty common genes in the AOCS data set only. Versican secreted by 
myeloid progenitor cells in the lung were found to support the 
establishment of breast cancer metastases (Gao et al., 2012). To study 
the overall expression of the proteoglycan family matrix proteins in the 
omental metastases, both lumican and versican were selected for 
validation. 
 
Absent from the genes listed in Table 6-1 is periostin. This gene had the 
greatest fold change in expression (fold change value = 24.051) when 
comparing high versus low CXCL12-expressing biopsies in the AOCS 
data set. Periostin is a cell adhesion protein originally identified in 
osteoblasts. It is involved in heart embryonic development, wound repair 
and tumour development and is up regulated in many cancers including 
ovarian cancer (Ismail et al., 2000; Matei et al., 2002). It has been 
suggested that periostin may play a role in metastasis and angiogenesis 
in an in vivo model of ovarian carcinoma (Zhu et al., 2010). Ovarian 
cancer cell derived lysophosphatidic acid may also stimulate periostin 
expression in adipose tissue derived stromal cells (Choi et al., 2011). 
Given the significance of this to the adipose tissue of the omentum and 
therefore the microenvironment HGSC metastases, periostin was also 
selected for validation.  
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6.5. Correlating the ECM genes selected for validation 
with CXCL12 in the biopsies of the AOCS and GSE 6008 & 
3149 data sets  
 
The genes selected for validation in the HGSC omental metastases, 
decorin, lumican, versican, collagen VI α3 and periostin were correlated 
with CXCL12 expression in the 285 and 245 ovarian cancer biopsies of 
the AOCS and GSE 6008 and 3149 data sets respectively (Table 6-2). A 
correlation coefficient was generated for each ECM gene with CXCL12 
expression, where a value of 0.8 or more was considered a strong 
positive correlation. The strength of the correlations was moderate, but 
positive in each case. This confirmed the association of these genes 
with CXCL12 expression in the ovarian cancer biopsies of the AOCS 
and GSE 6008 and 3149 data sets. 
 
Gene	  	   AOCS	  data	  set	  
correlation	  
GSE	  6008	  &	  3149	  
data	  set	  
correlation	  
Decorin 0.540	   0.550	  
Lumican 0.704	   0.668	  
Versican 0.580	   0.535	  
Collagen VI α3 0.545	   0.616	  
Periostin 0.579	   0.425	  
CXCL12 0.970	   0.908	  
 
Table 6-2 Correlation between CXCL12 and ECM gene expression in ovarian 
cancer biopsies. 
The ECM genes listed were correlated with CXCL12 expression across all of the 
ovarian cancer biopsies of the AOCS (285 biopsies) and the GSE 6008 and 3149 (245 
biopsies) data sets. The table indicates the correlation coefficients for each ECM gene. 
A correlation coefficient value of 0.8 or more was considered a strong positive 
correlation. p value ≤ 0.05. 
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6.6. Associating immune cell signatures with CXCL12 
in the biopsies of the AOCS and GSE 6008 & 3149 data 
sets 
 
Gene set signatures defining macrophage and other immune cell 
infiltrates (Abbas et al., 2005) were used to interrogate the differentially 
expressed genes associated with high levels of CXCL12. All immune cell 
signatures analysed were up regulated in high CXCL12 expressing 
biopsies (Table 6-3). This was with the exception of the neutrophils in 
the GSE 6008 and 3149 data set, where the gene set signature was not 
significantly up regulated (p = 0.759). Macrophage and monocyte gene 
signatures were amongst the most significantly up regulated of all the 
immune cell signatures analysed. Therefore the association between 
CXCL12 and increased macrophage infiltrates previously described in 
the laboratory (Kulbe et al., 2012) was further confirmed. Of the M1 and 
M2 macrophage phenotypes, the M1 gene signature was the most 
significantly up regulated in both data sets. 
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 AOCS data set p-values GSE 6008 & 3149 data set p-
values 
Immune cell  
type  
signatures 
Up 
regulated 
Down 
regulated 
Up 
regulated 
Down 
regulated 
Monocytes 4.38E-­‐25 1 8.04E-­‐11 1 
Macrophages 1.87E-­‐17 1 1.95E-­‐12 1 
M1 1.65E-­‐14 1 6.87E-­‐08 0.999 
M2 8.14E-­‐08 0.999 7.29E-­‐06 0.999 
T cells 7.52E-­‐24 1 3.89E-­‐06 0.999 
B cells 1.23E-­‐15 1 5.86E-­‐09 0.999 
Neutrophils 7.19E-­‐05 0.999 0.759 0.241 
 
Table 6-3 Up regulation of immune cell signatures in high CXCL12 expressing 
ovarian cancer biopsies. 
Publically available gene set signatures associated with immune cell subtypes were 
used to interrogate the gene expression microarray data of the AOCS and GSE 6008 
and 3149 data sets. High CXCL12 expressing ovarian cancer biopsies showed 
enrichment in all immune cell signatures analysed. Table lists the associated p-values 
for up and down regulated immune cell signatures. 
 
Genes within the macrophage gene set signature and differentially 
expressed in high CXCL12 expressing biopsies of the AOCS (Table 10-
3 in Appendix I) and GSE 6008 and 3149 (Table 10-4 in Appendix I) 
were identified. These genes were analysed to question whether the 
selected ECM genes appeared in the list. None of the ECM genes 
selected were associated with both high levels of CXCL12 and 
macrophage infiltrates in the biopsies. However it was noted that CD36, 
which is the receptor for thrombospondin 1 (Lopez-Dee et al., 2011) was 
significantly associated with CXCL12 and macrophage infiltrates (AOCS; 
2.709 fold change, GSE 6008 & 3149; 1.709 fold change, probe set p-
values less than 0.05). Thrombospondin 1 appeared in the top twenty 
common genes in both data sets (Table 6-1).  
 
In summary, decorin, lumican, versican, collagen VI α3, periostin and 
thrombospondin 1 were all selected to validate their association with 
CXCL12 by qRT-PCR in the human omental metastases of HGSC. 
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6.7. Optimisation and establishment of appropriate 
house-keeping genes for qRT-PCR gene expression 
validation in the human omental metastases of HGSC 
 
The human omental metastases were very heterogeneous in their 
cellular composition and therefore it was likely that the expression of 
routinely used house keeping genes measured by qRT-PCR would vary 
significantly between samples. Vandesompele J and colleagues studied 
the expression of ten different house keeping genes in a cell line, 
primary cells and several different tissue samples (Vandesompele et al., 
2002). These data were used to identify the error in gene expression 
data when single house keeping genes were used. A mathematical 
algorithm was generated to establish the combination and number of the 
most stably expressed house keeping genes that should be used in 
gene expression analyses within a given sample set. This algorithm is 
now publically available in the geNorm software 
(http://www.biogazelle.com/qbaseplus). 
 
On the basis of this report and those routinely used in the laboratory ten 
house keeping genes were selected (GAPDH, 18s, β2M, RPL34, UBC, 
HMBS, HPRT1, TBP, ACTB, and YWHAZ) for optimisation in the human 
omental metastases. The measured expression data for these genes in 
the omental metastases was imported into the geNorm software that 
calculated an M value for each gene (Figure 6-3a). This was a measure 
of gene expression stability across all the samples. The lower the M 
value was the more stable the expression. The software also generated 
a V value, which was a measure of the systematic pairwise variation in 
expression between all the tested genes in each sample (Figure 6-3b). 
On the basis of the nature of the samples, the software generated a 
threshold for the most suitable V value for the sample set. In conclusion 
it was established that for the given set of omental metastases samples, 
the geometric mean of the expression values for HPRT1, TBP, ACTB 
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and YWHAZ in each sample should be used as a house keeping gene 
reference for further gene expression analyses. 
 
 
 
Figure 6-3 House keeping reference gene optimisation in the human omental 
metastases of HGSC. 
Graphs generated by the geNorm software after input of the expression of ten house 
keeping reference genes in the omental metastases samples. a) The lowest geNorm 
calculated M value indicated the most stably expressed genes across all the samples. 
b) The geNorm V value was calculated by measuring the pairwise variation in 
expression of each gene in each sample. The V value below a given threshold suitable 
to the sample set identified the optimal number of house keeping genes to be used as 
a reference in subsequent experiments. 
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6.8. CXCL12 and ECM gene expression correlation 
validation in human omental metastases of HGSC 
 
The mRNA expression of the selected ECM genes; decorin, lumican, 
versican, collagen 6 α 3, periostin, and thrombospondin 1 together with 
CXCL12 in whole HGSC omental metastasis samples were measured 
by qRT-PCR. The strength of the correlations between all the ECM 
genes and CXCL12 was tested. The only ECM gene to show a 
significant positive correlation with CXCL12 was decorin (Figure 6-4). 
 
 
 
Figure 6-4 The correlation between CXCL12 and decorin mRNA expression in 
human omental metastases of HGSC. 
The relative mRNA expression levels of CXCL12 and decorin were measured by 
quantitative real-time PCR in ten samples of HGSC omental metastasis. The fold 
change in gene expression was calculated relative to the geometric mean of the cycle 
threshold values for the reference genes ACTB, YWHAZ, TBP and HPRT1. r = 
Spearman rank correlation coefficient. 
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The expression of CXCR4, the receptor for CXCL12, was also measured 
in all the HGSC omental metastasis samples. CXCR4 showed a 
significant positive correlation with 50% of the ECM genes analysed 
(Figure 6-5). 
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Figure 6-5 The correlation between CXCR4 and ECM gene mRNA expression in 
human omental metastases of HGSC. 
The relative mRNA expression levels of CXCR4, a) lumican, b) versican and c) 
periostin were measured by quantitative real-time PCR in eight samples of HGSC 
omental metastasis. The fold change in gene expression was calculated relative to the 
geometric mean of the cycle threshold values for the reference genes ACTB, YWHAZ, 
TBP and HPRT1. r = a) Spearman or b & c) Pearson rank correlation coefficient. 
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Figure 6-6 The correlation between immune cell infiltrates and thrombospondin 1 
mRNA expression in human omental metastases of HGSC. 
The relative mRNA expression levels of thrombospondin 1 were measured by 
quantitative real-time PCR in ten samples of HGSC omental metastasis. The fold 
change in gene expression was calculated relative to the geometric mean of the cycle 
threshold values for the reference genes ACTB, YWHAZ, TBP and HPRT1. The mRNA 
expression levels were correlated with the corresponding percentages of a) CD68 
positive macrophages and b) CD3 positive T cells in relation to the hematoxylin nuclear 
counterstain (data collected in chapter 3). r = Pearson rank correlation coefficient. 
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The expression of CXCL12 associated with immune cell infiltrates in the 
ovarian cancer biopsies of the AOCS and the GSE 6008 and 3149 data 
sets (Table 6-3). Therefore the immune cell infiltrate and Ki67 data for 
each HGSC omental metastasis sample collected in chapter 3 was then 
also correlated with the CXCL12, CXCR4 and ECM gene expression 
data. Thrombospondin 1 showed a significant negative correlation with 
CD68 positive macrophages and CD3 positive T cells (Figure 6-6). 
 
Periostin also showed a significant negative correlation with CD8 
positive T cells (Figure 6-7). However CXCL12 and CXCR4 did not 
correlate with the immune cell infiltrates, and no other correlations with 
the ECM genes were identified. 
 
 
 
 
Figure 6-7 The correlation between CD8 positive T cells and periostin mRNA 
expression in human omental metastases of HGSC. 
The relative mRNA expression levels of periostin were measured by quantitative real-
time PCR in nine samples of HGSC omental metastasis. The fold change in gene 
expression was calculated relative to the geometric mean of the cycle threshold values 
for the reference genes ACTB, YWHAZ, TBP and HPRT1. The mRNA expression 
levels were correlated with the corresponding percentages of CD8 positive T cells in 
relation to the hematoxylin nuclear counterstain (data collected in chapter 3). r = 
Spearman rank correlation coefficient. 
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6.9. Concluding statements 
 
Associations between CXCL12, ECM gene expression and immune cell 
infiltrates were identified in two independent gene expression microarray 
data sets. A small cohort of ECM genes was selected for validation by 
qRT-PCR in a sample set of human HGSC omental metastases. The 
GeNorm software established following a publication by Vandesompele 
and colleagues (Vandesompele et al., 2002) was used to test ten 
different house keeping genes across the sample set. The software 
generated an optimised house keeping reference for gene expression 
analysis. 
 
Only decorin of the six ECM genes analysed correlated with CXCL12 
when further analysed by qRT-PCR, and none of the immune cell 
infiltrates showed a significant correlation. This suggested that the 
associations observed in the primary ovarian cancer biopsies might not 
apply to the metastases. However CXCR4 did significantly correlate with 
lumican, versican and periostin, indicating that the expression of the 
receptor might be more relevant to these associations than the 
expression of the ligand. CXCR4 is a chemokine receptor within the 
described ‘TNF Network’ (Kulbe et al., 2005; Kulbe et al., 2007). The 
expression of inflammatory cytokines can activate the transcription factor 
NF-κB (Hagemann et al., 2005). Within a positive feedback loop, NF-κB 
itself can regulate the expression of inflammatory cytokines (Greten et 
al., 2004). Perhaps therefore, the associated expression of CXCR4 and 
the ECM genes lumican, versican and periostin are co-regulated by NF-
κB. 
 
Malek and colleagues recently reported that CXC chemokines inclusive 
of CXCL12 were amplified in the primary ovarian tumour but not in the 
metastases (Malek et al., 2011). CXCR4 is expressed on the malignant 
cells (Scotton et al., 2001) and the leukocytes (Tchernychev et al., 2010) 
within the ovarian cancer microenvironment. Perhaps at the site of 
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metastasis, the association between CXCR4 and ECM gene expression 
relates to enrichment in CXCR4 expressing cells and increased matrix 
deposition within the microenvironment that does not depend upon 
CXCR4 signalling per se. 
 
CD36 was identified amongst the genes up regulated in high CXCL12 
expressing biopsies and within the macrophage gene set signature. The 
ECM protein thrombospondin 1 is a ligand for the CD36 receptor, and 
inhibits angiogenesis through interaction with the receptor on endothelial 
cells (Hall et al., 2013; Lopez-Dee et al., 2011). Thrombospondin 1 
negatively correlated with CD68 positive macrophages and CD3 positive 
T cells. This perhaps suggests that in a microenvironment rich in 
immune cells and actively angiogenic (Leinster et al., 2012; Yang et al., 
2004), thrombospondin 1 may be down regulated.  
 
An infiltrate of CD8 positive T cells is associated with a good survival 
rate in ovarian cancer patients (Fridman et al., 2012). Periostin showed 
a significant negative correlation with CD8 positive T cells in the HGSC 
omental metastases, which may indicate that periostin is also associated 
with a poor prognosis, however this requires further investigation. 
 
6.10. Summary 
 
• 48 ECM genes associated with high levels of CXCL12 expression in 
two independent gene expression microarray data sets of 285 (AOCS) 
and 245 (GSE 6008 & 3149) ovarian cancer biopsies.  
• Six ECM genes were selected to validate the association with CXCL12 
expression by qRT-PCR in human omental metastases of HGSC. These 
genes were lumican, versican, decorin, periostin, thrombospondin 1, and 
collagen VI α 3. 
• CXCR4 positively correlated with lumican, versican and periostin. 
• CXCL12 positively correlated with decorin. 
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• CD68 positive macrophages negatively correlated with thrombospondin 
1. 
• CD3 positive T cells negatively correlated with thrombospondin 1. 
• CD8 positive T cells negatively correlated with periostin. 
 
Overall there was no significant association between CXCL12 and ECM 
gene expression in the human omental metastases of HGSC identified 
in this chapter. Consequently there was no justification to study the 
effect of neutralising CXCL12 signalling on ECM gene expression in the 
3D omental model. Therefore advancing the 3D omental model by 
introduction of an immune cell infiltrate became the focus of the next 
chapter. 
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Chapter 7 
7. Introducing an immune cell infiltrate to the 
3D omental model 
 
The established 3D omental model described in chapter 4 lacks any 
immune cell component. Following a review of recent literature 
describing available 3D models of ovarian cancer (section 1.4), there 
was clearly room in the field for the development of 3D models 
incorporating immune cells. Therefore the effect of including an 
inflammatory cell type to the established 3D omental model was 
investigated. A recent report from the laboratory described an increase 
in CD68 positive macrophages in ovarian cancer biopsies expressing 
high levels of the cytokines and chemokines of the TNF network, which 
includes CXCL12 (Kulbe et al., 2012). In addition both CXCL12 
signalling and macrophage infiltrates were both required for invasion and 
metastasis in a breast cancer in vivo model (Boimel et al., 2012). In 
chapter 3 an infiltrate of CD68 positive macrophages in human omental 
metastases of HGSC significantly correlated with increased Ki67 positive 
malignant epithelial cells (Figure 3-8). Therefore in this chapter 
macrophages were introduced into the 3D omental cell culture model 
and the influence of this on malignant cell proliferation was investigated. 
 
7.1. Introducing THP1 monocytic cell line derived 
macrophages to the 3D omental model 
 
The first experiments were carried out with the THP1 monocytic cell line 
that was established from a patient with acute monocytic leukaemia 
(Tsuchiya et al., 1980). These cells can be cultured in suspension in the 
presence of 0.05mM β-mercaptoethanol, and then differentiated into 
adherent macrophages through culture with 5ng/mL phorbol 12-
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myristate 13-acetate (PMA) for a minimum of 48 hours (Park et al., 
2007). The differentiated macrophages express the markers CD68, 
CD36, CD11b (Phillips et al., 2005) and CD14 (Daigneault et al., 2010). 
 
Even without a differentiation step, the THP1 cells share similar 
characteristics to tumour-associated macrophages. For instance, co-
culture of THP-1 cells with non-small cell lung cancer cell lines induced 
tumour cell expression of the angiogenic cytokine IL-8 (Chen et al., 
2003). Additionally these cells have been used to demonstrate how 
macrophage-tumour cell interactions stimulate IL-1β in THP1 cells 
leading to the activation of Wnt signalling in colon cancer cells 
supporting tumour growth. (Kaler et al., 2009). A later study further 
suggested that the stimulation of IL-1β in the THP1 cells and paracrine 
signalling in the tumour cells, downstream stabilised Snail and blocked 
TRAIL-induced apoptosis (Kaler et al., 2010). 
 
Initially THP1 derived macrophages were co-cultured in the 3D omental 
model with the ovarian cancer cell line AOCS1 (Figure 7-1). Analysis of 
immunohistochemistry stained omental metastases of HGSC 
demonstrated that CD68 positive macrophages were predominantly 
localised within the tumour deposits rather than in the surrounding 
stroma (Figure 3-5). Therefore to mimic these tumour-infiltrating 
macrophages in the 3D omental model, THP1 derived macrophages 
were detached and pooled together with the ovarian cancer cells to seed 
on the surface of the model. The numbers of macrophages to test in the 
model were deduced on the basis that CD68 positive macrophages 
constituted for 11.3% of the total tumour microenvironment in human 
omental metastases of HGSC as determined in chapter 3 (Figure 3-6). 
When co-culturing the AOCS1 ovarian cancer cells on the 3D omental 
model, 11.3% of the total number of cells in the model equated to 
approximately 37,000 macrophages. A titration of macrophage numbers 
ranging below and above this value was also tested in the 3D omental 
model. 
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Cross-sections of the 3D omental model were stained by 
immunofluorescence with a pan-cytokeratin antibody to identify the 
tumour cells and for CD68 to distinguish the macrophages (Figure 7-1a). 
The THP1 derived macrophages were also cultured on the 3D omental 
model without the tumour cells (Figure 7-1b). The immunofluorescence 
staining was controlled with tonsil sections illustrating the presence of 
pan-cytokeratin positive epithelial cells (Figure 7-1c) and CD68 positive 
macrophages (Figure 7-1d). This staining revealed that the THP1-
derived macrophages incorporated themselves into the collagen matrix, 
whilst the AOCS1 ovarian cancer cells remained viable on the surface of 
the model.  
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Figure 7-1 Co-culture of AOCS1 ovarian cancer cells and THP1 derived 
macrophages in the 3D omental model. 
Representative immunofluorescence images of 5 µm thick cross sections of the 3D 
omental models when 25K tumour-infiltrating mimicking THP1 derived macrophages 
(mϕ) were co-cultured a) with and b) without the ovarian cancer cell line AOCS1 for two 
weeks. Sections of human tonsil were used as a positive control for c) pan-cytokeratin 
positive epithelial cells and d) CD68 positive macrophages. Blue = Hoechst nuclei 
stain, Green = CD68, Red = pan-cytokeratin. 40x magnification, bar = 50 µm. 
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To assess whether the ovarian cancer cells were proliferating in the 
culture, immunohistochemistry stained sections of the 3D omental 
models were analysed using the Leica Ariol software to quantify the Ki67 
positive epithelial cells relative to the total cell counts (Figure 7-2). The 
AOCS1 ovarian cancer cells were proliferating in the model. However 
increasing the number of co-cultured THP1 derived macrophages had 
no significant effect on the proliferation of the ovarian cancer cell line 
AOCS1 in the 3D omental model.  
 
 
 
Figure 7-2 The effect of increasing numbers of THP1 derived macrophages on 
the proliferation of the ovarian cancer cell line AOCS1 in the 3D omental model 
Quantification of the proliferation indices of the ovarian cancer cell line AOCS1 on the 
3D omental models co-cultured with 0 – 100K of tumour-infiltrating mimicking THP1 
derived macrophages (mϕ). Tumour cells were cultured on the 3D omental model for 
two weeks. 3D omental model cross-sections were analysed by computer-aided 
microscopy and Leica Ariol software. Values are the number of Ki67 positively stained 
cells in relation to the hematoxylin nuclear counterstain. Bars indicate the means and 
standard deviations across all measurements. Collective data from three experiments. 
Data not statistically significant. 
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Following the successful co-culture of the THP1 derived macrophages in 
the 3D omental model, collaboration with MedImmune, Cambridge 
offered the opportunity to pursue introducing macrophages to the model 
further. A recent publication comparing the PMA differentiated THP1 
monocytic cell line with PBMCs suggested that PBMCs show significant 
increased LPS induced release of cytokines such as IL1-β, TNF-α, IL-6 
and IL-8 compared with the THP1 cells (Daigneault et al., 2010). In 
addition the phagocytosis function of the PMA differentiated THP1 cells 
was less efficient than that of PBMCs. However the differentiation of 
PBMCs to monocyte-derived macrophages reduced their capacity to 
phagocytose opsonised latex beads to a level that was comparable to 
the differentiated THP1 cells. Ultimately THP1 monocytic cells were 
originally established from a patient with acute monocytic leukaemia 
(Tsuchiya et al., 1980). Therefore the THP1 cells are likely to carry 
oncogenic mutations that could interfere with the growth of other cells 
within the 3D omental model and distort studies on the mutation status 
of co-cultured ovarian cancer cells. It was advised to discontinue work 
with this cell line and start to evaluate introducing PBMC derived 
macrophages to the 3D omental model. It was also advised to co-culture 
GFP labelled ovarian cancer cells in the model since this would aid 
differentiation between the macrophages and tumour cells within the 
matrix.  
 
7.2. Introducing peripheral blood monocytic cell 
(PBMC) derived macrophages to the 3D omental model 
 
PBMCs were extracted from the blood of a healthy human donor by 
density gradient centrifugation. The monocytes were isolated from this 
preparation by adherence and cultured in the presence of macrophage 
colony-stimulating factor (M-CSF) for one week to allow differentiation 
into macrophages.  
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PBMC-derived macrophages were co-cultured with the GFP positive 
SKOV3ip1 ovarian cancer cell line (Figure 7-3). The aim of the 
experiments was to investigate the effect of introducing the 
macrophages on ovarian cancer cell growth, proliferation, invasion and 
cytokine expression. The SKOV3ip1 cells were selected for co-culture 
since they were thought to be HGSC cells (section 4.1) and were 
invasive in the 3D omental model as described in chapter 4 (Figure 4-
10), whereas the AOCS1 cells were not invasive (Table 4-2). The 
SKOV3ip1 cells were co-cultured in the 3D model with (Figure 7-3c & d) 
and without (Figure 7-3a & b) the PBMC derived macrophages to 
determine what effect the macrophages may have on ovarian cancer cell 
invasion. Malignant cells may lose cytokeratin expression during the 
process of invasion (Huang et al., 2012). Hence, GFP-labelled ovarian 
cancer cells can be distinguished from other cell types in the model with 
greater accuracy than using pan-cytokeratin as a marker (Figure 7-1). 
 
11.3% of the total cell population in the microenvironment of the 3D 
omental model culturing the SKOV3ip1 ovarian cancer cells equated to 
approximately 17,800 macrophages. 20,000 PBMC derived 
macrophages were therefore introduced to the models (Figure 7-3). The 
CD68 positive macrophages can be clearly identified in 
immunofluorescence labelled cross-sections of the model (Figure 7-3c). 
The macrophages not only survived in the model, but they also 
incorporated themselves into the matrix (Figure 7-3c & d). Figure 7-3d 
demonstrates co-localised staining of GFP and CD68, suggesting that 
the CD68 positive macrophages may have a tendency to phagocytose 
the tumour cells cultured in the model. Alternatively, the co-localised 
staining may be a result of direct interactions between the tumour cells 
and macrophages. Such interactions mediated by integrins have been 
reported to promote tumour cell viability during metastasis (Chen and 
Massague, 2012). In addition, macrophage differentiation increases auto 
fluorescence (Daigneault et al., 2010), which may have also contributed 
to the fluorescence of the macrophages in the 488nm green channel as 
observed in Figure 7-3d. 
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Figure 7-3 Co-culture of SKOV3ip1 ovarian cancer cells and PBMC derived 
macrophages in the 3D omental model. 
Representative immunofluorescence images of 5 µm thick cross sections of the 3D 
omental models when ovarian cancer cell line SKOV3ip1 was co-cultured for two 
weeks a & b) without and c & d) with 20K tumour-infiltrating mimicking PBMC derived 
macrophages (mϕ). PBMCs were isolated from the blood of a healthy donor. a & c) 
Images showing CD68 immunostaining. b & d) Images showing merged CD68 and 
GFP immunostaining. Blue = Hoechst nuclei stain, Green = GFP, Red = CD68. 40x 
magnification, bar = 50 µm. 
 
 
Expression of CD68 observed in the 543nm red channel was specific to 
macrophages in the immunofluorescence labelled cross-sections of the 
model (Figure 7-3c). Therefore images of the CD68 staining alone were 
used to eliminate the macrophages from the images using the image 
analysis software ImageJ. Subsequently these images were used to 
quantify the tumour cell area and invasion as previously described in 
chapter 4. 
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There was time for only one experiment to be carried out in collaboration 
with MedImmune. However the observable trend of the data illustrated a 
decline in SKOV3ip1 ovarian cancer cell growth (Figure 7-4a), 
proliferation (Figure 7-4b) and invasion (Figure 7-5) in the presence of 
PBMC derived macrophages. This may support the concept that 
macrophages introduced into the 3D omental model undergo 
phagocytosis of the co-cultured tumour cells. Additionally the 
macrophages may be producing cytotoxic reactive nitrogen and oxygen 
intermediates and TNF-α that can induce apoptosis in the ovarian 
cancer cells (Sica and Mantovani, 2012). These tumoricidal activities of 
macrophages may be collectively contributing to the potential decline in 
tumour growth and invasion observed in the 3D omental model (Figure 
7-4 & 5). 
 
However, in ovarian cancer an infiltrate of macrophages is associated 
with a poor patient prognosis (Kryczek et al., 2007; Vaughan et al., 
2011). The 3D omental co-culture system may not have sufficient time 
for the microenvironment to polarise the macrophages into a tumour-
promoting phenotype. Therefore the macrophages may need to be 
polarised before incorporated into the model. Alternatively it would be 
interesting to maintain the cultures for an even longer time period than 
two weeks to determine whether the macrophages eventually become 
polarised and promote tumour cell growth. 
 
In more recent years the polarisation status of macrophages has been 
better appreciated as a continuum of phenotypes (Wynn et al., 2013), 
but for simplicity macrophages have been sub-categorised by their 
classical (M1) and tumour-associated (M2) phenotypes (Section 1.2.3). 
M2 macrophages have previously been further sub-divided to M2a, b 
and c macrophages in accordance with the activating stimuli (Mantovani 
et al., 2004). Broadly speaking, the M2a macrophages activated by IL-4 
and IL-13 are involved in phagocytosis, and would therefore have 
tumoricidal capabilities. Whereas at the opposite end of the spectrum, 
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the M2c macrophages activated by IL-10, are more driven towards 
regulation of the immune system. These macrophages would be more 
representative of those that promote tumour progression. Interestingly, 
the M2c macrophages also have greater involvement in ECM deposition. 
It would be important to consider polarising the macrophages more 
specifically towards an M2c phenotype to better support the malignant 
microenvironment of the developing 3D omental model, and to establish 
a system where ECM remodelling could be measured. 
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Figure 7-4 The effect of PBMC derived macrophages on the growth and 
proliferation of the SKOV3ip1 ovarian cancer cell line on the 3D omental model 
Graphs illustrating the quantified a) growth and b) proliferation indices of the ovarian 
cancer cell line SKOV3ip1 on the 3D omental models co-cultured with and without 20K 
tumour-infiltrating mimicking PBMC derived macrophages (mϕ). PBMCs were isolated 
from the blood of a healthy donor. Tumour cells were cultured on the 3D omental 
model for two weeks. Photographs of immunofluorescence stained sections were taken 
across the whole section of each model. Each treatment group was tested with 
duplicate models. The tumour area (µm2) on each photograph was quantified as a 
measure of tumour growth. To quantify proliferation indices, 3D omental model cross-
sections were analysed by computer-aided microscopy and Leica Ariol software. 
Values are the number of Ki67 positively stained cells in relation to the hematoxylin 
nuclear counterstain. Bars indicate the means and standard deviations across all 
measurements. Data from a single experiment. Data not statistically significant. 
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Figure 7-5 The effect of PBMC derived macrophages on the invasion of the 
SKOV3ip1 ovarian cancer cell line in the 3D omental model 
Graph illustrating the quantified invasion index of the ovarian cancer cell line SKOV3ip1 
in the 3D omental models co-cultured with and without 20K tumour-infiltrating 
mimicking PBMC derived macrophages (mϕ). PBMCs were isolated from the blood of a 
healthy donor. Tumour cells were cultured on the 3D omental model for two weeks. 
Photographs of immunofluorescence stained sections were taken across the whole 
section of each model. Each treatment group was tested with duplicate models. The 
invasion index from each photograph was determined. The invasion index is a factor of 
the number of invading particles, tumour area (µm2) and invasion distance (µm). Bars 
indicate the means and standard deviations across all measurements. Data from a 
single experiment. Data not statistically significant. 
 
 
Cytokine production can be used as a measure of macrophage 
polarisation. The inflammatory cytokines TNF-α and IL1-β are known to 
promote malignant transformation and metastasis (Balkwill and 
Mantovani, 2012). In addition, many oncogenic mutations are drivers of 
inflammatory signalling pathways. For example RET activation in thyroid 
carcinomas induces the expression of the pro-inflammatory cytokine IL1-
β, the angiogenesis inducing cytokine IL-8, and also CXCR4 in the 
malignant cells. (Grivennikov et al., 2010; Mantovani et al., 2008). 
Therefore in this 3D omental model where there are direct cell 
interactions between immune, malignant and stromal cell types, the 
Chapter 7 – Introducing macrophages to the 3D omental model 
 184 
levels of cytokines and chemokines were investigated compared to 
control models which were absent for the PBMC derived macrophages 
(Figure 7-6). RNA was extracted from the 3D omental models and qRT-
PCR was performed on the reverse transcribed cDNA to analyse the 
relative expression of a panel of cytokines and chemokines. There were 
detectable increases in cytokine and chemokine levels in the presence 
of PBMC derived macrophages (Figure 7-6). There was an increase in 
the relative expression levels of the pro-inflammatory and classical 
macrophage associated cytokines IFN-γ (Figure 7-6a), IL-12 (Figure 7-
6c), IL1-β (Figure 7-6e) and IL-6 (Figure 7-6f), however there was no 
detectable increase in TNF-α (Figure 7-6b). Given the high levels of 
TNF-α already expressed by ovarian cancer cells as previously 
described by the TNF network (Kulbe et al., 2012), any increase in the 
levels of TNF-α within the metastatic microenvironment mimicked by the 
3D omental model, may not be easily measured by qRT-PCR. 
 
Interestingly there was an increase in the anti-inflammatory, tumour-
associated macrophage related cytokine IL-10 (Figure 7-6d). Tumour-
associated macrophages promote angiogenesis (Wynn et al., 2013) and 
there was also an increase in the angiogenic cytokine IL-8 (Figure 7-6g) 
in the 3D omental model in the presence of PBMC derived 
macrophages. There was however no detectable increase in VEGF 
(Figure 7-6h). This may be consequential to the absence of vascular 
endothelial cells in the model system, or due to the normoxic growth 
conditions that the 3D omental models were cultured in, as angiogenic 
macrophages are driven by hypoxia (Wynn et al., 2013). 
 
In addition, following the significant but minimal effect of an antibody 
targeting CXCL12 in the 3D omental model as described in chapter 5, 
introducing PBMC derived macrophages to the model increased the 
relative expression levels of CXCL12 (Figure 7-6i). Therefore the 
CXCL12 targeted antibody may have a greater impact on the growth, 
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survival and invasion of ovarian cancer cells co-cultured in a 3D omental 
model that includes a macrophage infiltrate. 
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Figure 7-6 The effect of PBMC derived macrophages on the relative gene 
expression of cytokines and chemokines in the 3D omental model 
The relative mRNA expression levels measured by quantitative real-time PCR of a) 
IFNγ, b) TNFα, c) IL-12, d) IL-10, e) IL1-β, f) IL-6, g) IL-8, h) VEGF and i) CXCL12 in 
the 3D omental model when the ovarian cancer cell line SKOV3ip1 were co-cultured 
with and without 20K tumour-infiltrating mimicking PBMC derived macrophages (mϕ). 
PBMCs were isolated from the blood of a healthy donor. Tumour cells were cultured on 
the 3D omental model for two weeks. Bars represent the fold change in gene 
expression calculated relative to the geometric mean of the cycle threshold values for 
the reference genes ACTB, YWHAZ, TBP and HPRT1. n = 1. 
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7.3. Conclusions and future work 
 
These data shown here in this chapter is preliminary work that sets 
scope for much further optimisation and development. From this chapter 
the following points can be considered for future work: 
 
• Complete titrations and ratio controls between the numbers of 
macrophages versus the other cells in the 3D omental model 
needs to be established and optimised. 
• Are the macrophages phagocytosing the co-cultured tumour 
cells? Are the macrophages active in other tumoricidal 
mechanisms within the model? 
• PBMC derived macrophages are a better cell type to use in the 
co-culture system than THP1 derived macrophages.  
• The expression of any genes of interest in the 3D omental model 
can be analysed by qRT-PCR. 
• Gene expression and cellular interactions in the 3D omental 
model with an introduced macrophage infiltrate may be more 
accurate to the clinical situation if the models were cultured in 
hypoxic conditions. 
• Ovarian cancer cell lines that are grown on the 3D omental model 
must now be chosen with greater caution. 
 
Once established, a 3D cell culture model mimicking an inflammatory 
infiltrate of macrophages in omental metastases of HGSC, could be 
used to study the impact of macrophage polarisation on the tumour 
microenvironment. Similarly the influence of the stromal and malignant 
components of the microenvironment on the macrophages themselves 
could also be investigated. With an inflammatory cell component the 
model would be more appropriate for ovarian cancer and inflammation 
studies, and would be a phenomenal tool for testing potential therapeutic 
targets. Data from this thesis provided preliminary data for the 
CANBUILD project grant proposal, for which the European Research 
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Council awarded €2.43 million to the laboratory earlier this year. The 
CANBUILD project will continue and advance the work of the 3D 
omental model development including incorporation of immune cell 
subtypes. 
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Chapter 8 
8. Discussion 
 
8.1. Implications to the field of ovarian cancer research 
 
The work of this thesis approaches two important areas of current 
research into HGSC. The first is the study of the metastases. In the clinic 
HGSC patients present with widespread peritoneal metastases and it is 
this aggressive dissemination of the disease that is reflected in the poor 
overall survival rates. Yet there still seems to be a strong focus in the 
field of research around the development of the primary tumours. 
Without disputing the importance of this work, survival rates have not 
changed in the last 30 years. This somewhat suggests that a shift in 
paradigm towards what distinguishes the metastases from the primary 
mass is required when it is the metastases that pose the real clinical 
problem.  
 
The metastasis of HGSC is different from many other cancers. HGSC 
cells disseminate freely in the peritoneal fluids and do not necessarily 
require access to the blood or lymphatic vessels to colonise other 
organs. Women predominantly present at such a late stage in disease 
progression, that the opportunity to monitor metastasis development has 
long passed. There is therefore a demand for appropriate models of 
HGSC to study this stage of the disease hence the other topic 
investigated in this thesis. 
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8.2. Future work on inflammatory infiltrates in the 
tumour microenvironment of HGSC 
 
Inflammation in the tumour microenvironment was recently recognised 
as one of the hallmarks of tumour development (Hanahan and 
Weinberg, 2011). The work of chapter 3 aimed to characterise the 
inflammatory cell infiltrates of HGSC omental metastases, and identified 
a positive correlation between CD68 positive macrophages and Ki67 
positive epithelial cells (Figure 8-1). The next question would be to 
delineate the polarisation of those macrophages in the selected patient 
samples. 
 
Since the completion of this work, Dr Steffen Boehm in the laboratory 
established a TMA of all the omental metastases with additional samples 
collected. However TMA cores cover an even smaller localised area of 
the metastases than the whole tissue sections. If malignant cells from 
the centre of an omental deposit dominate a TMA core, immune 
infiltrates surrounding that deposit (as observed in chapter 3), may fail to 
be included in the analysis. 
 
By immunohistochemistry, classically polarised macrophages 
expressing the cell surface receptors CD40, CD80 and MHC class II 
could be quantified with the Leica Ariol imaging software. TAMs 
expressing CD163 in the ascites of HGSC patients were recently 
associated with reduced relapse free survival (Reinartz et al., 2013). 
This could also be used as a marker of TAMs by immunohistochemistry 
in the omental metastases. It may also be possible to digest the omental 
specimens and measure inflammatory cell infiltrates by flow cytometry, 
however it is important here to be wary of the disruption of cell surface 
proteins by the digestion method. In addition the observation of 
inflammatory cell localisation within the metastases is lost using FACS 
analysis. 
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Figure 8-1 Summary of cellular interactions in HGSC metastasis. 
An increase in tumour-promoting macrophages within the microenvironment of HGSC 
correlated with an increase in proliferative Ki67 positive tumour cells. The mesothelial 
cells promoted tumour growth and invasion. The expression of CXCL12 may increase 
tumour cell survival. The expression of CXCR4 and its ligand associated with the 
expression of the extracellular matrix genes decorin (DCN), lumican (LUM), versican 
(VCN) and periostin (POSTN). M1 classically polarised macrophages may engulf 
tumour cells within the metastatic microenvironment. M2 tumour-promoting 
macrophages could potentially interplay with the mesothelial cells, stimulating their 
contractility, activation and EMT, leading to increased matrix deposition. 
 
 
Chapter 8 - Discussion 
 192 
Dr Steffen Boehm was able to further define the T cell populations in the 
established TMA, and identified a significant reduction in Ki67 positive 
epithelial cells with increased CD8 positive T cells (manuscript in 
preparation). This agrees with previous studies associating a CD8 
positive T cell infiltrate with improved patient prognosis (Fridman et al., 
2012).  
  
In the human omental metastases TMA, no significant correlations were 
identified with CD4 positive T cells and Ki67 positive epithelial cells. 
Perhaps further discrimination of memory, FOXP3 positive regulatory 
and helper T cells would prove otherwise.  
 
Descriptive analyses of inflammatory infiltrates in the metastases really 
carry little meaning unless the numbers are correlated with a cellular 
function, such as malignant epithelial cell proliferation for example (as 
described in chapter 3). By immunohistochemistry it would also be 
possible to quantify the number of apoptotic cells using the TUNEL 
(Terminal Transferase dUTP Nick End Labelling) assay. TUNEL is a 
marker of DNA degradation. This would give a better indication of how 
well tumour cells are surviving in the metastases especially after 
chemotherapy.  
 
The TMA cores would be beneficial here also to correlate the 
inflammatory cell infiltrates with the scored expression of inflammatory 
cytokines and chemokines such as CXCL12 (Figure 8-1). An 
understanding of this may give an indication of the cytokines and 
chemokines predisposing the omental metastasis microenvironment to 
support the infiltrate of particular inflammatory cells. These cytokines 
and chemokines may then be targeted to diminish the tumour supporting 
inflammatory cell population, and recruit the tumour-targeting 
inflammatory cells. 
 
Cytokeratin 7 (Lengyel, 2010) and CA-125 expression (Bast, 2003; 
Perets et al., 2013) are markers often used as a measure of ovarian 
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cancer epithelial cell content in immunohistochemistry sections. 
However cytokeratin 7 expression can be very heterogeneous (data not 
shown). In chapter 3 the malignant epithelial cell areas of whole tissue 
sections were defined to quantify the number of Ki67 positive cells. 
These areas could therefore be better defined with CA-125 
immunostaining. These areas could then be used to calculate an index 
for the tumour versus stroma content of each of the samples. This may 
be useful to correlate with the expression of certain cytokines and 
chemokines to define where in the metastases they are predominantly 
expressed. 
 
The intensity of immunohistochemical stains can be quantified on the 
Ariol. Therefore the intensity of Herovici staining and expression of 
αSMA for example, could be quantified to give an indication of collagen 
deposition and stromal activation respectively in the omental 
metastases. 
 
In time it would be particularly interesting to relate all the collated data 
on these omental metastases to clinical data, such as patient survival 
and response to chemotherapy. However the collection of samples for 
this particular tissue bank started with the beginning of the work for this 
thesis four years ago, therefore at the time of writing this thesis it was 
too early to establish five-year survival rates. In addition, when collecting 
the samples, if there was a more severe case, the surgeons ethically 
chose not to operate, and we did not receive a sample. Consequently 
the patients from whom we received samples are likely to survive longer, 
which will further increase the time before survival data can be recorded. 
This also meant that a high percentage of the samples collected were 
not colonized with disease, rendering them unsuitable for the 
immunohistochemistry studies. 
 
The ascites are also rich in inflammatory cells. It would perhaps be 
useful diagnostically to examine and compare the inflammatory infiltrates 
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of the ascites with those of the metastases. It could then be questioned 
whether the immune cell composition of the ascites is predictive of that 
in the metastases. An established data set such as this could then later 
be compared with potential blood biomarkers. The difficulty with such a 
study is the logistics of acquiring all the necessary samples from each 
patient. For this thesis ascites could not be collected from the same 
patients that omental specimens were received from. The procedure of 
draining the ascites was carried out some time before surgery and in a 
completely different hospital that was not easily accessible to Barts 
Cancer Institute. 
 
8.3. Future work on the 3D omental model of HGSC 
metastasis 
 
One focus of this thesis was to establish, optimise and develop a 3D 
omental cell culture model that mimics HGSC colonisation in the 
omentum. The model was originally established in Ernst Lengyel’s 
laboratory at the University of Chicago (Kenny et al., 2007). Lengyel and 
colleagues isolated their primary fibroblasts and mesothelial cells from 
benign omental specimens. The patients they collected samples from 
did not have cancer, endometriosis or any inflammation. All of the 
omental samples collected for this thesis were from ovarian cancer 
patients, and this was one difference between the model established 
here and the original Lengyel model. Normal omentum was not 
accessible for the work in this thesis. The potential to obtain small 
samples of omentum when surgeons routinely remove scarred tissue 
from previous abdominal surgeries was investigated, however this has 
been awaiting ethical approval.  
 
The original model was designed to study early adhesion events in 
ovarian cancer metastasis, whereas the model established in this thesis 
was intended for studying more developed omental deposits. Hence the 
models for this thesis were composed with cancer-associated primary 
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cells and successfully kept in culture for two weeks as opposed to five 
days. The Lengyel laboratory has now scaled their 3D omental model to 
be suitable for 384 well high throughput adhesion assays 
(communication from Prof Ernst Lengyel). Generating high throughput 
assays with this model will be of significant interest to pharmaceutical 
companies for testing therapeutic targets.  
 
Patient sourced samples with varying levels of disease are likely to yield 
primary cells with different levels of activation. This often implicated the 
reproducibility of results experimenting with the 3D omental model in this 
thesis. Ideally several experimental replicates are required to produce 
results with statistical significance, which was limited by the availability 
of samples and the number of primary cells isolated. 
 
Lengyel and colleagues characterised their HPMCs by the positive 
expression of cytokeratin 8/18 and vimentin, and the negative 
expression of the collagen synthesising enzyme prolyl-hydroxylase. The 
HPFs were proved to be positive for vimentin, prolyl-hydroxylase and 
trichrome staining which indicated the presence of collagen fibrils. 
However it was not clearly illustrated that the HPFs were negative for 
cytokeratin 8/18. A large proportion of the HPFs collected for this thesis 
were positive for cytokeratin 8/18 suggesting that these cells were 
activated HPMCs (Figure 8-1). With the controversy in the field about the 
legitimate markers that define a fibroblast, it seems insufficient to 
characterise the HPFs purely by their ability to synthesise collagen. At 
the beginning of the work for this thesis, the primary cells cultured on 
coverslips were studied for E-Cadherin and α-SMA positivity by 
immunofluorescence (data not shown). The E-Cadherin expression was 
not significantly different in the HPMCs compared with the HPFs 
however α-SMA expression was higher in the HPFs, further supporting 
the concept that these cells were activated. The primary cells were also 
stained as cytospins for FAPα and αVβ1 integrin, to try and differentiate 
the HPMCs from the HPFs, but this also came with little success. 
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HPMCs are also negative for the epithelial marker EpCam (Ranieri et al., 
2013). Despite the absence of distinguishing cell surface markers, the 
primary cells were autofluorescent and particularly sensitive to the 
processing required for FACS (Figure 5-3). The auto fluorescence would 
have interfered with the cell sorting process even if cell surface markers 
were available. Without definitive markers for distinguishing the primary 
cells, it was concluded that the HPMCs would be identified by their 
morphology, and that the 3D omental models would be predominantly 
cultured with cytokeratin negative human embryonic fibroblasts instead 
of the HPFs. HPFs were used when they were available. 
 
The key finding from the establishment of the 3D omental model in this 
thesis was the importance of the HPMCs in promoting tumour cell 
growth and invasion (Figure 8-1). As previously mentioned the 
availability of human omentum samples and primary cell yields limited 
the rate at which experiments could be carried out. To investigate the 
role of the HPMCs further, it would be hugely beneficial to immortalise 
the HPMCs from at least three patients, and use these cells in 
subsequent experiments. A method for the immortalisation of primary 
cells often involves the exogenous expression of Telomerase Reverse 
Transcriptase (hTERT) (Fridman and Tainsky, 2008). This method alone 
is not usually successful for the immortalisation of epithelial cells, 
however it was used in combination with small interfering RNA silencing 
of p53 (Yang et al., 2007b) and retinoblastoma (Yang et al., 2007a) to 
immortalise human primary ovarian surface epithelial cells. An 
alternative method of immortalising primary cells involves transfecting 
the cells with Simian Virus 40 T antigen (Lundberg et al., 2000). This 
inactivates tumour suppressor proteins. Such interference with the 
expression and activation of tumour suppressor genes and proteins 
respectively may however generate undesirable oncogenic attributes in 
the immortalised cells. 
 
At the beginning of this thesis, the LP-9 mesothelial cell line was used to 
establish the 3D omental model (data not shown). Unfortunately these 
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cells have a mesenchymal morphology and do not resemble the 
cobblestone appearance of the primary mesothelial cells described in 
the Lengyel 3D model (Kenny et al., 2007). Therefore the use of these 
cells in the 3D omental model established for this thesis was 
discontinued. The mesenchymal morphology of these cells may be an 
indication that these cells were activated in the immortalisation process. 
 
Several measurable read outs could be used to study the activation of 
HPMCs, for example α-SMA expression, migration and the secretion of 
growth factors and cytokines. Iwanicki and colleagues demonstrated the 
interactions between the myosin network, talin I and αVβ1 integrin in 
ovarian cancer cells that drive the contractility and displacement of 
mesothelial cells in the presence of invading spheroids (Iwanicki et al., 
2011). Time-lapse video microscopy and the displacement of fluorescent 
beads in matrices were assays used in this study that could be used to 
investigate the effect of therapeutic targets on the role of HPMCs in 
HGSC metastasis. 
 
It is possible that the cytokine and chemokine signalling network that is 
up-regulated in HGSC (Kulbe et al., 2012) is contributing to the 
contractile nature of the HPMCs in response to invading tumour cells. 
Sanz-Moreno and colleagues describe how cytokine signalling via JAK1 
and the phosphorylation of myosin light chain (MLC) 2 in myosin II leads 
to increased contractility in stromal fibroblasts and melanoma cells 
(Sanz-Moreno et al., 2011). As the siRNA silencing of myosin II in 
invading ovarian cancer cells leads to the reduced contractility and 
clearance of interacting mesothelial cells (Iwanicki et al., 2011), perhaps 
similar cytokine signalling mechanisms are involved more directly in 
mesothelial cell contractility. Matrix contraction assays and the 3D 
omental model itself could be used to evaluate this. 
 
Matrix deposition is also indicative of stromal activation (Erler and 
Weaver, 2009) . Communications with Ernst Lengyel reveal that ovarian 
Chapter 8 - Discussion 
 198 
cancer cells do in fact activate the HPMCs through TGFβ signalling, 
which leads to an increase in fibronectin production (manuscript in 
preparation). TGFβ is a driver of EMT. Therefore it would be interesting 
to investigate the implication of potential therapeutic targets on the 
expression of mesenchymal markers such as the loss of E-Cadherin and 
cytokeratins and the increase in N-Cadherin and vimentin (Wan et al., 
2013) in the activation of HPMCs. Proving that HGSC drives activation 
and EMT in HPMCs would have clinical relevance given that the 
CLOVAR model described by Veerhaak RG and colleagues associates 
a mesenchymal signature with the worst prognosis in HGSC patients 
(Verhaak et al., 2013). 
 
The 3D omental model as a whole will offer its greatest value to 
pharmaceutical companies where there is a necessity to bridge the void 
between cells grown on plastic that provide quick results, to in vivo 
experiments which take a long time and are expensive to run. The void 
is of course made greater by the fact that the results from the in vitro 
experiments often do not reproduce in vivo. Supernatants from the 3D 
omental models can be collected and could be analysed on a multiplex 
cytokine secretion platform such as the Luminex. Equally both RNA and 
protein can be extracted from the 3D models for the performance of 
gene expression and protein arrays. The recently described CLOVAR 
(Verhaak et al., 2013) and PROVAR (Yang et al., 2013b) models could 
be applied to the 3D omental model after treatment with a potential 
therapeutic agent, to predict whether the therapy could improve patient 
survival. In addition the 3D omental model could be used to test 
therapies in combination with Paclitaxal and Carboplatin. Potentially 
treatment of the model with less than optimal concentrations of current 
chemotherapy drugs over a period of one week or more could 
recapitulate molecular changes in the model associated with the 
development of chemoresistance. 
 
What is critical to the translation of results from the 3D omental model to 
the clinical situation is that the model truly resembles the subtype of 
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ovarian cancer under question. This involves insuring that the correct 
cell line subtype is co-cultured with the model. In light of the recent 
reports from Domcke et al (Domcke et al., 2013) and Anglesio et al 
(Anglesio et al., 2013), it has become clear that many of the ovarian 
cancer cell lines that we were using were not representative of the 
subtype that it was classified to be. The significance of these reports to 
this thesis was that the SKOV3ip1 cells were not representative of 
HGSC (Domcke et al., 2013) and the RMG1 cells were unclassified 
(Anglesio et al., 2013). The AOCS1 cells were confirmed to have TP53 
mutations characteristic of HGSC (communication from Dr Carla 
Milagre) and the TOV21G cells were classified as CCC (Anglesio et al., 
2013). The TOV21G cells were also found to be hypermutated (Domcke 
et al., 2013), which perhaps suggests that they have the capacity to 
evolve quickly and readily adapt to novel environments, owing to their 
level of chemoresistance. 
 
Despite recent revelations regarding the identity of cell lines (Anglesio et 
al., 2013; Domcke et al., 2013), the original aim in chapter 4 was to 
optimise the growth of HGSC and CCC cell lines on the 3D omental 
model. Although HGSC is the focus of this thesis, the work of this 
chapter illustrates that the 3D omental model could be used for research 
into more than one subtype of the disease.  
 
During the course of this thesis, over one hundred human omental 
specimens were digested to isolate HPMCs. One particular specimen 
from patient G33 was especially diseased. The digestion process 
yielded no HPMCs or HPFs, however after a period of time in culture 
colonies of HGSC cells were growing. Over the course of a year these 
cells were expanded and used as model cell line in the laboratory. The 
cells were wild type for the R175H mutation in exon 5 and the R273H 
mutation in exon 8 of the TP53 gene which are two of the most 
frequently occurring TP53 mutations in HGSC (Ahmed et al., 2010; 
Cancer Genome Atlas Research, 2011; Lee et al., 2007b). However, the 
cells carried a W146* substitution mutation in exon 5 (data not shown). 
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This mutation introduces a premature stop codon, and translates a 
truncated protein (IARC TP53 database). It is yet to be confirmed 
whether the truncated protein in this new cell line is stable enough to be 
detected by western blot. 
 
The new HGSC G33 cell line was successfully grown on the 3D omental 
model. In other projects in the laboratory it was shown to be relatively 
inert in terms of cytokine production (communication from Dr Hagen 
Kulbe) and it formed spheroids in hanging drop cell culture plates 
(communication from Dr Oliver Pearce). 
 
The low levels of cytokines produced by this cell line may indicate that 
the cells have a greater dependency on the tumour microenvironment 
for survival. Since the recent publications by Domcke et al (Domcke et 
al., 2013) and Anglesio et al (Anglesio et al., 2013), the value of the new 
HGSC G33 cell line to the laboratory has increased, and could be a 
great resource in future studies, particularly those involving the 3D 
omental model.  
 
It was clear from the work optimising the growth of four cell lines on the 
3D omental model, that individual cell lines will react quite differently to 
the omental microenvironment that cannot always be predicted by their 
growth in animal models. For instance, IGROV1 cells that grow very well 
in animal models did not grow at all on the 3D omental model. The 
translation of in vitro data to animal model data will always present 
limitations, however a human 3D model mimicking metastasis such as 
this will produce more reliable and accurate results than any other in 
vitro system currently available. 
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8.4. Chemokine signalling in a the 3D omental model 
 
The efficacy of an antibody targeting the chemokine ligand CXCL12 was 
tested in the 3D omental model. The purpose of this was to develop an 
in vitro model for further studies into the association between CXCL12 
and ECM remodelling in HGSC metastasis. These data generated by 
the model showed a statistically significant reduction in tumour cell 
growth with antibody treatment (Figure 8-1). The concentration of the 
antibody tested in the 3D model was determined from previous work in 
the laboratory. This previous work demonstrated an optimal inhibition of 
the migration of the CCC cell line TOV21G in the transwell migration 
assay at 10µg/mL of antibody. Ideally, given accessibility to larger 
volumes of the 114_3H1 antibody, a greater range of concentrations 
would have been tested in the 3D omental model to further confirm that 
the observed effect of the antibody was truly dependent upon the activity 
of the compound tested. In addition, the dosing experiment would have 
been particularly relevant since the effects therapeutic agents would 
have on cells grown in the 2D transwell migration assay, would differ 
quite significantly to their effects when cells are cultured in the 3D 
omental model.  
 
A commercially available antibody targeting CXCL12 also showed a 
trend towards a decrease in tumour growth with increasing antibody 
concentrations (data not shown). Although these data were not 
statistically significant, the observed trends were reproducible of those 
seen with the antibody 114_3H1. This therefore supported the 
conclusion that the 114_3H1 antibody was active and effective at 
neutralising CXCL12 in the 3D omental model. 
 
The 114_3H1 antibody elicited no significant effect on tumour cell 
proliferation in the 3D omental model as measured by Ki67 positivity. 
However using tumour cell area as a measure of growth, the CXCL12 
targeted antibody significantly reduced tumour growth. Together this 
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suggested that CXCL12 was more important in the survival of the 
tumour cells in the 3D omental model rather than their proliferation 
(Figure 8-1). This conclusion could be consolidated further using 
alternative cell viability assays in the model such as the CellTiter blue 
assay. 
 
In chapter 6 more ECM genes correlated with CXCR4 than CXCL12 
expression. In future studies it could be important to consider targeting 
the receptor CXCR4 with the molecular inhibitor AMD3100. The 3D 
omental models were treated with AMD3100 in a single experiment 
during the work for this thesis. Conversely to targeting the ligand 
CXCL12, targeting the receptor had no inhibitory effect on the growth of 
the HGSC cell line AOCS1 or the invasion of the CCC cell line TOV21G 
in the 3D omental model (data not shown). Further experiments with 
AMD3100 were required, however greater confidence was gained in the 
efficacy of the ligand targeted antibody 114_3H1. 
 
Success with the efficacy of this therapeutic agent and others in the 3D 
omental model further supported its potential role in the drug discovery 
process. Furthermore the 3D omental model could now be used to 
develop current concepts and investigate hypotheses surrounding the 
TNF network in HGSC metastasis. For instance, in this thesis the 
importance of the HPMCs in tumour growth in the model was identified 
(Figure 8-1). The role of the CXCR4 pathway in cell adhesion and 
integrin signalling is also well known (Hartmann et al., 2005). Therefore 
perhaps chemokine signalling plays an important role in HPMC 
activation and in αVβ1-fibronectin interaction mediated HPMC clearance 
(Iwanicki et al., 2011). Chemokine gradients could be incorporated into 
the 3D collagen matrix of the model, to determine whether they play a 
role in driving the clearance of the HPMCs. 
 
Collaborative studies with the postdoctoral scientists in the laboratory 
using the 3D omental model proved that the model could be used to 
validate the expression of any genes of interest associated with the TNF 
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network, and its cross-talk with other networks, such as EGFR 
signalling. CXCL12 has been described to be amplified in primary 
ovarian tumours, but not in the matched peritoneal metastases (Malek et 
al., 2011). This signalling pathway may therefore carry greater 
significance in the growth of the primary tumour, which might explain the 
conclusive but not so greatly potent inhibitory effect of the CXCL12 
targeted antibody 114_3H1 on tumour growth when mimicking 
metastasis in the 3D omental model. Overall however the important role 
of CXCL12 in ovarian cancer progression is reflected in the correlation of 
its expression in patient biopsies with poor survival (Popple et al., 2012). 
Hence targeting CXCL12 in the 3D omental model and measuring its 
impact on tumour growth will be an important model system for studying 
HGSC progression. 
 
8.5. Association between CXCL12 and ECM 
remodelling 
 
The association between CXCL12, ECM remodelling and cell-matrix 
interactions was identified in two independent gene expression 
microarray data sets. Efforts were employed to validate this by qRT-PCR 
in human omental metastases of HGSC. 
 
Bioinformatics and interrogation of these data sets can generate a 
wealth of information about the sample set. It would perhaps be useful to 
generate similar microarray data from the HGSC omental metastasis 
samples. Despite the quantity of data generated from these high-
throughput gene expression platforms, it can often be difficult to find the 
most appropriate and accurate method to analyse such large volumes of 
data. Over 5,000 genes were differentially expressed in high CXCL12 
expressing ovarian cancer biopsies, which was filtered to 48 genes of 
interest. Six of these 48 genes were finally validated in the omental 
metastases therefore there are many genes that could still be validated. 
Consequently, due to the very small number of genes measured by 
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qRT-PCR, strong conclusions cannot be drawn from the results, but the 
results to this chapter can be considered as an indication of what may 
be occurring in the HGSC metastatic microenvironment. Likewise, 
comparatively to the 285 and 245 ovarian cancer biopsies of the AOCS 
and GSE 6008 and 3149 data sets, only ten samples of HGSC omental 
metastases were analysed in this chapter. 
 
However, of the genes and samples analysed in this chapter, only an 
increase in decorin expression significantly correlated with an increase 
in CXCL12 expression (Figure 8-1). The geNorm software used to 
validate the house keeping reference for the sample set was considered 
a reliable tool for data analysis. The software developers claim the 
method (Vandesompele et al., 2002) has been cited more than 3,000 
times, and that more than 16,000 scientists across more than 126 
countries use the software (http://www.biogazelle.com/qbaseplus).  
 
The lack of consistency of the qRT-PCR results with the analyses of the 
gene expression microarray data may have been consequential to the 
differences between the microenvironment of primary tumours and 
metastases (Malek et al., 2011). More ECM genes did however 
positively correlate with CXCR4 (Figure 8-1), providing some 
confirmation of the link between CXCR4 and CXCL12 signalling and 
ECM remodelling in HGSC metastasis. 
 
CD36, the receptor for thrombospondin 1 associated with a macrophage 
infiltrate in high CXCL12 ovarian cancer biopsies. The expression of the 
ECM gene thrombospondin 1 was evaluated in the HGSC omental 
metastases, but correlated negatively with CD68 positive macrophages. 
In future studies it would be important to also analyse the expression of 
CD36 itself in the metastases to better validate the bioinformatics data. 
However given ECM genes were the interest of this chapter, priority was 
given to studying thrombospondin 1 expression. 
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Periostin displayed a negative correlation with CD8 positive T cells. It 
would be interesting to link the CD8 positive T cell infiltrate associated 
good prognosis in ovarian cancer with a reduction in periostin 
expression. However as previously mentioned, at the time of writing this 
thesis the established bank of omental metastases was not mature 
enough to acquire patient survival data to test this. Correlating the ECM 
gene expression with patient survival and response to chemotherapy 
when the clinical data becomes available would be an important future 
study to consider. In addition work analysing further immune cell 
infiltrates could also be later correlated with the ECM gene expression 
data. For instance it would be of particular interest to investigate the 
association between M1 and M2 macrophage subtypes and ECM gene 
expression in the HGSC metastatic microenvironment. 
 
In future work it may also be of interest to investigate and differentiate 
the expression of ECM genes by the tumour cells and the surrounding 
stroma. Digestion of the omental metastases and subsequent FACS 
analysis could be used to isolate individual cell types for RNA extraction 
and gene expression analysis. Alternatively laser-capture 
microdissection could also be used to separate tumour and stromal 
areas from tissue sections. 
 
It is also very important to consider here that gene expression analysed 
at the mRNA level may not necessarily translate to expression at the 
protein level. Expression of the ECM proteins could now be analysed by 
immunohistochemistry and correlated with CXCL12 and CXCR4 in the 
omental metastases TMA established by Dr Steffen Boehm in the 
laboratory. This TMA includes more than ten samples, which would also 
increase the statistical significance of the results. 
 
The work of the new CANBUILD project team in the Balkwill laboratory 
of Barts Cancer Institute, London will involve building a matrix that is 
representative of that in HGSC omental metastases. Therefore the work 
of this chapter initiates an indication of the ECM composition of the 
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metastatic microenvironment. The ambition is to be able to modulate 
and control the properties of the matrix, to study the impact on tumour 
progression. Preliminary to this, the CANBUILD team are studying the 
matrix density of the omental metastases, which could later be 
associated with the immune cell infiltrate and clinical data connected to 
the samples. 
 
8.6. Introducing a macrophage infiltrate to the 3D 
omental model 
 
The network of inflammatory cytokines and chemokines in the tumour 
microenvironment regulates an influx of immune cells (Balkwill et al., 
2012). The established multicellular 3D omental model lacked an 
inflammatory infiltrate, and the culture of immune cells in 3D models of 
ovarian cancer was absent in the field (Lengyel et al., 2013). Previous 
work in the laboratory described an association with CXCL12 expression 
and CD68 positive macrophage infiltrates in ovarian cancer biopsies 
(Kulbe et al., 2012)(Figure 8-1). In addition work for this thesis correlated 
CD68 positive macrophages with Ki67 positive epithelial cells in omental 
metastases of HGSC. Given this collectively, for the final chapter of this 
thesis macrophages were introduced to the 3D omental model in 
collaboration with MedImmune, Cambridge. This work demonstrated that 
PBMC derived macrophages incorporated and survived within the matrix 
of the 3D omental model, and induced measurable changes in cytokine 
and chemokine expression.  
 
GFP and CD68 expression levels could be measured in parallel by qRT-
PCR to normalise the cytokine and chemokine expression levels to the 
number of tumour cells and macrophages in the models respectively. Of 
course it would also be important to confirm the changes detected at the 
mRNA level with secreted cytokine and chemokine levels in the 3D 
omental model supernatants measured by ELISA or Luminex. For 
normalisation in this instance, the number of GFP positive tumour cells 
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and CD68 positive macrophages in the 3D models could be quantified 
from immunohistochemistry staining with the Leica Ariol software as 
described in chapters 3 and 5. Alternatively, it would be useful to 
develop a method to separate the cells post culture in the 3D omental 
model. Enzymatic degradation of the matrix, and subsequent FACS of 
the cells could further aid the delineation of which cells in the model are 
interacting with each other. 
 
When the 3D omental model inclusive of macrophages was co-cultured 
with the SKOV3ip1 cells, there was a reduction in tumour cell growth, 
proliferation and invasion, which was potentially due to the phagocytic 
and tumoricidal activities of the macrophages (Figure 8-1). Whether 
phagocytosis of tumour cells is taking place in the 3D omental model is a 
question that needs to be answered. To further study whether 
phagocytosis is occurring in the 3D omental model, the macrophages 
could be treated with an inhibitor that perturbs their phagocytic function. 
The impact of this on tumour growth in the model could then be 
investigated.  
 
GFP positive tumour cells and CD68 positive macrophages co-stained 
by immunofluorescence could also be studied in detail at high 
magnifications to endeavour to identify double nuclei as an indicator of 
phagocytosis. However given the macrophages in the 3D omental model 
sections were fluorescing in the red and green channels of the confocal 
microscope (Figure 7-3) after immunofluorescence staining, perhaps the 
use of fluorescent-labelled cell tracker dyes would be a more accurate 
method of detecting the cell subtypes. This way a relatively strong 
detected fluorescence in the 405nm wavelength could be used to 
distinguish the macrophages, whilst fluorescence in the 568nm 
wavelength that can often omit greater background levels could be used 
for the nuclei. Even when the THP1 and PBMC derived macrophages 
were cultured alone in the model, the macrophages were fluorescing in 
the 488nm and 568nm channels of the confocal microscope. This 
suggests that there was some auto fluorescence generated from these 
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cells, which can occur through their interactions with the ECM 
(communication from MedImmune).  
 
As previously mentioned alternative cell viability assays could be used to 
consolidate the observed reduction in tumour cell proliferation in this 
final chapter. In light of the recent studies on the legitimacy of 
characterised ovarian cancer cell lines (Anglesio et al., 2013; Domcke et 
al., 2013) the SKOV3 cell line was not confirmed as HGSC. On the basis 
that the positive correlation between CD68 positive macrophages and 
Ki67 positive epithelial cells described in chapter 1 was observed in 
omental metastases of HGSC, work with the SKOV3ip1 cells in the 3D 
omental model was stopped. Since the completion of this thesis and the 
establishment of the novel G33 HGSC ovarian cancer cell line, further 
work to study the interactions between macrophages and G33 spheroids 
in the 3D omental model is being addressed in the laboratory. 
 
It was concluded from this final chapter that PBMC derived 
macrophages were a better model cell type to use in the 3D omental 
model than the THP1 derived macrophages. The THP1 cells were 
reported to secrete lower levels of pro-inflammatory cytokines when 
stimulated and were less efficient at phagocytosis than PBMCs 
(Daigneault et al., 2010). In addition the THP1 cells were likely to bear 
an oncogenic phenotype since they originated from an acute monocytic 
leukaemia patient (Tsuchiya et al., 1980). However the former report 
also suggested that differentiated THP1 cells better resemble PBMC 
derived macrophages when they are treated with PMA for 48 hours and 
then subsequently allowed to rest in culture before used in an assay 
(Daigneault et al., 2010). At times when primary cells are unavailable, 
supporting experimentation with THP1 cells using this method may be 
an option. This may have even greater value particularly when primary 
cells can elicit significant degrees of variation between donors, which 
could affect the accuracy of data collected from 3D omental models co-
cultured with these cells. 
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For the collaborative work with MedImmune in this final chapter, PBMCs 
were differentiated in M-CSF. Human serum can also be used to 
differentiate PBMCs (Daigneault et al., 2010)(communication from Dr 
Cristina Ghirelli), which may be more physiologically relevant and may 
drive the cells into a less polarised phenotype. For the purpose of this 
thesis, the aim was to mimic the microenvironment of a developing 
omental metastasis; a phase where the tumour deposits are within their 
growth phase and the proliferation of cells could be measured and 
experimentally influenced. Therefore non-polarised macrophages were 
introduced to the model in an effort to represent infiltrating leukocytes 
from the vasculature. Arguably the original observation correlating CD68 
positive macrophages with Ki67 positive epithelial cells was determined 
from more established omental metastases, but many of those analysed 
were of a microscopic scale, and would therefore be within their growth 
phase. For future work the differentiation and polarisation status of the 
macrophages introduced to the 3D omental model would have to be 
evaluated on the basis of the experimental question being tested. To 
study the influence of the tumour microenvironment on the 
macrophages, less polarised macrophages may have to be introduced 
to the model, and vice versa the macrophages may need to be driven to 
a particular polarisation status prior to their co-culture in the 3D omental 
model. In addition to better replicate the clinical situation, tumour cells 
may need to be cultured on or in the model for a greater length of time 
before the macrophages are introduced, to mimic macrophages 
infiltrating a developing tumour deposit. The work of this final chapter 
clearly demonstrated that the macrophages invade and incorporate 
within the matrix of the model; therefore introducing the macrophages at 
a later stage in the co-culture system should be feasible. Again, arguably 
it is important to consider the localisation of the macrophages under 
question. In chapter 1 macrophages were found localised within and 
surrounding the tumour deposits of omental metastases (Figures 3-5 & 
8-1). As well as supporting the growth and proliferation of tumour 
deposits, at the periphery of a tumour macrophages can facilitate the 
remodelling of the ECM to allow tumour cell invasion (Wynn et al., 
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2013). Therefore to study these cellular mechanisms it may be more 
relevant to culture the macrophages in the 3D omental model for a 
period of time to encourage their incorporation into the matrix, prior to 
introducing the tumour cells. By this method the macrophages would be 
in a suitable position to localise at the invasive margin of the developing 
tumour growth on the surface of the model. Pre-established spheroids 
within the matrix could on the other hand be introduced to the 
macrophages in the model secondly, to mimic their localisation 
surrounding the developing deposit. 
 
Discussion thus far has emphasised the preliminary nature of the work in 
this final chapter, but has highlighted the wealth of options for future 
model development. Recent work has endeavoured to better define 
intermediate macrophage phenotypes, where a binary classification is 
no longer sufficient. Differences between the origins of tissue resident 
and peripheral blood macrophages were reported for instance (Gomez 
Perdiguero and Geissmann, 2013). The effect of each of these subtypes 
on the growth of HGSC deposits in the omentum could be evaluated in 
the 3D model. 
 
Previous publications have described differences in the transcriptional 
profiles of PBMCs from patients of pancreatic, lung and renal cancers for 
example compared with control patients (Baine et al., 2011; Burczynski 
et al., 2005; Chang et al., 2013; Showe et al., 2009). PBMC-derived 
macrophages co-cultured in the 3D omental model could be used to 
study the molecular switches that drive this change in transcriptional 
signatures in HGSC. 
 
Furthermore introducing to the 3D omental model macrophages derived 
from the ascites of HGSC patients would even better resemble the real 
clinical situation. Recently Ko SY and colleagues described how 
expression of the homeobox gene HOXA9 that is associated with a poor 
prognosis in ovarian cancer, increases chemotaxis in peritoneal 
macrophages and increases their expression of M2 tumour associated 
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markers including CD163 (Ko et al., 2014). In human tumour samples 
with increased expression of the HOXA9 gene, there was a decrease in 
CD8 positive T cell infiltrates and an increase in T regulatory cells and 
tumour-associated macrophages. Therefore a 3D omental model co-
culturing peritoneal or ascites derived macrophages could be used to 
further study tumour-macrophage interactions such as those described 
in this report. 
 
Once such a 3D omental model with a mimicking macrophage infiltrate 
has been appropriately established, many of the questions raised in 
other chapters of this thesis could be further addressed. For instance the 
role of the CXCR4-CXCL12 chemokine pathway that drives 
inflammatory cell recruitment in tumours (Balkwill, 2004; Leinster et al., 
2012; Schioppa et al., 2003) could be studied in the development of 
omental metastases of HGSC. In addition models with and without 
exposure to chemotherapy agents such as Paclitaxal and Carboplatin 
could be used to determine whether such therapies beneficially or 
detrimentally polarise the macrophages in the tumour microenvironment 
for metastatic colonisation of the omentum. The potential benefits of 
non-steroidal anti-inflammatory drugs (NSAIDs) to cancer patients are 
currently topical in the field (Balkwill and Mantovani, 2012; Rothwell, 
2013). A human inflammatory 3D model could equally be used to 
underpin the molecular mechanisms involved in disease stabilisation or 
regression following treatment. 
 
The work of chapter 4 identified the importance of the HPMCs in the 
development of omental tumour deposits in the 3D model, and proposed 
the potential for cytokine driven HPMC contractility and activation (Sanz-
Moreno et al., 2011)(Figure 8-1). The influx of immune cells into the 
omental microenvironment following disease colonisation may play a 
significant role in this. An established inflammatory 3D model could be 
used to mimic and study these potential mesothelial cells: macrophage 
interactions. 
 
Chapter 8 - Discussion 
 212 
An increasingly complex 3D omental model opens options for 
investigating many cell type interactions in the development of HGSC 
omental deposits. Ernst Lengyel’s laboratory recently described the how 
the lipids and adipokines in adipose tissue promote tumour cell 
proliferation and invasion respectively (Nieman et al., 2011). 
Communications with Ernst Lengyel also indicated that their laboratory 
was endeavouring to incorporate adipocytes into their previously 
established 3D omental model. Previous reports described how 
macrophages were recruited to adipose tissue (Sun et al., 2011; 
Weisberg et al., 2003), and that these adipose associated macrophages 
secreted increased levels of pro-inflammatory cytokines such as TNF-α 
and IL-6. Combining Ernst Lengyel’s adipocyte 3D omental model with 
one containing macrophages, could aid the investigation into the 
possible relationship between macrophages and adipocytes in driving 
HGSC metastasis in a microenvironment that is already naturally rich 
with adipocytes. 
 
The opportunity to incorporate an immune cell infiltrate to the 3D 
omental model goes beyond only macrophages. Other immune cell 
subtypes such as CD4 positive and regulatory T cells could be 
introduced to the model either singly or together with the macrophages. 
αFAP positive fibroblasts in the tumour microenvironment have been 
suggested to play a very significant role in suppressing a tumour-
targeted immune response (Kraman et al., 2010). Matthew Kraman and 
colleagues used a transgenic mouse model to delete the αFAP positive 
cell population that perturbed the development of Lewis lung and 
pancreatic carcinomas. This effect was only observed in the cancers 
where an immune response had already been initiated. Treatment with 
TNF-α and IFN-γ neutralising antibodies reversed the induced hypoxic 
necrosis of the tumour and stromal cells caused by the depletion of 
αFAP positive cells. More recently a report from the same laboratory 
described how CXCL12 sourced from this small population of αFAP 
positive fibroblasts coated the tumour cells in a mouse model of 
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pancreatic cancer and inhibited the cytotoxicity of CD8 positive T cells 
(Feig et al., 2013). Treatment with the CXCR4 inhibitor AMD3100 
allowed the recruitment of T cells and promoted tumour regression. 
Given the 3D omental model already includes fibroblasts, potentially the 
significance of the small subset of αFAP positive stromal cells in the 
progression of HGSC within an inflammatory microenvironment could be 
tested if the model also incorporated T cells. 
 
8.7. Concluding statements 
 
Undeniably, there are several further cell types that play pivotal roles in 
the tumour microenvironment that have not been mentioned here 
(Balkwill et al., 2012). In ex vivo cultures ovarian cancer spheroids 
interacted extensively with mesenchymal stem cells (Touboul et al., 
2013). The omentum is also very well vascularised, giving rise to further 
signalling pathways communicating with endothelial cells and pericytes 
of both pre-established vessels and those involved in the process of 
angiogenesis. Chemokine signalling and tumour progression are 
furthermore driven by a hypoxic microenvironment (Anglesio et al., 
2011b; Schioppa et al., 2003) that conventional cell culture techniques 
do not convey. Ideally the perfect 3D cell culture model would include all 
the cell types and conditions of the tumour microenvironment. Often this 
cannot even be achieved in animal models where mice with impaired 
adaptive immune systems are utilised to avoid human xenograft 
rejection. The establishment of such a complex cell culture model is the 
ambition of the recently founded CANBUILD project team in the Balkwill 
laboratory of Barts Cancer Institute, London. The European Research 
Council funds the team and the work of this thesis provided the 
preliminary data for the project’s proposal. 
 
In the realms of the drug discovery process, there is forever a 
disconnection between the in vitro and animal experiments, which 
creates difficulties to justify pushing targets through to clinical trials. A 
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3D multicellular in vitro model could bridge this gap and become an 
essential tool for testing combination, and even personalised therapies. 
In addition, the use of this complex model mimicking the omentum will 
also carry value in testing therapies for other cancers that metastasise to 
the peritoneum, including colorectal cancers. 
 
It is without dispute that this 3D omental model will not make in vivo 
models completely redundant in research and drug development, 
however experiments using the 3D model will be far less expensive in 
terms of financial and time costs, which are favourable attributes for both 
academic and industrial institutions. It has already been proved by the 
work of Prof Ernst Lengyel and colleagues, that the 3D omental model 
can be reproduced in a 384 well format, rendering it a suitable assay for 
small scale or high throughput screens. In addition each cellular and 
extracellular component of the 3D model can be more easily 
manipulated and regulated in than in an in vivo model. Ultimately the 3D 
model is a human model, which will always recapitulate the human 
disease setting better than a murine counterpart. The assay is neither 
restricted by ethics and fully supports the focus of the three R’s 
(reduction, replacement and refinement) when conducting animal 
experiments. The 3D omental model can be generated to represent 
ovarian cancer metastases of a particular subtype or mutation status, 
and it can be hoped that with further development, autologous models 
could be created for testing patient specific therapies. 
 
The poor prognosis associated with HGSC stems from the late stage 
disease presentation and the widespread metastasis throughout the 
peritoneum. It is becoming increasingly evident that the metastatic 
microenvironment is quite different from the primary tumours in ovarian 
cancer (Malek et al., 2011). Following recent developments in our 
understanding of the origins of ovarian cancer (Kurman, 2013), we are 
now more astute to treating ovarian cancer subtypes as individual 
diseases, which must translate in our experimental design and choice of 
cell lines. However given the real clinical problem associated with this 
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disease is the peritoneal spread it is critical that we seek therapeutic 
targets associated with the metastases. The 3D omental model 
established in this thesis and further developed by the CANBUILD team 
will aid the identification of these targets, and the development of 
therapeutic interventions. With this it can be hoped that following thirty 
years of little improvement in the survival rates of ovarian cancer 
patients, a shift in paradigm and progression in treatment regimes may 
reduce the severity of diagnosis and offer patients confidence that they 
can live with a better quality of life for longer.  
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10. Appendices 
10.1. Appendix I: Supplementary data 
 
Gene Fold change 
chemokine (C-X-C motif) ligand 12 14.33127613 
collagen, type X, alpha 1 11.77985505 
lumican 9.109582398 
collagen, type III, alpha 1 7.558319183 
decorin 7.175963403 
versican 6.289583754 
TIMP metallopeptidase inhibitor 3 6.205274356 
collagen, type V, alpha 1 6.185612833 
collagen, type V, alpha 2 6.03244568 
collagen, type I, alpha 1 5.942290308 
vascular cell adhesion molecule 1 5.74151157 
cartilage oligomeric matrix protein 5.407498397 
fibrillin 1 4.912413639 
actin, alpha 2, smooth muscle, aorta 4.824726047 
fibronectin 1 4.822990822 
thrombospondin 1 4.775156404 
plasminogen activator, urokinase 4.768927985 
SPARC (osteonectin) 4.22897384 
collagen, type VI, alpha 3 4.192198622 
collagen, type I, alpha 2 3.928224315 
matrix metallopeptidase 11 (stromelysin 3) 3.83949525 
protein tyrosine phosphatase receptor type C 3.834024497 
plasminogen activator inhibitor type 1 3.725180397 
actin, gamma 2, smooth muscle, enteric 3.642892403 
ADAM metallopeptidase domain 12 3.607230262 
transforming growth factor beta 1 induced 
transcript 1 
3.373300685 
nidogen 2 (osteonidogen) 3.283834603 
laminin, alpha 4 3.06510418 
matrix metallopeptidase 2 (type IV 
collagenase) 
2.904500569 
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nidogen 1 2.886898881 
gap junction protein, alpha 1, 43kDa 2.883873436 
plexin C1 2.756617893 
collagen, type XVI, alpha 1 2.655875711 
cysteine-rich, angiogenic inducer, 61 2.638213266 
lectin, galactoside-binding, soluble, 1 2.550982506 
biglycan 2.540618456 
collagen, type IV, alpha 1 2.47126342 
integrin, beta 2 2.446855377 
elastin microfibril interfacer 1 2.438230988 
myosin, light chain 9, regulatory 2.397138418 
myosin light chain kinase 2.297410958 
spondin 2, extracellular matrix protein 2.232495807 
neuropilin 1 2.205313558 
transforming growth factor, beta-induced 2.204489896 
microfibrillar-associated protein 2 2.196129265 
collagen, type IV, alpha 2 2.135848543 
plasminogen activator, tissue 2.090273259 
laminin, beta 1 2.028368486 
 
Table 10-1 The fold change values of 48 genes up regulated in the high CXCL12 
expressing biopsies of the AOCS data set also common to the GSE 6008 and 
3149 data set. 
Table listing the 48 differentially expressed cell-matrix interactions and ECM 
remodelling genes when comparing their expression in the 50 highest versus the 50 
lowest CXCL12 expressing ovarian cancer biopsies. The genes listed here are those in 
the AOCS data set and common to the GSE 6008 and 3149 affymetrix gene 
expression array data set. Fold change values are averaged from each gene probe set. 
p value ≤ 0.05. 
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Gene Fold change 
lumican 11.558 
collagen, type V, alpha 2 8.694 
fibronectin 1 6.404 
SPARC (osteonectin) 6.351 
collagen, type III, alpha 1 6.240 
collagen, type I, alpha 1 6.137 
TIMP metallopeptidase inhibitor 3 6.060 
collagen, type V, alpha 1 5.635 
vascular cell adhesion molecule 1 5.264 
fibrillin 1 5.057 
thrombospondin 1 5.045 
decorin 4.923 
collagen, type VI, alpha 3 4.581 
actin, alpha 2, smooth muscle, aorta 4.410 
matrix metallopeptidase 2 (type IV 
collagenase) 
4.197 
matrix metallopeptidase 11 (stromelysin 3) 4.193 
plasminogen activator inhibitor type 1 3.556 
collagen, type XVI, alpha 1 3.498 
cartilage oligomeric matrix protein 3.280 
nidogen 2 (osteonidogen) 3.190 
cysteine-rich, angiogenic inducer, 61 3.167 
versican 3.164 
transforming growth factor beta 1 induced 
transcript 1 
3.162 
collagen, type I, alpha 2 3.144 
transforming growth factor, beta-induced 3.029 
collagen, type X, alpha 1 3.019 
ADAM metallopeptidase domain 12 2.973 
biglycan 2.892 
myosin, light chain 9, regulatory 2.856 
chemokine (C-X-C motif) ligand 12 2.764 
nidogen 1 2.749 
plasminogen activator, urokinase 2.717 
microfibrillar-associated protein 2 2.679 
myosin light chain kinase 2.678 
elastin microfibril interfacer 1 2.655 
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laminin, beta 1 2.603 
laminin, alpha 4 2.559 
collagen, type IV, alpha 1 2.504 
gap junction protein, alpha 1, 43kDa 2.481 
plasminogen activator, tissue 2.436 
lectin, galactoside-binding, soluble, 1 2.379 
plexin C1 2.328 
integrin, beta 2 2.191 
collagen, type IV, alpha 2 2.184 
protein tyrosine phosphatase receptor type C 2.140 
actin, gamma 2, smooth muscle, enteric 2.124 
spondin 2, extracellular matrix protein 2.083 
neuropilin 1 2.058 
 
Table 10-2 The fold change values of 48 genes up regulated in the high CXCL12 
expressing biopsies of the GSE 6008 and 3149 data set also common to the 
AOCS data set. 
Table listing the 48 differentially expressed cell-matrix interactions and ECM 
remodelling genes when comparing their expression in the 50 highest versus the 50 
lowest CXCL12 expressing ovarian cancer biopsies. The genes listed here are those in 
the GSE 6008 and 3149 affymetrix gene expression array data set and common to the 
AOCS data set. Fold change values are averaged from each gene probe set. p value ≤ 
0.05. 
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Gene Fold change 
lymphotoxin beta receptor (TNFR 
superfamily, member 3) 
-1.131616039 
protein tyrosine phosphatase, receptor type, 
C 
1.13505687 
CD300c molecule 1.15173752 
CD84 molecule 1.19923003 
colony stimulating factor 2 receptor, alpha, 
low-affinity (granulocyte-macrophage) 
1.210582268 
colony stimulating factor 2 receptor, alpha, 
low-affinity (granulocyte-macrophage) 
1.210903576 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 3 
1.214603058 
colony stimulating factor 2 receptor, alpha, 
low-affinity (granulocyte-macrophage) 
1.218547541 
CD33 molecule 1.269361861 
signaling lymphocytic activation molecule 
family member 1 
1.269852752 
SLAM family member 7 1.269981022 
interleukin 10 1.280623156 
CD209 molecule 1.310874507 
low density lipoprotein-related protein 1 
(alpha-2-macroglobulin receptor) 
1.321366842 
toll-like receptor 4 1.324133329 
interferon gamma receptor 1 1.33809499 
CD80 molecule 1.35002511 
integrin, alpha X (complement component 3 
receptor 4 subunit) 
1.351124152 
tumor necrosis factor (ligand) superfamily, 
member 14 
1.364360028 
macrophage receptor with collagenous 
structure 
1.364737939 
colony stimulating factor 2 receptor, alpha, 
low-affinity (granulocyte-macrophage) 
1.39067681 
egf-like module containing, mucin-like, 
hormone receptor-like 2 
1.391370913 
interferon gamma receptor 1 1.393709641 
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C-type lectin domain family 4, member A 1.412309433 
CD40 molecule, TNF receptor superfamily 
member 5 
1.463765592 
CD163 molecule 1.470314972 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 1 
1.472273846 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 2 
1.491065131 
integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
1.49365124 
endoglin 1.509373226 
CD300a molecule 1.517304571 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 1 
1.51897657 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 2 
1.534522657 
integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
1.540794702 
sialic acid binding Ig-like lectin 1, 
sialoadhesin 
1.593832955 
toll-like receptor 4 1.597868185 
toll-like receptor 4 1.614484659 
CD300 molecule-like family member f 1.648166427 
secreted phosphoprotein 1 1.67216327 
chemokine (C-C motif) ligand 18 (pulmonary 
and activation-regulated) 
1.712673294 
chemokine (C-C motif) ligand 18 (pulmonary 
and activation-regulated) 
1.733217618 
CD74 molecule, major histocompatibility 
complex, class II invariant chain 
1.736459907 
low density lipoprotein-related protein 1 
(alpha-2-macroglobulin receptor) 
1.764913502 
triggering receptor expressed on myeloid 
cells 2 
1.765413442 
toll-like receptor 4 1.804733734 
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C-type lectin domain family 4, member A 1.831602731 
stabilin 1 1.840315916 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 4 
1.852621159 
CD300a molecule 1.870152775 
stabilin 1 1.9033815 
Fc fragment of IgG, low affinity IIIb, receptor 
(CD16b) 
1.908836469 
SLAM family member 8 1.911165522 
lymphocyte antigen 86 1.934924438 
CD84 molecule 2.01648301 
platelet/endothelial cell adhesion molecule 2.033580494 
CD74 molecule, major histocompatibility 
complex, class II invariant chain 
2.058409447 
Fc fragment of IgG, low affinity IIc, receptor 
for (CD32) 
2.118460086 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 1 
2.139579706 
latexin 2.163830519 
glycoprotein (transmembrane) nmb 2.218326743 
sialic acid binding Ig-like lectin 1, 
sialoadhesin 
2.26871802 
Fc fragment of IgG, low affinity IIc, receptor 
for (CD32) 
2.296616299 
integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
2.318384464 
platelet/endothelial cell adhesion molecule 2.326640299 
integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit) 
2.425879093 
platelet/endothelial cell adhesion molecule 2.428000064 
integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit) 
2.446855377 
insulin-like growth factor 1 (somatomedin C) 2.467476991 
insulin-like growth factor 1 (somatomedin C) 2.551831551 
chemokine (C-X-C motif) ligand 11 2.556396115 
CD36 molecule (thrombospondin receptor) 2.686326408 
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protein tyrosine phosphatase, receptor type, 
C 
2.692544941 
CD36 molecule (thrombospondin receptor) 2.703676107 
CD36 molecule (thrombospondin receptor) 2.738252745 
CD14 molecule 2.760683304 
SLAM family member 7 2.838395853 
Fc fragment of IgG, low affinity IIb, receptor 
(CD32) 
2.903086451 
SLAM family member 8 3.062866033 
protein tyrosine phosphatase, receptor type, 
C 
3.114887339 
chemokine (C-X-C motif) ligand 11 3.170899496 
glycoprotein (transmembrane) nmb 3.211112872 
Fc fragment of IgG, high affinity Ib, receptor 
(CD64) 
3.355217161 
CD163 molecule 3.379356064 
CD163 molecule 3.558453751 
protein tyrosine phosphatase, receptor type, 
C 
3.834024497 
lymphocyte antigen 96 4.018962142 
insulin-like growth factor 1 (somatomedin C) 4.304344053 
chemokine (C-X-C motif) ligand 10 4.484603172 
insulin-like growth factor 1 (somatomedin C) 4.684374381 
chemokine (C-X-C motif) ligand 9 5.770426244 
 
Table 10-3 Macrophage signature genes in high CXCL12 expressing ovarian 
cancer biopsies of the AOCS data set. 
A publically available gene set signature associated with macrophages was used to 
interrogate the gene expression microarray data of the AOCS data set. High CXCL12 
expressing ovarian cancer biopsies showed enrichment in macrophage gene 
signatures. Table lists all the genes associated with macrophages and high expression 
of CXCL12 in the biopsies with the corresponding fold change values for each gene 
probe set. p value ≤ 0.05. 
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Gene Fold change 
poliovirus receptor -1.094811277 
integrin, beta 3 (platelet glycoprotein IIIa, 
antigen CD61) 
-1.088293523 
chemokine (C-C motif) ligand 17 -1.055380932 
integrin, beta 3 (platelet glycoprotein IIIa, 
antigen CD61) 
-1.048696369 
CD300c molecule 1.068651148 
C-type lectin domain family 4, member A 1.085003434 
CD163 molecule 1.098397774 
poliovirus receptor 1.100142278 
signaling lymphocytic activation molecule 
family member 1 
1.110156307 
chemokine (C-C motif) ligand 18 (pulmonary 
and activation-regulated) 
1.120202175 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 2 
1.122434874 
SLAM family member 8 1.142414091 
toll-like receptor 4 1.150457705 
C-type lectin domain family 4, member A 1.154750033 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 2 
1.155149407 
CD40 molecule, TNF receptor superfamily 
member 5 
1.1611291 
integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
1.169747631 
endoglin 1.179377571 
sialic acid binding Ig-like lectin 1, 
sialoadhesin 
1.186170149 
leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 4 
1.190080308 
triggering receptor expressed on myeloid 
cells 2 
1.195460247 
CD300a molecule 1.195911812 
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integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
1.196499459 
chemokine (C-C motif) ligand 18 (pulmonary 
and activation-regulated) 
1.199596037 
CD84 molecule 1.208472952 
CD40 molecule, TNF receptor superfamily 
member 5 
1.22393359 
Fc fragment of IgG, low affinity IIc, receptor 
for (CD32) 
1.25512673 
Fc fragment of IgG, low affinity IIIb, receptor 
(CD16b) 
1.267594021 
interferon gamma receptor 1 1.290301376 
sialic acid binding Ig-like lectin 1, 
sialoadhesin 
1.304110673 
scavenger receptor class B, member 2 1.314859149 
lymphocyte antigen 86 1.326899064 
scavenger receptor class B, member 2 1.338297334 
integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
1.35163333 
Fc fragment of IgG, low affinity IIc, receptor 
for (CD32) 
1.361960092 
low density lipoprotein-related protein 1 
(alpha-2-macroglobulin receptor) 
1.493771381 
protein tyrosine phosphatase, receptor type, 
C 
1.502458085 
endoglin 1.504804445 
stabilin 1 1.509919671 
Fc fragment of IgG, low affinity IIb, receptor 
(CD32) 
1.522381822 
Fc fragment of IgG, high affinity Ib, receptor 
(CD64) 
1.532299878 
latexin 1.550880539 
stabilin 1 1.605912238 
platelet/endothelial cell adhesion molecule 1.616925083 
platelet/endothelial cell adhesion molecule 1.622624317 
chemokine (C-X-C motif) ligand 11 1.630053469 
chemokine (C-X-C motif) ligand 11 1.641899621 
SLAM family member 8 1.647210931 
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CD36 molecule (thrombospondin receptor) 1.703728151 
chemokine (C-X-C motif) ligand 10 1.711583601 
CD36 molecule (thrombospondin receptor) 1.712641394 
platelet/endothelial cell adhesion molecule 1.712653905 
insulin-like growth factor 1 (somatomedin C) 1.872892105 
low density lipoprotein-related protein 1 
(alpha-2-macroglobulin receptor) 
2.050509235 
protein tyrosine phosphatase, receptor type, 
C 
2.092077389 
protein tyrosine phosphatase, receptor type, 
C 
2.14001381 
insulin-like growth factor 1 (somatomedin C) 2.165799688 
integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit) 
2.191357554 
CD14 molecule 2.195483266 
chemokine (C-X-C motif) ligand 9 2.249026866 
CD163 molecule 2.303025895 
lymphocyte antigen 96 2.381283658 
CD163 molecule 2.562992321 
glycoprotein (transmembrane) nmb 2.814810658 
insulin-like growth factor 1 (somatomedin C) 2.942212048 
insulin-like growth factor 1 (somatomedin C) 4.259370331 
 
Table 10-4 Macrophage signature genes in high CXCL12 expressing ovarian 
cancer biopsies of the GSE 6008 and 3149 data set. 
A publically available gene set signature associated with macrophages was used to 
interrogate the gene expression microarray data of the GSE 6008 and 3149 data set. 
High CXCL12 expressing ovarian cancer biopsies showed enrichment in macrophage 
gene signatures. Table lists all the genes associated with macrophages and high 
expression of CXCL12 in the biopsies with the corresponding fold change values for 
each gene probe set. p value ≤ 0.05. 
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10.2. Appendix II: Publication 
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Abstract
High-grade serous ovarian cancer (HGSC) disseminates early and extensively throughout the peritoneal space,
causing multiple lesions that are a major clinical problem. The aim of this study was to investigate the cellular
composition of peritoneal tumour deposits in patient biopsies and their evolution in mouse models using
immunohistochemistry, intravital microscopy, confocal microscopy, and 3D modelling. Tumour deposits from the
omentum of HGSC patients contained a prominent leukocyte infiltrate of CD3+ T cells and CD68+ macrophages,
with occasional neutrophils. Alpha-smooth muscle actin+ (α-SMA+) pericytes and/or fibroblasts surrounded these
well-vascularized tumour deposits. Using the murine bowel mesentery as an accessible mouse peritoneal tissue
that could be easily imaged, and two different transplantable models, we found multiple microscopic tumour
deposits after i.p. injection of malignant cells. Attachment to the peritoneal surface was rapid (6–48 h) with an
extensive CD45+ leukocyte infiltrate visible by 48 h. This infiltrate persisted until end point and in the syngeneic
murine ID8 model, it primarily consisted of CD3+ T lymphocytes and CD68+ macrophages with α-SMA+ cells
also involved from the earliest stages. A majority of tumour deposits developed above existing mesenteric blood
vessels, but in avascular spaces new blood vessels tracked towards the tumour deposits by 2–3 weeks in the
IGROV-1 xenografts and 6 weeks in the ID8 syngeneic model; a vigorous convoluted blood supply was established
by end point. Inhibition of tumour cell cytokine production by stable expression of shRNA to CXCR4 in IGROV-1
cells did not influence the attachment of cells to the mesentery but delayed neovascularization and reduced
tumour deposit size. We conclude that the multiple peritoneal tumour deposits found in HGSC patients can be
modelled in the mouse. The techniques described here may be useful for assessing treatments that target the
disseminated stage of this disease.
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